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Abstract 
  
Double-stranded breaks (DSBs) are toxic DNA lesions that if left unrepaired, 
lead to mutations, chromosomal aberrations, and oncogenesis.  The DNA Damage 
Response (DDR) is a complex network of signaling pathways designed to detect 
and repair DNA breaks and thus acts as a critical anti-cancer barrier.  The MRN 
complex, consisting of the proteins MRE11, RAD50, and NBS1, is a sensor of 
DSBs and has roles in facilitating activation of the ataxia-telangiectasia mutated 
(ATM) kinase, the master regulator of the DDR pathway.  ATM phosphorylates a 
variety of proteins involved in initiating cellular responses important for 
safeguarding the genome, such as DNA repair, cell cycle checkpoints, and if the 
damage is too catastrophic to be fixed, apoptosis.  A second DNA DSB sensor 
exists called the KU70/KU80 heterodimer, which binds and activates the kinase 
DNA-dependent protein kinase, catalytic subunit (DNA-PKcs).   
To investigate the apparently redundant roles of MRN and KU70/80 in DNA 
damage kinase signaling, we utilized cells derived from mouse models deficient in 
either MRN, KU, or both in conjunction with pharmacologic inhibitors for the 
respective kinases of each DNA damage sensor, ATM and DNA-PKcs.  We found 
that when MRN is deficient, DNA-PKcs effectively substitutes for ATM.  
Surprisingly, in the absence of both MRN and KU, ATM is still recruited to the 
chromatin and can facilitate local chromatin responses, including phosphorylation 
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of the histone variant H2AX and recruitment of MDC1.  This data implies that MRN 
is not absolutely required for activation of ATM, as previously thought.   
 Our lab has previously described that the MRE11 C-terminus interacts with 
cyclin-dependent kinase 2 (CDK2), a kinase important for S-phase cell cycle 
progression, and that this interaction has roles for homology-directed DSB repair 
in normally dividing cells.  Interestingly, the MRE11 C-terminus is absent in an 
inherited patient allele causing ataxia-telangiectasia-like disorder 1 (ATLD1).  To 
further understand roles of the MRE11-CDK2 interaction in the DDR, we treated 
cells with ionizing radiation (IR) to induce DSBs.  We found that DNA damage 
disrupts this interaction in an ATM-dependent manner and causes a reduction in 
CDK2 catalytic activity.  Next, we found that genetic disruption of the interaction in 
cells lacking either the MRN complex or the MRE11 C-terminus also led to 
decreased levels of CDK2 activity, mimicking IR-induced disruption of the 
interaction.  Taken together, our data reveal a novel pathway of S-phase 
checkpoint regulation by the MRE11-CDK2 interaction.  
 To gain greater insight into roles of the MRN complex in cancer, we 
engineered a mouse model with B lymphocytes lacking MRN or MRN-nuclease 
activities.  Both forms of MRN deficiency led to characteristics of cancer, including 
oncogenic translocations between C-MYC and the immunoglobulin locus.  
Surprisingly, these B lymphocytes did not progress to detectable B lineage 
lymphoma, even in the absence of p53.  Moreover, MRE11-deficiencies prevented 
tumorigenesis in a mouse model strongly predisposed to spontaneous B-cell 
lymphomas.  Our findings indicate that MRN is not a classic tumor suppressor and 
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instead imply that certain functions of the MRN complex, such as MRE11 nuclease 
activity, are required for oncogenesis.  These data also suggest that MRE11 
nuclease activity can be targeted for cancer therapy development.  
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Chapter I 
Introduction 
 
The Hallmarks of Cancer 
 Cancer is a leading cause of death in people of all ages in the United States 
and around the world.  According to the American Cancer Society, about half of all 
men and one-third of all women in the US will develop cancer during their lifetimes.  
In 2000, Douglas Hanahan and Robert Weinberg proposed six fundamental 
hallmarks of cancer[1].  Since then, much progress has been made in 
understanding the complexities of cancer and additional hallmarks have been 
identified[2].  Two important hallmarks, evading growth suppressors and genomic 
instability/mutation, lie at the heart of my thesis work (Figure 1.1).   
One of the most fundamental traits of cancer cells is their ability to 
proliferate indefinitely[1, 2].  Normal cells carefully control the production and 
release of growth-promoting signals that control entry and progression through the 
cell cycle, while cancer cells deregulate these signals.  Uncontrolled growth of 
cancer cells in part leads to tumor formation[1, 2].  Additionally, DNA damage 
response mechanisms are essential in maintaining genomic stability and 
preventing chromosomal translocations and mutations.  Defects in genome 
maintenance and repair are selectively advantageous and instrumental for tumor 
progression[1, 2].  Thus, a better understanding of the cell cycle machinery that 
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controls cell growth and the DNA repair machinery that maintains stability of the 
genome are critical not only in deciphering mechanisms of neoplastic 
transformation, but also for the development of anti-cancer drugs and treatments.  
 
The DNA Damage Response 
 
Sources and types of DNA Damage 
           The DNA in our cells is damaged every day.  These lesions are dangerous 
because they can block important processes such as replication and transcription, 
and if not properly repaired, can lead to mutations and chromosomal aberrations 
that threaten the survival of both cells and organisms[3].   
There are numerous types of DNA damage caused by a varying array of 
sources.  Lesions can be spontaneous, induced endogenously, by radiation, or by 
chemicals[4].  DNA lesions can arise from endogenous physiological processes 
such as during the replication process and by reactive oxygen species that arise 
as by-products from oxidative respiration[5].  One of the most prominent sources 
of environmental damage to DNA is ultra-violet light (UV light), which can induce 
~100,000 lesions per exposed cell per hour[6].  Ionizing radiation (IR) also 
generates various forms of DNA damage, the most toxic of which is DNA double-
strand breaks (DSBs)[7].  Some ionizing radiation results from radioactive decay 
of naturally occurring radioactive compounds.  Exposure to natural or man-made 
radioisotopes also occurs during cancer radiotherapy[8].  Chemicals that are 
known to cause mutations and cancer are known as mutagens or 
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carcinogens.   Examples of carcinogens include: Mitomycin C (MMC), an 
alkylating agent that inhibits DNA synthesis by covalently reacting with DNA, 
forming crosslinks; Aphidicolin, a specific inhibitor of DNA polymerase α; 
hydroxyurea, an inhibitor of DNA synthesis; Camptothecin (CPT), an inhibitor of 
the DNA enzyme topoisomerase I; and Bleomycin, which induces oxidative stress 
and DNA damage via single-strand breaks (SSBs) and DSBs[5, 9-12].  
DSBs are among the most toxic DNA lesions and result from either 
endogenous or exogenous sources[13].  Naturally occurring DSBs are generated 
spontaneously during DNA synthesis when the replication fork encounters a 
damaged template and during specialized processes of immune development, 
including V(D)J recombination and class switch recombination 
(CSR)[14].  Programmed DSBs during meiosis are essential for the exchange of 
genetic information between homologous chromosomes and for correct 
chromosome segregation[3].  Environmental sources of DSBs include ionizing 
radiation (X-rays and gamma rays), topoisomerase poisons, and radiometric 
drugs[15].  
 
DNA DSB repair pathways 
Cells have evolved complex signaling mechanisms, together known as the 
“DNA damage response” (DDR), to detect, signal, and repair DNA breaks (Figure 
1.2).  Cells defective in DDR mechanisms often exhibit hypersensitivity to DNA 
damaging agents, and many defects in the DDR can lead to human 
disease[3].   The diverse range of DNA lesion types requires multiple, distinct DNA 
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repair mechanisms[16].  In mismatch repair, detection of mismatches triggers a 
single-strand incision that is then acted upon by nuclease, polymerase, and ligase 
enzymes[17].  In base-excision repair, a damaged base is often recognized by a 
DNA glycosylase enzyme that mediates removal of the base[18].  During 
nucleotide excision repair (NER), the damage is excised as a 22-30 base 
oligonucleotide, producing single-stranded DNA (ssDNA) that is acted upon by 
DNA polymerases and associated factors before being ligated[19, 20].  For DSB 
repair, two principle methods are used: non-homologous end joining (NHEJ) and 
homologous recombination (HR) (Figure 1.3). 
 
Non-homologous end-joining 
NHEJ is a “cut and paste” method of DSB repair.  In NHEJ, DSBs are 
recognized by the KU protein (a heterodimeric complex consisting of KU70 and 
KU80 proteins) that binds and activates the protein kinase DNA-dependent protein 
kinase, catalytic subunit (DNA-PKcs)[21, 22].  Since DSBs can occur with a variety 
of different ends, several processing enzymes are required to fix the 
breaks.  ARTEMIS, a member of the metallo-β-lactamase superfamily of enzymes, 
has both a DNA-PKcs-independent 5’-to-3’ exonuclease activity towards DNA-
containing ds-ssDNA transitions and DNA hairpins, each of which might be 
important for processing of DNA termini during NHEJ[23].  Repair by NHEJ is 
completed by ligation of the DNA ends, which is carried out by X-ray repair cross-
complementing protein 4 (XRCC4) and DNA ligase IV[24-26].   A less well-
characterized KU-independent NHEJ pathway, known as microhomology-
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mediated end-joining (MMEJ) or alternative end-joining, also exists and results in 
sequence joins[27].  Both NHEJ and MMEJ are error-prone but can operate in any 
phase of the cell cycle.  Core members of the NHEJ pathway perform direct roles 
in ligating the programmed DSBs produced during both V(D)J recombination and 
CSR[28-30].  NHEJ is inhibited by end-resection (HR), the process by which 5’-3’ 
nucleolytic degradation generates ssDNA.  
 
Homologous recombination 
Repair by HR is generally error-free and restricted to the S and G2 phases 
of the cell cycle when sister chromatids are more easily accessible following 
replication.  The MRN complex, a sensor of DSBs, is required for the recruitment 
and activation of the ataxia-telangiectasia mutated (ATM) kinase[31-34].  HR 
involves processing of the DSB to yield a 3’ ssDNA overhang.  It is thought that 
the nuclease activities of MRE11, along with DNA endonuclease RBBP8 (CTIP), 
collaborate to resect the DNA ends to an intermediate form[35-37].  The DNA ends 
are further processed into ssDNA by exonuclease 1 (EXO1) and Bloom syndrome 
protein (BLM) helicase[38-40].  The ssDNA is then rapidly bound by the ssDNA-
binding protein termed replication protein A (RPA) which melts the DNA’s 
secondary structure[41].  A mediator complex containing breast cancer type 1 
susceptibility proteins 1 and 2 (BRCA1/2), BRCA1-associated RING domain 
protein 1 (BARD1), and partner and localizer of BRCA2 (PALB2) catalyze the 
nucleation of RAD51 recombinase (RAD51) onto the free 5’ end of a dsDNA-
ssDNA junction, such that RPA is replaced by RAD51 to form a 
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nucleofilament[42].  The RAD51 nucleoprotein filament captures duplex DNA and 
searches for homology sequences (usually a sister chromatid) which is followed 
by strand invasion and finally resolution[42-44]. The critical role of HR in 
suppressing genomic instability is reflected in the early embryonic lethality of mice 
lacking Rad51, Brca1, and Brca2[45-47].   
 
Chromatin response in DSB repair 
Chromosomal DSBs in eukaryotes exhibit a rapid and extensive response 
in the chromatin flanking the break, highlighted by the phosphorylation of the 
histone H2AX in mammalian cells (denoted as γH2AX)[48].  The H2AX 
phosphorylation site, Serine 139, is a common recognition site for the 
phosphatidylinositol 3-kinase-related kinases (PIKK) family members, including 
ATM, ataxia-telangiectasia mutated- and Rad3-related (ATR), and DNA-PKcs[48-
51].  All have the potential to phosphorylate H2AX, but ATM appears to be the 
main kinase associated with γH2AX formation under normal physiological 
conditions[34, 50].  The γH2AX mark around a DSB can extend more than 1 
megabase from the break[52].  Many DNA damage response proteins, such as 
Mediator of DNA damage checkpoint protein 1 (MDC1), the MRN complex, ATM, 
p53-binding protein 1 (53BP1) and BRCA1/BARD1, accumulate on γH2AX-
containing chromatin[53-56].  MDC1 is the critical adaptor protein that directly 
interacts with γH2AX[56].  Interestingly, BRCA1 and MRN/ATM can also associate 
with DSBs in H2AX-/- cells, suggesting γH2AX-independent roles at the 
DSB[57].  The recruitment of 53BP1 and BRCA1 to γH2AX chromatin is indirect, 
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requiring the activity of the E3 ubiquitin ligases RNF8 and RNF168[58, 59].  Thus, 
it is clear that chromatin changes after DNA damage are essential for the 
recruitment of DDR factors and other chromatin-modifying components, which 
together, are thought to promote DSB repair and amplify DSB signaling[52, 60].  
 
DNA Damage Response signaling  
The DNA damage response is a complex network of signaling pathways 
designed to detect, signal, and repair DNA lesions.  The presence of a DNA lesion 
is recognized by sensor proteins, allowing for recruitment of mediator proteins, 
transducers and effectors, and initiation of cellular responses such as transcription, 
cell cycle checkpoints, chromatin remodeling, DNA repair, and 
apoptosis/senescence[3].  The master regulators of the signaling network are the 
protein kinases ATM and ATR.  ATM is recruited and activated by DSBs, whereas 
ATR is recruited and activated by RPA-coated ssDNA[31, 41, 61].  The two primary 
targets of ATM and ATR are checkpoint kinases 1 and 2 (CHK2 and CHK1), 
respectively[62-64].  CHK2 and CHK1, together with ATM and ATR, act to reduce 
cyclin-dependent kinase (CDK) activity by various mechanisms[62].  Inhibition of 
the CDKs slows down or arrests cell cycle progression at the G1-S, intra-S, and, 
G2-M cell cycle checkpoints, which allows for DNA repair to occur before either 
replication or mitosis begins[65, 66].  Additionally, ATM and ATR enhance repair 
by inducing the transcription of DNA repair proteins, by recruiting repair factors to 
the damage, and by activating DNA repair proteins by modulating their 
phosphorylation, acetylation, ubiquitylation, or SUMOylation[67, 68].  If the above 
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events allow for effective DNA repair, inactivation of the DDR occurs, allowing for 
resurgence of normal cell functioning[3].  Alternatively, if the damage cannot be 
fixed, chronic DDR signaling triggers cell death by apoptosis or cellular 
senescence (permanent removal from the cell cycle)[69-72].   
 
The DDR and human disease  
Genomic instability is a fundamental hallmark of cancer[1, 2].  In lymphoid 
tumors, genomic instability frequently corresponds to chromosomal 
translocations[73].  These translocations result when proto-oncogene loci fuse 
together with antigen receptors by an aberrant antigen-receptor recombination 
mechanism[74].  Defects in mismatch repair can cause microsatellite instability 
which is common in colorectal and endometrial carcinomas[17].  Additionally, 
inherited defects in the DDR machinery commonly predispose patients to 
cancer[3].  Thus, problems in the DDR arising from mutational or epigenetic 
inactivation of DDR components allow for malignant progression.  Therefore, the 
DDR is often viewed as an important barrier to cancer.   
 Accumulation of DNA lesions in neurons is associated with 
neurodegenerative disorders such as Alzheimer’s, Huntington’s and Parkinson’s 
diseases[75].  Furthermore, there are roughly 40 known diseases that result from 
expansions or contractions of genetic unstably DNA repeat sequences[75].  These 
neuromuscular and neurodegenerative diseases include fragile X syndromes, 
Friedrich’s ataxia, diabetes mellitus type 2, and Huntington’s disease[75-77].   
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 Genomic rearrangements involving DDR factors occur during immune-
system development resulting in immunodeficiency[78].  For example, patients 
with mutations in NHEJ factors are often B- and T-cell immune deficient, whereas 
ataxia-telangiectasia (A-T) and Nijmegen breakage syndrome (NBS) patients are 
prone to sometimes fatal infections due to an impaired immune system[79, 
80].  Furthermore, many lymphomas and leukemias of B- and T-cell origin arise 
from impaired V(D)J recombination[74].  Because meiotic recombination involves 
DSB generation, certain DDR defects can cause human infertility[81, 82].  Finally, 
there is evidence that aging is in part caused by accumulated DNA 
damage[83].  With this knowledge, it makes sense that studying the DDR can 
elucidate ways in which we can treat cancer and human diseases.   
 
Kinases of the DNA Damage Response 
 
Ataxia-telangiectasia mutated kinase 
 ATM is the central kinase of the DNA damage response.  ATM is a serine-
threonine kinase that is activated in response to DNA DSBs and is a member of 
the PIKK family of serine/threonine kinases, which also includes DNA-PKcs, ATR, 
and mechanistic target of rapamycin kinase (MTOR) kinases[31, 84, 85].  ATM 
phosphorylates a variety of proteins involved in DNA repair, cell cycle checkpoint 
control, and apoptotic responses, including CHK2, p53, BRCA1, H2AX, structural 
maintenance of chromosome protein 1 (SMC1), ARTEMIS, and NBS1[48, 86-
91].  Phosphorylation of these and other substrates by ATM initiates cell cycle 
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arrest at G1/S, intra-S, and G2/M checkpoints and also promotes DNA 
repair[92].  Mutations in the ATM gene are responsible for the rare autosomal 
recessive disorder ataxia-telangiectasia, which is characterized by cerebellar 
degeneration, immunodeficiency, and an increased risk of cancer[93].  Cells from 
individuals with A-T exhibit defects in DNA damage-induced checkpoint activation, 
radiation hypersensitivity, and an increased frequency of chromosomal 
aberrations[94].   
 The functional relationship between ATM and the MRN complex was initially 
discovered when it was found that patients with similar clinical phenotypes 
observed in AT patients had mutations in MRE11 (A-T like disorder or ATLD)[95, 
96].  Loss of any of the individual components of the MRN complex results in 
embryonic lethality in mice[97-99].  ATLD patients express low levels of mutant 
MRN protein, so ATLD most likely represents MRN hypomorphism rather than 
complete loss of the complex[100].  Interestingly, ATLD cells with mutant MRE11 
have markedly reduced activation of ATM by DNA DSBs and reduced ATM-
dependent phosphorylation of downstream substrates, demonstrating that MRN is 
required for optimal ATM activation following DNA DSB induction[96, 100].  The 
work in Chapter II expands upon and updates previous models for MRN’s 
requirement in ATM activation.   
 ATM is mostly a nuclear protein, where it exists as an inactive 
homodimer.  DNA damage, however, converts the inactive homodimer to an active 
monomer form that phosphorylates a large number of substrates[101, 
102].  Additionally, ATM autophosphorylation occurs at Serine 1981 at the same 
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time as monomerization/activation of ATM in response to DNA damage[101].  The 
transformation of inactive ATM into an active kinase has been observed with 
purified proteins, Xenopus egg extracts, and human cell extracts in vitro[31, 103, 
104].  In addition to the presence of DNA DSBs, there are reports that ATM can be 
activated by oxidative stress or reactive oxygen species[105].    
One murine model of ataxia-telangiectasia was created by disrupting the 
Atm locus via gene targeting[106].  Mice homozygous for the disrupted Atm allele 
are viable, but display growth retardation, neurologic dysfunction, male and female 
infertility, defects in T-lymphocyte maturation, and sensitivity to 
radiation[106].  The majority of mice developed malignant thymic lymphomas and 
several chromosomal abnormalities were detected in the tumors[106].  Fibroblasts 
from these mice grow slowly and exhibit abnormal G1 checkpoint 
function[106].  Thus, Atm-deficient mice recapitulate the ataxia-telangiectasia 
phenotype in humans and provide a mammalian model to further study the 
disease[106]. 
 ATM is a known tumor suppressor frequently mutated in a broad range of 
human cancers[107].  Along with its tumor suppressor capabilities, the 
hypersensitivity of ATM-defective cells to IR has sparked interest in ATM as a 
therapeutic target for cancer therapy.  Early studies demonstrated that caffeine 
inhibits the catalytic functions of both ATM and ATR[108, 109].  KuDOS 
Pharmaceuticals (acquired by AstraZeneca in 2005) developed the first potent and 
selective ATM inhibitor: KU-55933.  KU-55933 confers marked sensitization to IR 
and DNA DSB-inducing chemotherapeutics, such as the topoisomerase II 
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inhibitors etoposide and doxorubicin, in cancer cells.  Importantly, in cells derived 
from A-T patients, which express no functional ATM, no radiosensitization was 
observed, further confirming the selectivity of the compound for ATM[110].  Even 
though no ATM inhibitors are in clinical development yet, the in vitro studies carried 
out to date clearly show that pharmacological ATM inhibition has great potential as 
a cancer therapy in combination with radiotherapy or certain chemotherapeutic 
drugs.   
  
DNA-dependent protein kinase, catalytic subunit kinase 
DNA-PKcs is a member of the PIKK family of kinases[111].  DNA-PKcs is 
required for NHEJ and V(D)J recombination.  Cells lacking DNA-PKcs are highly 
radiosensitive and have defects in V(D)J recombination[112].  DNA-PKcs 
deficiency in mice is associated with severe combined immunodeficiency 
(SCID)[112, 113].  Importantly, DNA-PKcs interacts with the DNA DSB sensor, 
KU[21].  KU and DNA-PKcs only interact in the presence of DNA and recruitment 
of DNA-PKcs to sites of DNA damage in vivo is KU-dependent[21].  DNA-PKcs 
has serine/threonine kinase activity and phosphorylates a number of 
substrates.  The protein kinase activity of DNA-PKcs is required for NHEJ, and 
inhibitors of DNA-PKcs kinase activity radiosensitize cells and inhibit DSB repair, 
making DNA-PK a possible therapeutic target.   
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Ataxia-telangiectasia and rad3-related protein kinase  
ATR is another member of the PIKK family of kinases.  ATR is essential for 
the viability of replicating human and mouse cells and is activated in S-phase to 
regulate the firing of replication origins and the repair of damaged replication 
forks[114].  Mutations in ATR are rare and the only current link between ATR gene 
mutation and disease exists in a few patients with the rare Seckel Syndrome, which 
is characterized by growth retardation and microcephaly[115].  Disruptions in the 
ATR pathway cause genomic instability.  ATR is activated in response to persistent 
ssDNA, which is a common intermediate formed during DNA damage detection 
and repair[116, 117].  Once ATR is activated, it phosphorylates CHK1, initiating a 
signal transduction cascade that culminates in cell cycle arrest[63, 118].  In 
addition to its role in activating the DNA damage checkpoint response, ATR is 
thought to function in unperturbed DNA replication[119].  Atr heterozygous mice 
develop normally and demonstrate a significantly increased tumor risk by 18 
months of age, while homozygous Atr mice exhibit high numbers of chromosomal 
breaks, proliferation defects in cell culture, and early embryonic lethality[120-122]. 
 
Sensors of DNA double-strand breaks 
 
The MRE11/RAD50/NBS1 complex 
The MRN complex is a multi-protein complex consisting of meiotic 
recombination 11 (MRE11), DNA repair protein RAD50, and Nijmegen breakage 
syndrome 1 (NBS1) proteins[123].  The MRN complex is an important player in the 
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DDR, as it senses and physically binds to areas of DNA damage rapidly after insult, 
tethers and bridges the broken DNA ends together over both long and short 
distances, and is involved in activating pathways of DNA repair and cell cycle 
checkpoints[123, 124].   Importantly, MRE11 and RAD50 are conserved 
throughout evolution across all domains of life, whereas NBS1 is specifically found 
in eukaryotes and is less well conserved[123].  Another significant function of MRN 
is its involvement in activation of the ATM signaling pathway.  Activated ATM 
phosphorylates a variety of proteins involved in DNA repair, cell cycle checkpoint 
control, and apoptosis[31, 32, 125, 126] (Figure 1.4). 
 
MRE11 
MRE11 is a nuclear protein that has both exo- and endo-nuclease activities.  
This includes dsDNA 3’ to 5’ exo-nuclease activity, as well as ssDNA endo-
nucleolytic activity[39, 127-129].  The N-terminus of MRE11 has four highly 
conserved nuclease domains as well as a phosphodiesterase domain[130].  The 
third nuclease domain contains a highly conserved histidine residue (H129) that 
has been shown by both in vitro and structural studies to act directly in DNA 
catalysis by stabilizing the sugar-phosphate moiety during nucleolysis[130-
132].  Surprisingly, in yeast, mutation of this histidine residue causes only a mild 
radiation hypersensitivity phenotype[133, 134].  More recently, our lab has shown 
that MRE11-nuclease deficiency by mutation of the H129 residue causes a striking 
array of phenotypes in mice, including early embryonic lethality and severe 
genomic instability[135].  The nuclease activities also have important roles in 
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homology-directed DNA repair and roles in activating the ATR kinase[129, 136-
138].  MRE11 functions as a dimer to bind both sides of a DSB and stabilize them 
in close proximity to each other.  The nucleolytic activities of MRE11 can then go 
on to process the bound ends once inside the dimer[139].  The MRE11 C-terminus 
is more disordered and less conserved than the N-terminus, and contains the 
DNA-binding domain in budding yeast[123].  The C-terminal domain is the portion 
of MRE11 mutated in a distinct patient allele that causes ataxia-telangiectasia-like 
disorder 1 (ATLD1)[100].  Our lab discovered that the C-terminal portion of MRE11 
is required for its interaction with cyclin dependent kinase 2 (CDK2)[140].  I 
describe roles for the MRE11-CDK2 interaction in the DNA damage response in 
Chapter III of this thesis. 
  
RAD50 
RAD50 is another member of the MRN complex, which has both ATPase 
and adenylate kinase functions[141, 142].  The protein encoded by this gene is 
highly similar to yeast Rad50, which also functions in DSB repair[143].  RAD50 
protein contains a long internal coiled-coil domain that folds back on itself, bringing 
the N- and C-termini together to form a globular ATPase head domain[144, 
145].  MRE11 and RAD50 form a heterotetramer together that functions as the 
DNA binding and processing core of the complex[146, 147].  Rad50-null mice are 
embryonic lethal, while hypomorphic Rad50-mutant mice exhibit growth defects, 
cancer predisposition, and hematopoietic failure[97, 148]. 
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NBS1 
NBS1 is less well-conserved than the other members of the complex, but 
has a yeast homolog known as Xrs2[149].  The NBS1 protein contains three 
functional regions: the forkhead-associated (FHA) domain and BRCA1 C-terminus 
(BRCT) domain at the N-terminus, several SQ motifs (consensus phosphorylation 
sites by ATM and ATR kinases) in the central region, and an MRE11-binding 
region on the C-terminus[150, 151].  Previously, it was thought that NBS1 provides 
the MRN complex with its signaling role by binding to and activating ATM in 
response to DNA DSBs, however, our lab has recently shown that this interaction 
is not absolutely required for activation of ATM[34, 152].  Mutations in NBS1 are 
associated with Nijmegen breakage syndrome (NBS), a radiation-hypersensitivity 
disease[153].  Characteristics of NBS include microcephaly, growth retardation, 
immunodeficiency, and a predisposition to cancer[154]. Though Nbs1-null mice 
are not viable, mice with Nbs1 heterozygosity or hypomorphism are predisposed 
to oncogenesis[98, 125].      
 
Ataxia-Telangiectasia-Like Disorder 
Mutations in MRE11 cause the disease known as ataxia telangiectasia like-
disorder (ATLD)[100].  ATLD is a rare autosomal recessive disorder characterized 
clinically by progressive cerebellar degeneration resulting in ataxia[100].  Patient 
cells have low levels of the MRN complex, defects in cell cycle checkpoint 
activation, hypersensitivity to radiation, and an increase in chromosomal 
aberrations as compared to controls, all consistent with a defect in DNA repair[96, 
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100].  The disorder shares some phenotypic features of A-T, but telangiectasia and 
immunodeficiency are not present in ATLD.  Patients have a varied predisposition 
to cancer[100].   
To date, several ATLD patient alleles have been identified.  MRE11ATLD1 
was the first reported ATLD allele and contains a nonsense mutation that truncates 
76 amino acid residues from the C-terminus of MRE11.  MRE11ATLD1 patients and 
mice exhibit genomic instability, but do not appear to be prone to cancer[100].  The 
MRE11ATLD17 mutation results in substitution at a highly conserved residue in the 
N-terminal phosphodiesterase domain[155].  MRE11ASM mutation causes skipping 
of exon 10 of MRE11.  Two brothers with MRE11ATLD17 and MRE11ASM mutations 
died prematurely of pulmonary adenocarcinoma, while the brothers’ heterozygous 
family members did not have ATLD or lung cancer[156].   
In addition to inherited mutations causing ATLD, MRE11 has been found to 
be mutated in both inherited and sporadic cancers.  Mutational analysis of MRE11 
in primary tumors has revealed a heterozygous mutation encoding MRE11 R572Q 
in a lymphoma[157].  The mutation resides in an interesting region of MRE11 
known as a glycine-arginine-rich (GAR) motif which has been shown to be 
important for MRE11 exonuclease activity and activation of ATR[137].  Alterations 
of the GAR motif arginines in mice cause radiation hypersensitivity, a trait common 
among cancer-prone genomic instability syndromes[137, 158-160].  Studies from 
our lab have determined that the varied spectrum of disease-associated MRE11 
mutations impact DNA damage signaling and disease outcomes by distinct 
mechanisms[161] (Figure 1.5). 
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Mouse and cellular models of MRE11 
We have a better understanding of the functions and roles of MRN in large 
part due to the generation of mouse models of the complex.  As stated previously, 
knockout alleles of Mre11, Rad50, and Nbs1 are all embryonic lethal in mice[97, 
99, 162].  Interestingly, Mre11-nuclease deficiency in mice is also embryonic 
lethal[163].  Embryonic lethality, thus, is an issue that must be overcome to fully 
understand the biological functions of MRE11.  To bypass the embryonic lethality 
conferred by Mre11 deficiencies, our lab disabled the MRN complex through use 
of mouse embryonic fibroblasts (MEFs) that originally contained one Mre11-null 
allele and one Cre/LoxP conditional allele[135].  Exposure to Cre recombinase via 
adenovirus converts these cells to MRE11-null cells which also causes deficiency 
of RAD50 and NBS1[163].  Buis et al., studied Mre11-nuclease deficiency by 
mutating a conserved histidine residue in the nuclease domain to an arginine 
(H129N).  MRE11-null MEFs display growth retardation, defects in ATM activation 
and the G2/M checkpoint, and an increase in chromosomal 
abnormalities[135].  On the other hand, MRE11-nuclease deficient MEFs display 
intact ATM activation, but have a defect in DNA repair and are hypersensitive to 
IR similar to MRE11-deficient cells[163]. These findings suggest that nucleolytic 
processing by MRE11 is an essential function of fundamental importance in DNA 
repair, distinct from MRN control of ATM signaling.   
 Mice expressing one of the MRE11 alleles inherited in ATLD were recently 
derived[95].  The mutation, which causes truncation of the MRE11 C-terminus, had 
a profound effect on maternal embryonic viability, revealing a requirement for the 
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MRN complex in early embryogenesis.  Cells derived from Mre11ATLD1/ATLD1 mice 
had low levels of the MRN complex, impaired ATM signaling, marked 
chromosomal instability, but no predisposition to malignancy[164].  However, low 
levels of the MRN complex in ATLD-associated mutations prevent structure-
function analyses through study of patient cells lines.  To overcome this limitation, 
our lab previously engineered cell lines that express MRE11 mutants of interest at 
approximately physiologic levels and in which endogenous wild-type MRE11 can 
be inactivated through addition of adeno-cre virus in vitro[165].  Surprisingly, 
expression of Mre11ATLD1 at physiologic levels in mouse cells rescued ATM 
signaling and G2/M checkpoint activation[165].  This data provides evidence that 
reduced ATM signaling in MRE11ATLD1 patients likely results primarily from low 
levels of the MRN complex since expression of Mre11ATLD1 to normal levels in 
mouse cells supports ATM activity. 
 
Post-translational modifications of the MRN complex 
The components of the MRN complex are phosphorylated by PIKK 
enzymes and other kinases, with varying effects on DNA repair as well as on ATM 
signaling[166].  MRE11 is phosphorylated on at least five C-terminal SQ/TQ sites 
by ATM and ATR following DNA damage, and these modifications reduce the 
affinity of MRN for DNA, resulting in lower levels of ATM recruited to damage 
sites[167].  RAD50 is also phosphorylated by ATM[88].  NBS1 is phosphorylated 
by ATM on Serines 278 and 343, modifications that are required for S-phase 
checkpoint control and radiation-induced DNA damage 
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responses[168].  Furthermore, several studies have shown that NBS1 is a target 
of CDK phosphorylation[169, 170].  NBS1 Serine 432 phosphorylation occurs in S, 
G2, and M phases of the cell cycle and requires CDK activity.  Data indicates that 
CDK-dependent NBS1 Serine 432 phosphorylation is critical for promoting MRN-
dependent resection and HR and is also needed for MRN-dependent recovery 
from replication arrest[169, 171].  Finally, a recent study showed that NBS1 is a 
target of K63-linked ubiquitination by the E3 ligase S-phase kinase associated 
protein 2 (SKP2) and that this modification affects ATM autophosphorylation, 
recruitment to chromatin via MRN interaction, and ATM substrate 
phosphorylation[172].  
Roles for MRN in lymphoid malignancy 
Programmed DSBs occur during V(D)J recombination, class switch 
recombination, and somatic hypermutation (SHM), important processes for the 
development of the adaptive immune system in all vertebrates[173].  These 
processes occur in developing B and T lymphocytes to generate immunoglobulin 
(Ig) and T-cell receptor (TCR) diversity, which allows for effective recognition of 
diverse pathogens and antigens[174].  During V(D)J recombination, exons 
encoding the V, D, and J segments are combined in various ways to form mature 
Ig and TCR genes.  Each segment is flanked by recombination-signal sequences 
(RSS) that are recognized by the recombination activating gene (RAG) protein 
complex.  This complex creates a blunt DSB at the signal sequence and a DNA 
hairpin at the coding end.  These structures are then processed and ligated by 
NHEJ repair mechanisms[174]. 
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Lymphoid malignancies are cancers that affect the blood, bone marrow, 
lymph, and lymphatic system.  Although present in non-lymphoid tumors, 
chromosomal translocations represent the hallmark of lymphoid malignancies[78].  
One example of a common translocation is found in Burkitt’s lymphoma[175].  This 
cancer carries a reciprocal translocation that results in the fusion of the coding 
region of the proto-oncogene protein (C-MYC) with the immunoglobulin heavy 
chain (IgH), which places C-MYC under the control of the of IgH locus[175].  The 
translocations that are found in lymphoid malignancies are caused by problems 
that occur during the programmed DSB repair in V(D)J combination.  These 
translocations result when paired DSBs on separate chromosomes are fused 
together erroneously[174].  
 It is known that the MRN complex has roles in proper V(D)J recombination.  
While homozygous mutations for the Mre11, Rad50, or Nbs1 genes cause 
embryonic lethality in mice, humans and mice with hypomorphic mutations in 
MRE11 or NBS1 present clinically with immunodeficiency, likely caused by defects 
in DSB repair pathways due to loss of the MRN complex[100, 135, 162, 176].  
Furthermore, mouse thymocytes with a hypomorphic mutation in Mre11 have an 
increased number of trans-rearrangements, suggesting that mutations in MRN can 
lead to aberrant V(D)J recombination[164].  Finally, studies have shown there is 
an increase of unrepaired coding-ends associated with hypomorphic Mre11 or 
Nbs1 mutations in developing mouse lymphocytes[177].  Taken together, 
understanding the mechanisms of how malignant translocations occur and the 
DNA repair mechanisms by which they are prevented are important for the 
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development of therapeutics in lymphoid cancers.  The work in Chapter IV 
elucidates roles for the MRN complex, and specifically MRE11 nuclease activity, 
in lymphogenesis. 
 
The KU70/KU80 heterodimer 
The KU70/80 heterodimer is an abundant, highly conserved DNA-binding 
protein and sensor of DNA DSBs[178].  KU70/80 is found in both prokaryotes and 
eukaryotes and plays essential roles in the maintenance of genome integrity.  In 
eukaryotes, KU is a heterodimer consisting of two subunits, KU70 and KU80[179, 
180].  KU is best known for its central role as the initial DNA end-binding factor in 
classical NHEJ pathway.  KU binds DSBs with high affinity through its central ring 
structure formed by the intertwined strands of the KU70 and KU80 subunits[179, 
180].  It is not currently known how KU is ejected from DSBs.  At a DSB, KU directly 
and indirectly interacts with several NHEJ factors and processing 
enzymes[26].  For example, KU binds and activates the DNA-PKcs kinase and, 
together, KU and DNA-PKcs make up the DNA-PK holoenzyme[179].  KU is 
central to the protection of organisms through its participation in NHEJ to repair 
DSBs generated through V(D)J recombination[113].  KU also functions to prevent 
tumorigenesis and senescence since Ku-deficient mice show increased cancer 
incidence and early onset aging[113, 181].  It is unclear why eukaryotes have two 
DNA DSB sensors (MRN and KU).  The work in Chapter II contributes to a better 
understanding of the interplay between these two sensor complexes.   
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Cell cycle regulation 
 
Cyclins and CDKs control cell cycle progression 
  The cell cycle is controlled by several mechanisms to ensure correct cell 
division.   Cell division consists of two consecutive processes: DNA replication and 
segregation of replicated chromosomes into two separate cells.  Cell division is 
divided into several stages[182].  Mitosis is the process of nuclear division and 
interphase is the stage between two M phases.  The stages of mitosis include 
prophase, metaphase, anaphase, and telophase.  Interphase includes the G1, S, 
and G2 phases.  Replication of DNA occurs during S phase.  S phase is preceded 
by a gap called G1 during which the cells prepares for DNA synthesis and is 
followed by G2 during which the cell prepares for mitosis.  Cells in G1 can enter a 
resting state called G0 before committing to DNA replication.  Cells in G0 account 
for a major portion of non-growing, non-proliferating cells in the human body[182].   
 The transition from one cell cycle phase to another is regulated by different 
proteins[183].  One of the key sets of regulatory proteins is the CDKs which are a 
family of serine/threonine protein kinases.  When activated, CDKs induce 
downstream processes by phosphorylating targeting proteins.  CDK protein levels 
remain stable during the cell cycle, in contrast to their activating proteins, the 
cyclins.  Cyclin protein levels rise and fall during the cell cycle; binding of cyclins 
activate their CDK partners.  Different cyclins are required at different phases of 
the cell cycle.  The three D cyclins (Cyclin D1, Cyclin D2, and Cyclin D3) bind to 
CDK4 and to CDK6; CDK-Cyclin D complexes are essential for entry into 
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G1.  Cyclin E associates with CDK2 to regulate progression from G1 into S 
phase.  Cyclin A also binds with CDK2 and this complex regulates progression in 
the S phase.  Furthermore, Cyclin A complexes with CDK1 to promote entry into 
M phase.  Mitosis is also regulated by Cyclin B binding to CDK1[183].   
 In addition to cyclin binding, CDK activity is also regulated by 
phosphorylation on conserved threonine and tyrosine residues.  CDK activity can 
be counteracted by cell cycle inhibitory proteins, called CDK inhibitors, which bind 
to CDKs alone or to CDK-Cyclin complexes.  The intracellular localization of 
different cell cycle-regulating proteins also contributes to cell cycle 
progression[183] (Figure 1.6).  
 
Regulation of CDK activity 
Regulation hierarchies are critical in ensuring the completion of one cell 
cycle phase before the beginning of the next.  The mechanisms that control these 
important tasks are highly conserved in evolution.  Kinase activity of all CDKs 
requires the binding of a positive regulatory subunit known as the 
cyclins[184].  Both cyclins and CDKs are subject to post-translational regulation by 
phosphorylation.  The assembly of a CDK with its corresponding cyclin yields only 
a partially active complex and full activity occurs after phosphorylation of the CDK 
on a conserved threonine residue close to the ATP-binding cleft (Threonine 172 in 
CDK4/6, Threonine 160 in CDK2, and Threonine 161 in CDK1)[183].  The 
activating threonine residue is located in a loop of amino acids called the T-loop 
that blocks access of ATP to the catalytic domain.  Analysis of the crystal structure 
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of CDK2-Cyclin A complexes indicates that the CDK-Cyclin interaction causes a 
conformational change in the CDK, making the T-loop more accessible for the 
activating phosphorylation[185].  The phosphorylation causes a further 
conformational change in the T-loop, making the catalytic cleft fully accessible to 
ATP[185].  In addition to greatly stimulating kinase activity, the activating threonine 
phosphorylation has also been suggested to enhance stability of some CDK-Cyclin 
complexes[185]. 
CAK or CDK-activating kinases are responsible for catalyzing the activating 
threonine phosphorylation.  The phosphorylation of CDKs by CAK is antagonized 
by the action of a specific phosphatase known as KAP.  Phosphorylation of CDKs 
can also negatively regulate their kinase activity[183].  The inhibitory 
phosphorylations occur near the N termini of all CDKs, specifically on Tyrosine 15 
of CDK2 and CDK1, and on Tyrosine 17 on CDK4 and CDK6.  In the case of CDK2 
and CDK1, there is also a second inhibitory phosphorylation involving Threonine 
14[186].  Phosphorylation of these sites results in inhibition of CDK activity even in 
the presence of the CAK-catalyzed activating phosphorylation.  Wee1-like protein 
kinase (WEE1) and membrane-associated tyrosine-and-threonine-specific cdc2-
inhibitory kinase (MYT1) have been identified as the kinases responsible for the 
phosphorylation of the inhibitory sites on CDK2 and CDK1[187-189].  WEE1 and 
MYT1 are bifunctional kinases that can phosphorylate both tyrosine and threonine 
residues, although WEE1 shows a preference for Tyrosine 15 and MYT1 for 
Threonine 14[187-189].  The inhibitory phosphorylations of CDKs are removed by 
the action of the CDC25 family of protein phosphatases[190].   Interestingly, the 
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CDC25 proteins are themselves substrates of CDKs-Cyclins, and their 
phosphorylation stimulates the phosphatase activity.  For example, CDK2-Cyclin 
E phosphorylates M-phase inducer phosphatase 1 (CDC25A) at the G1/S 
transition, and the activity of CDC25A is necessary for CDK2-Cyclin E activation, 
thus creating a positive feedback loop. The activity of CDC25A is high from the 
G1/S boundary to mitosis, and is required for the activation of CDK2-Cyclin A.  The 
CDC25 phosphatases also play important roles in the DNA damage-induced 
checkpoints[191-193]. 
Another important mechanism for regulating CDK-Cyclin activity is their 
interaction with inhibitory proteins.  Several CDK inhibitors have been identified 
and can be divided into two families: the INK4 family (p16, p15, p18, and p19) and 
the CIP/KIP family (p21, p27, and p57)[194-196].  The INK4 family of CDK 
inhibitors block the progression of the cell cycle in G1 by binding either CDK4 or 
CDK6 and inhibiting the action of Cyclin D[194, 195].  The CIP/KIP family of CDK 
inhibitors act more broadly and can block the activity of all CDK-Cyclin complexes 
and are characterized for their role as negative regulators of G1 phase cell cycle 
progression[197].  The expression of p21 is under the transcriptional control of the 
p53 tumor suppressor gene[198].  p21 is activated by p53 in response to DNA 
damage and is also upregulated during replicative cellular 
senescence[199].  Proliferating cell nuclear antigen (PCNA) has been found in 
p21/CDK/Cyclin complexes, suggesting a function in DNA replication or DNA 
repair[197, 199].  The expression and activation of p27 increases in response to 
transforming growth factor β (TGF-β), contributing to growth arrest[200, 201].  p27 
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appears to regulate CDK-Cyclin complexes in a manner similar to that of 
p21[202].   
 Elimination of both positively and negatively acting cell cycle effectors is 
important for orderly cell cycle progression.  The ubiquitin-mediated proteasome 
system is the main pathway employed for the degradation of cell cycle 
factors[203].  Two structurally and functionally similar complexes, the Skp-Cullin-
Fox (SCF) complex and the anaphase-promoting complex (APC), target specific 
cell cycle components for ubiquitination at discrete points in the cell 
cycle[203].  The SCF complex is employed at the end of G1, through S and into 
early G2 phase, whereas APC becomes active at the end of G2 and mediates the 
transition through mitosis[204, 205].  Both SCF and APC act as E3 ubiquitin 
ligases leading to degradation of marked complexes (Figure 1.7).   
 
CDK substrates 
 When CDKs are active, target proteins become phosphorylated on CDK 
consensus sites, resulting in changes that are physiologically relevant for cell cycle 
progression.  The most frequently studied target is the substrate of CDK4/6-Cyclin 
D, the retinoblastoma tumor suppressor gene (RB)[206].  During G1, RB becomes 
phosphorylated and this leads to disruption of the complex with the histone 
deacetylase protein (HDAC) and release of the transcription factors E2F-1 and DP-
1, which positively regulate the transcription of genes whose products are required 
for S-phase progression, including Cyclin A, Cyclin E, and CDC25[207, 
208].  During G1/S the CDK2-Cyclin E complex phosphorylates its inhibitor p27, 
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inducing its proteasome-dependent degradation[209, 210].  CDK2-Cyclin E 
phosphorylates Histone H1 and this activity may be important for chromosome 
condensation required during DNA replication[211, 212].  Histone H1 is also a 
substrate for CDK1-Cyclin B[213].  Cyclin A-dependent kinases regulate initiation 
of DNA replication by phosphorylation of DNA polymerase α primase[214].  Other 
CDK substrates include CDKs own regulators WEE1 and CDC25, and cytoskeletal 
proteins such as nuclear lamins and microtubules, which are required for correct 
mitosis[188, 190, 215].  Interestingly, CDK2 has also been shown to have a role in 
suppressing MYC-induced senescence, which suggests that inhibition of CDK2 
may have therapeutic potential in MYC-driven cancers[216].   
 
CDK2 and the DNA Damage Response 
 To further understand the functions of CDK2 in vivo, researchers generated 
Cdk2 knockout mice.  Surprisingly, these mice were viable, indicating CDK2 is not 
an essential gene in the mouse[217].  Alternatively, knockout of Cyclin A2 in mice 
leads to early embryonic lethality[218].  It was also found that CDK2 is required for 
germ cell development, as both male and female Cdk2-null mice are 
sterile.  CDK2-null MEFs proliferate but enter in a delayed fashion into S 
phase.  Ectopic expression of CDK2 in CDK2-null MEFs rescued the delayed entry 
into S phase[217].  Thus, loss of CDK2 affects the timing of S phase, suggesting 
that CDK2 is involved in regulating progression through the mitotic cell cycle.   It is 
not known why CDK2 is dispensable for cell proliferation.  Perhaps 
phosphorylation of CDK2 substrates is not essential or there are other kinases that 
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can phosphorylate essential CDK2 substrates.  Likewise, other CDKs may step in 
and substitute in the case of another non-functional CDK. 
Only recently has CDK2 catalytic activity been associated with DNA 
damage response pathways.  Two studies identified NBS1 as a CDK 
substrate[170, 219].  The authors found that NBS1 is phosphorylated by CDK2 on 
Serine 432 in human whole-cell extracts.  Mutant forms of NBS1 could not be 
modified by CDK2 and were defective in protecting cells from death due to IR-
induced DNA damage.  These studies determined that CDK2 activity has a role in 
the DNA damage response and that NBS1 is a specific target of CDK2 within the 
DNA repair machinery[170, 219].  More questions remain such as what other DNA 
repair proteins are targets of CDK phosphorylation and what aspects of the MRN-
complex function depend on CDK activity.  
 The repair of DNA DSBs is tightly regulated by the cell cycle.  In G1, the 
error-prone NHEJ is the predominant repair pathway, while in S and G2, there is 
an increase in repair of DSBs by HR which is mostly error-free[220].  However, 
there are still gaps in our knowledge about how DSBs are directed for repair by 
these two different and competing repair pathways.  In mammals, CTIP is a key 
protein responsible for cell cycle regulation of resection during HR and is regulated 
by cell-cycle specific post-translational modifications[37, 221, 222].  During G1, 
CTIP protein levels are suppressed by proteasome-mediated degradation and as 
cells enter S phase, the protein levels rise again[223].  Additionally, CTIP is a 
substrate of S phase specific CDK activity and contains two well-conserved CDK 
phosphorylation sites[35].  Researchers found that CTIP is required for repair of 
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DSBs by HR in S and G2 and that the function of CTIP in HR is dependent on 
CDK-dependent CTIP phosphorylation on Serine 327 and subsequent interaction 
with BRCA1[224-226].  Interestingly, cells expressing CTIP protein that cannot be 
phosphorylated at Serine 327 are defective in HR.  This data creates a model by 
which phosphorylation of CTIP on Serine 327 as cells enter S phase/recruitment 
of BRCA1 functions as a molecular switch to shift DSB repair from NHEJ to the 
more efficient repair pathway, HR[225].  Additionally, CTIP is phosphorylated on 
Threonine 847; this phosphorylation event is required for CTIP to localize to DSBs 
and modification of this site leads to increased genomic instability[35].  A recent 
study identified novel (lesser-conserved) CDK phosphorylation sites on CTIP and 
phosphorylation of these sites induce association of CTIP with NBS1[227].  They 
went on to show that CTIP is phosphorylated by ATM after DNA damage.  Notably, 
CDK-mediated phosphorylation of CTIP is required for CTIP to be phosphorylated 
by ATM after DNA damage, which is important for end resection and HR by 
promoting recruitment of BLM and EXO1 to DSBs[227].    
 It is known that MRE11, of the MRN complex, provides nuclease activities 
required for initiation of resection during HR[163].  Interaction of MRN with both 
CTIP and BRCA1 assist in these functions[226].  CTIP interaction is required to 
enhance MRE11 nuclease activity, and for efficient resection in vivo, CTIP must 
interact with BRCA1.  Thus the formation and dissolution of the MRN-CtIP-BRCA1 
complex during S and G2 regulates resection capacity[35].  Our lab further 
investigated the relationship between CTIP and the MRN complex.  Buis et al. 
discovered that the C-terminus of MRE11 (which is absent in an inherited patient 
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allele causing ATLD) controls the phosphorylation status and overall levels of CTIP 
protein, and through this process, controls formation of the MRN-CtIP-BRCA1 
complex during S and G2[140].  Furthermore, the C-terminus of MRE11 directly 
interacts with CDK2 bound to Cyclin A.  This data supports the hypothesis that the 
MRE11-CDK2 interaction facilitates the phosphorylation of CTIP in normally 
dividing cells[140].   It will be important in future studies to understand how the 
interaction between CDK2 and the MRE11 C-terminus might activate CDK2 
substrates other than CTIP.  My work in Chapter III elucidates functions of this 
interaction during the DNA damage response.   
 Finally, CDK2-Cyclin A has been found to have roles in regulating V(D)J 
recombination[228].  The generation of lymphocyte-specific antigen receptors by 
V(D)J recombination is controlled by levels of RAG2 protein, which accumulates 
in G1 phase of the cell cycle, but is rapidly degraded at the G1-S transition, 
continuing until the next entry to G1[229].  This ensures that the DSBs generated 
by RAG2 can be repaired correctly by NHEJ, which is active during G1, and thus 
prevents genomic instability.  A recent report showed that CDK2-Cyclin A opposes 
RAG2 accumulation (conversely, RAG2 is induced by p27 and other CDK 
inhibitors)[228].  More specifically, they found that Threonine 490 on RAG2 is an 
essential CDK phosphorylation site, and its mutation abolishes degradation of 
RAG2 protein[228].  In thymocytes of mice expressing a mutation in RAG2 
Threonine 490, aberrant recombination events accumulate.  These observations 
suggest that restriction of RAG2 accumulation to the G0 and G1 cell cycle phases 
promote correct repair of V(D)J recombination intermediates by NHEJ[228].  The 
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cell cycle dependence of V(D)J recombination suggests it may be interesting in 
future studies to determine how genetic disruption of the MRE11-CDK2 interaction 
alters lymphogenesis and V(D)J recombination in mice.   
 
The cell cycle checkpoints 
 
Overview of cell cycle checkpoints 
DNA damage checkpoints are biochemical pathways that delay or arrest 
cell cycle progression in response to DNA damage[92].  Originally, a checkpoint 
was defined as a specific point in the cell cycle when the integrity of DNA was 
examined or checked before allowing progression through the cell cycle.  More 
recently, checkpoint responses have become more clearly defined as constant 
surveillance and response systems that continuously monitor the integrity of the 
genome and control cell-cycle progression[92].  DNA damage checkpoints are 
positioned before the cell enters S phase (G1-S checkpoint), during S phase (intra-
S-phase checkpoint), and after DNA replication (G2-M checkpoint).  The DNA 
damage checkpoints have three components: sensors, signal transducers, and 
effectors[230, 231].  Although the G1/S, intra-S, and the G2/M checkpoints are 
distinct, the damage sensor molecules that activate the various checkpoints 
appear to either be shared by all three pathways or to play a primary sensor role 
in one pathway and a backup in the others[69, 231, 232] (Figure 1.8).  My thesis 
is focused on understanding the role of the MRN complex in the intra-s-phase 
checkpoint, described in the next few sections.  
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DNA replication in S-phase 
 DNA replication or DNA synthesis is the process of producing two identical 
copies of DNA from one original DNA molecule and occurs in the S phase of the 
cell cycle[233].  The process of replication is highly conserved across evolution.  
Accurate replication of the genome ensures the transmission of genetic material 
from parental cells to daughter cells and is critical for the survival all organisms.  
DNA is made up of a double helix structure consisting of two complementary 
strands, which are separated during the replication process[234].  Each strand 
serves as a template for the production of its counterpart, a process which is known 
as semi-conservative replication[233].   
DNA replication begins at specific locations in the cell called origins of 
replication[235].  First, assembly of the pre-replication complex occurs during late 
M phase and early G1 when CDK activity is low, thus ensuring that DNA replication 
occurs only once per cell cycle[235].  In eukaryotes, the origin recognition complex 
(ORC), which includes cell division cycle 6 (CDC6) and DNA replication factor 
CDT1 (CDT1), recognize the origins of replication and load the mini-chromosome 
maintenance (MCM2-7) helicase onto the origin, forming the pre-replication 
complex[236-238].  MCM2-7 is phosphorylated by cell division cycle 7-relted 
protein kinase (CDC7) and various CDKs, which displaces CDC6 and recruits 
MCM10[237].  Next, the factors DNA replication complex GINS protein PSF1 
(GINS) and cell division control protein 45 homolog (CDC45) are recruited to the 
origin[236].  CDC45 then recruits key components of the replisome, including the 
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replicative DNA polymerase α and its primase[239, 240].  At this point, DNA 
replication can now begin. 
First, the two strands of the DNA double helix are separated by the MCM 
helicase.  Unwinding of the DNA at the origin and synthesis of new strands results 
in the formation of replication forks, which form bi-directionally from the origin[241].  
Once the two strands are separated, primase adds RNA primers to the template 
strands[242].  DNA polymerase synthesizes the new strands in a 5’ to 3’ direction 
by adding nucleotides that complement each template strand[240].  The leading 
strand is continuously extended by the DNA polymerase with high pocessivity, 
while the lagging strand is extended discontinuously from each primer, which forms 
Okazaki fragments[243].  Next, RNase removes the primer RNA fragments.  DNA 
Ligase then fills in a single nick on the leading strand and several nicks on the 
lagging strand[244].   This completes the formation of a newly replicated DNA 
molecule.   
 
The intra-S-phase checkpoint 
 The intra-s-phase checkpoint is activated to delay progression through S-
phase allowing time for DNA repair to occur and to prevent genomic 
instability[245].  There are in fact several types of intra-s-phase checkpoints.  The 
first is activated by DNA DSBs in genomic loci outside of active replicons.  Thus, 
the DSB-induced intra-s-phase checkpoint acts independently of replication 
forks.  The other intra-s-phase checkpoints include the replication-dependent intra-
s-phase checkpoint (or replication checkpoint), and the S-M checkpoint, which 
both respond to problems with replication[245].  To clarify, my thesis research is 
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focused on the DSB-induced intra-s-phase checkpoint (herein called “the intra-s-
phase checkpoint”).  Previous studies reported two parallel branches of the intra-
s-phase checkpoint that slow down ongoing DNA synthesis in S-phase[191, 
192].  The first is controlled by the ATM signaling machinery, which controls CHK2-
mediated degradation of CDC25A (Figure 1.9A-B).  Inhibition of CDK2 activity 
downstream of this pathway blocks loading of CDC45 onto chromatin.  CDC45 is 
a protein required for the recruitment of DNA polymerase α into the assembled 
pre-replicons, so the inhibition of CDK2 activity prevents the initiation of new origin 
firing[191, 192].  Another branch of the intra-s-phase checkpoint involves ATM-
mediated phosphorylation of NBS1 and SMC1[246].  Mutations of ATM 
phosphorylation sites on NBS1 (Serine 343) and SMC1 (Serines 957 and 966) 
result in S-phase checkpoint defects[246].  This data highlights that understanding 
the functional relationships between ATM and the MRN complex can provide 
further insight into the mechanisms that regulate abnormal ionizing radiation 
responses.  Importantly, it is possible that there are several mechanisms or 
pathways that induce the s-phase checkpoint.  My thesis was aimed at elucidating 
how the MRN complex, through interaction with CDK2, functions in S-phase 
checkpoint control and suggests a new model for induction of an S-phase 
checkpoint through functions of the MRE11 C-terminus. 
 
Radioresistant DNA Synthesis 
Defects in the intra-s-phase checkpoint result in the inability of cells to 
reduce their rate of replication after IR[247].  This phenomenon, known as 
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radioresistant DNA synthesis, was first reported in cells derived from patients with 
ataxia-telangiectasia who have mutations in the ATM gene[248].  The RDS 
phenotype has also been reported in cells with defects in other components of the 
checkpoint, including ATM, ATR, CHK2, CHK1, CDC25A, NBS1, MRE11, SMC1, 
MDC1, 53BP1, and BRCA1 and BRCA2[64, 191, 192, 249-254].  The assay for 
measuring RDS has become a “gold standard” to test whether or not any new 
candidate protein is required for the intra-s-phase checkpoint[247].  In this assay, 
the rate of replication is measured by incorporation of radioactively labeled 
thymidine, followed by a quantification method such as liquid scintillation or 
autoradiography[230, 232].  Currently, DNA synthesis rate measurements have 
remained an attractive first-line diagnostic tool for patients with A-T.    
 
DNA repair and the cell cycle as targets in cancer therapy 
Cancer is a disease of genomic instability and uncontrolled cell division[1, 
2].  Thus, targeting DNA repair mechanisms and the cell cycle components are 
likely promising avenues for cancer therapy (Figure 1.10).  Deregulation of both 
CDKs/Cyclins and DNA repair genes occur frequently in certain types of cancer.  
As examples, Cyclin E1 or E2 amplifications are key oncogenic events in uterine 
and ovarian cancers[255, 256].   The CDK inhibitor p27 is downregulated in many 
cancers, although the genetic loss of p27 is fairly rare[257, 258].  Xeroderma 
pigmentosum and trichothiodystrophy are autosomal recessive disorders caused 
by defects in nucleotide excision repair[259].  The disease Fanconi Anemia (FA), 
which leads to bone marrow failure, is caused by defects in the FA proteins which 
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are responsible for repairing DNA intra- and inter-strand crosslinks[260].  Finally, 
both BRCA1 and BRCA2, which are involved in the HR repair pathway, are found 
in approximately 5-7% of hereditary breast cancers[261].  
Translating all this knowledge into successful clinical development of CDK 
and DNA repair inhibitors has been challenging.  The first generation of CDK 
inhibitors developed were relatively nonspecific and are often referred to as pan-
CDK inhibitors (i.e. Roscovitine developed by Cyclacel)[262].  A second-
generation class of CDK inhibitors was next developed with the aim of increasing 
selectivity for CDK1 and CDK2 and increasing potency.  Many seemed to be 
promising in preclinical trials, but only a few progressed past Phase 1 clinical 
trials[202].    
In recent years, the focus has transitioned to targeting CDK4 and CDK6, 
specifically.  The actions of CDK4/6 through phosphorylation of RB control the 
transition from G1 to S phase[206].  The rationale for targeting CDKs 4 and 6 is 
that these inhibitors would elicit G0/G1 arrest, act directly on RB to suppress gene 
expression and proliferation, and would be actionable in tumors that exhibit 
deregulation of CDK4 and CDK6 activity as opposed to other CDKs[263].  Three 
CDK4/6 inhibitors, abemaciclib, palbociclib, and ribociclib, have reached early 
phase clinical trials.   Results from Phase III trials investigating palbociclib in 
patients with advanced-stage estrogen receptor (ER)-positive breast cancer have 
demonstrated substantial improvement in progression-free survival[264].   
Radiation therapy continues to be a main treatment in a variety of cancers.  
Exposure of tumors to ionizing radiation causes DSBs, which are deleterious to 
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cell survival.  Chemotherapy is also a popular treatment which is used to stop or 
slow the growth of cancer cells.  However, chemotherapy is a systemic therapy 
that affects the entire body.    Thus, new treatments are needed to avoid the harsh 
side effects of both radiation and chemotherapy.  Perhaps the most promising DNA 
repair therapy is that of poly(ADP-ribose) polymerases (PARP) inhibitors, which 
are used in a therapeutic strategy termed “synthetic lethality”[265].  PARPs are a 
family of nuclear proteins that function in DNA damage recognition.  PARP1 has 
been shown to either directly or indirectly influence the repair of DNA in multiple 
pathways, including base-excision repair (BER), single-stranded break (SSB) 
repair, and alternative-NHEJ[266].  The PARP1 inhibitor known as Olaparib 
(AstraZeneca) suppresses SSB and BER repair pathways, thus causing PARP to 
be trapped onto SSBs, resulting in replication fork-stalling, fork collapse, and 
DSBs[267, 268].  In normal cells, these breaks would be repaired by the mostly 
error-free HR pathway.  However, in tumor cells mutant for either BRCA1 or 
BRCA2, which are crucial for repair by HR, the breaks are instead repaired by 
error-prone pathways, causing catastrophic damage and cell death[266-268].  
Olaparib is currently FDA approved for treatment in recurrent ovarian cancer and 
germline-BRCA, HER2-negative metastatic breast cancer[269].    
Challenges remain, including development of highly selective molecules 
against other CDKs and DNA repair factors, understanding mechanisms of drug-
resistance to these inhibitors, determining appropriate patient populations, and 
gaining a better understanding of both the pharmacology and biology that will 
assist in development of useful drug combinations.   
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Thesis Summary 
 The specific aims of my thesis were to further uncover how MRN functions 
in DNA damage kinase activation, cell cycle checkpoint control, and tumorigenesis.  
In Chapter II, I set out to gain a deeper understanding of the interplay between the 
two main DNA damage kinase sensors, MRN and the KU heterodimer, along with 
their respective kinases, ATM and DNA-PKcs.  We hypothesized that loss of both 
DNA DSB sensors would prevent DNA damage response signaling.  To test our 
hypothesis, we utilized mouse models in our lab that are deficient for MRN, KU, or 
both.  To our surprise, we found that loss of both MRN and KU still allowed for 
ATM signaling, implying that MRN is not absolutely required for activation of ATM.  
In Chapter III, I worked to uncover the biological functions of the interaction 
between the DNA repair protein MRE11 and the cell cycle kinase CDK2.  We 
hypothesized that the MRE11-CDK2 interaction is a component of the intra-s-
phase checkpoint.  To test our hypothesis, we utilized mutants genetically lacking 
the MRE11-CDK2 interaction in our experiments.  Interestingly, we found that the 
MRE11 C-terminus is important for maintaining normal levels of CDK2 activity.  In 
Chapter IV, we aimed to uncover roles for the MRN complex in oncogenesis.  We 
hypothesized that mice lacking the MRN complex or MRE11 nuclease activity in B 
cells would development B-cell specific tumors.  To test our hypothesis, we 
generated mice lacking MRE11 or MRE11 nuclease activity in B-lymphocytes and 
monitored them for tumor development.  We found that, contrary to our hypothesis, 
the mice did not develop pro-B lymphomas, implying that MRN is not a classic 
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tumor suppressor, and that certain functions of the complex, such as the nuclease 
activity of MRE11, may be required for progression to cancer.    
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Chapter II 
 
 
 
Recruitment and Activation of the ATM Kinase in the Absence of 
 DNA-Damage Sensors* 
 
 
 
Abstract 
DNA double-strand breaks (DSBs) are among the most toxic forms of DNA 
damage, and if left unrepaired, are potent causes of genome instability.  The DNA 
damage response is a complex network of signaling events that initiates cellular 
responses important for the repair of DNA damage.  There are two main kinases 
that control rapid responses to DNA double-strand breaks: ataxia-telangiectasia 
mutated kinase (ATM) and DNA-dependent protein kinase, catalytic subunit (DNA-
PKcs).  Previous knowledge in the field has shown that ATM is recruited and 
activated by the MRE11-RAD50-NBS1 (MRN) sensor complex at DNA DSBs.  
Likewise, DNA-PKcs is recruited and activated by the sensor KU70/KU80 
heterodimer complex at DSBs.  Although much is known about how MRN and KU 
                                                          
* Contents of this chapter have been published in the following paper and have been modified for this thesis: 
Andrea J. Hartlerode, Mary J. Morgan, Yipin Wu, Jeffrey Buis, and David O. Ferguson. Recruitment and 
Activation of the ATM kinase in the absence of DNA-damage sensors.  Nature Structural and Molecular 
Biology, (2015). 
MJM contributed to Figures 2.2-2.6 
AJH contributed to Figures 2.1-2.2, and 2.6 
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along with their respective kinases function in isolation, it is unclear how they might 
influence each other at DSBs during the DNA damage response.  
 To gain further insight into the interplay between the two main DNA 
damage sensor complexes, our lab generated mouse cells containing targeted 
mutant alleles of Mre11 and/or Ku70 and used pharmacologic kinase inhibition of 
ATM and DNA-PKcs on the cells in in vitro experiments.  Interestingly, we found 
that ATM can be activated by DSBs in the absence of MRN.  When MRN is 
deficient, DNA-PKcs efficiently substitutes for ATM in facilitating local chromatin 
responses.  In the absence of both MRN and KU, ATM is still recruited to chromatin 
where it phosphorylates H2AX and triggers the G2-M cell-cycle checkpoint, 
although the DNA-repair functions of MRN are not restored.  These results suggest 
that, in contrast to straightforward recruitment and activation by MRN and KU, the 
interchange between the two DNA damage sensors and their respective kinases 
is more complicated than previously thought.  We also show that MRN is not 
absolutely required for recruitment and activation of ATM.   
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Introduction 
DNA DSBs are highly toxic forms of DNA damage.  In eukaryotes, there are 
two major DNA DSB repair pathways: homologous recombination (HR) and non-
homologous end-joining (NHEJ).  Before DNA repair can occur, sensor proteins 
must detect the damage and initiate the DNA damage response (DDR), a complex 
network of signaling events that lead to initiation of cellular processes including 
DNA repair, cell cycle checkpoints, and in some cases, apoptosis or senescence.   
The failure to repair DNA DSBs can be detrimental to cells and organisms alike, 
leading to carcinogenesis as well as DNA repair disorders with an array of clinical 
manifestations such as sensitivity to radiation, suppression of the immune system, 
a predisposition to cancer, and neurodegeneration[1].   
 At the apex of the DNA damage response are the two major, highly 
conserved DNA-damage sensor complexes, MRN and KU[2, 3].  MRN and KU are 
both thought to recruit and activate kinases that are members of the 
phosphatidylinositol 3-kinase-related kinase (PIKK) family of serine/threonine 
kinases: ATM and DNA-PKcs, respectively[4, 5].  Although there is much known 
about how both MRN and KU function on their own to recruit and activate ATM 
and DNA-PKcs, there is still a great deal to learn about how they may interact with 
each other during the DNA damage response (Figure 2.1A).  Furthermore, it is 
unclear why in most metazoans two separate kinases are needed in the DNA 
damage response and how activation of either kinase is accomplished in the 
context of apparently redundant sensors.   
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The ATM kinase functions at the top of the DSB signaling cascade and has 
a vast number of substrates that coordinate many cellular outcomes.  Inherited 
mutations in ATM cause the disease ataxia-telangiectasia (A-T), patients of which 
present with a predisposition to cancer, immunodeficiency, and neurological 
degeneration[6].  The previous understanding of ATM activation was that MRN is 
absolutely required for DSB sensing and binding, and recruitment and activation 
of ATM[7-9].  Roles for MRN in the activation of ATM are supported by studies 
showing: 1) mutations in MRN result in human diseases with A-T like features, 2) 
there is defective activation of ATM observed in MRN-mutant and deficient cells, 
and 3) there is enhanced ATM kinase activity observed in the presence of MRN in 
vitro[6, 8, 10-12].     
 The KU70/KU80 heterodimer complex also binds DSBs, and activates the 
DNA-PKcs kinase[13].  Together, KU and DNA-PKcs make up the DNA-PK 
holoenzyme[13].  KU is a very abundant cellular protein and exhibits high affinity 
for DNA DSBs[14].  Unlike ATM and its many functions, the primary role of DNA-
PK is direct participation in DSB repair in the NHEJ pathway[15].  Mice deficient in 
DNA-PKcs, and those lacking Ku70 or Ku80, are immune-deficient and have 
defective V(D)J recombination, which requires NHEJ[16, 17]. 
The cellular responses to DSBs are sophisticated and involve many 
proteins that must be tightly regulated to generate the necessary outcome.  A 
deeper understanding of these processes is important for uncovering the 
pathogenic mechanisms of cancer and for the designing of successful cancer 
treatments.  However, answering these questions will be a difficult challenge.  To 
 72 
 
gain mechanistic insight into the earliest events in the mammalian DSB response, 
we examined cells lacking one or both DSB-sensing complexes and treated them 
with inhibitors for one or both PIKK DSB kinases.  We found cells with normal 
levels of MRN are dependent on ATM for facilitating chromatin responses after 
ionizing radiation-induced damage.  In cells that lack MRN, DNA-PKcs efficiently 
substitutes for ATM.  Most intriguingly, we discovered that removal of KU in the 
absence of the MRN complex restores several ATM-dependent responses, 
demonstrating that MRN is not absolutely required for recruitment and activation 
of ATM.   
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Results 
Generation of MRN-deficient and MRN/KU-deficient cells 
We disabled the MRN complex through use of mouse embryonic fibroblasts 
(MEFs) that originally contained one Mre11-null allele and one conditional allele.  
Exposure to Cre recombinase via adenovirus converts these cells to Mre11−/−, 
which also causes deficiency of RAD50 and NBS1 (termed MRN deficiency) most 
likely because of instability of the proteins in the absence of MRE11 
(Figure2.1B)[10].  Control cells used for experiments were initially Mre11Cond/+, 
which we converted to Mre11−/+ via Cre recombinase in parallel with other 
genotypes to control for effects of addition of Cre adenovirus.  Through mouse 
breeding, Andrea Hartlerode, a senior investigator in the lab, also generated MEFs 
of these MRN genotypes combined with germline knockout of Ku70 (Ku70−/−).  
Removal of Ku70 does not require use of a conditional allele, and it causes 
deficiency of its heterodimeric partner Ku80 (termed Ku-deficiency), as previously 
described (Figure 2.1C)[17]. 
 
Early recruitment of MRN complex and KU to DNA damage 
To better understand the multifaceted interplay between the DNA damage 
sensor complexes in the immediate aftermath of DSB induction, we utilized live-
cell imaging coupled with microirradiation to examine the localization of both MRN 
and KU to sites of DNA damage.  Andrea Hartlerode and I performed these 
experiments together.  We first transfected GFP-tagged human NBS1 into MEF 
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cells to track MRN recruitment to laser-induced damage in real-time.  MRN was 
recruited within 15 to 30 seconds after damage, and KU deficiency did not appear 
to affect its recruitment (Figure 2.2A).  To track KU, we transfected GFP-tagged 
KU70 and KU80 and found that KU recruitment was faster than laser stripes could 
be generated.  Instead of taking time-lapse images, we pulsed the laser at a single 
location while simultaneously recording video.  We detected KU at damage sites 
within 1 second after damage, and it continued to accumulate for approximately 
10 seconds in most cells.  Loss of the MRN complex did not appear to affect KU 
recruitment (Figure 2.2B).  Therefore, immediately after DNA damage, the 
absence of either sensor does not substantially affect overall accumulation of the 
other. 
 
Localization of KU to DSBs in the absence of the MRN complex 
 To gain a deeper understanding of KU localization to sites of DSBs in the 
absence of MRE11 at later timepoints following DSB induction, I examined KU foci 
formation in both control and MRE11-deficient cells on a time-course of 5 minutes 
to 2 hours after ionizing radiation treatment (Figure 2.3A).  We hypothesized that 
KU might localize at DSBs longer or faster, or otherwise may be more abundant in 
MRE11-deficient cells versus control cells.   Even though KU is an abundant 
protein and a major DSB sensor in mammalian cells, it has been nearly impossible, 
in the past, to visualize it at single DSB sites in cells by fluorescence microscopy.  
Stephen Jackson’s group showed in 2013 that this inability to detect KU and other 
DNA repair proteins at DNA ends arises because a large portion of these proteins 
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are associated with chromatin via RNA.  Thus, the group developed a new 
technique which combines RNAse A and detergent-based pre-extraction with high-
resolution microscopy, allowing for detection of KU at DSBs in cells[18].  In my 
hands, KU70 foci were too small to count, and so I utilized ImageJ to quantify the 
fluorescent intensity of nuclei as a measure of KU70 foci formation at DSBs (Figure 
2.3B).     
My results showed minimal KU70 foci formation in the absence of DNA 
damage in both control and MRE11-deficient cells.  Cells lacking the MRN complex 
displayed a higher baseline of KU70 fluorescent intensity, which could be reflective 
of an increased number of spontaneous DSBs when MRN is absent.  When DNA 
damage is induced via ionizing radiation, KU70 is rapidly recruited to DSBs (within 
5 minutes) in both control and MRE11-deficient cells.  Interestingly, both control 
and Mre11-/- cells reached the same maximal peak of KU70 foci formation at 5 
minutes post-ionizing radiation.  KU70 foci formation began to decrease at 30 
minutes and plateaued out to two hours following ionizing radiation treatment in 
both cells lines.  Interestingly, KU70 mean fluorescent intensity returned to its 
baseline after 5 minutes post-ionizing radiation in Mre11-/- cells, but remained 
increased relative to control cells.  I examined KU70 foci formation in Ku70-/- cells 
as control for antibody specificity, and as expected, these cells formed no KU70 
foci.    
My results did not support our hypothesis that in the absence of the MRN 
complex, KU70 is recruited faster or more abundantly to DSBs, which would 
suggest an antagonistic model of interplay between the two DSB sensor proteins.  
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Possible explanations may be that I missed the maximal peak of KU70 foci 
formation in Mre11-/- cells or spontaneous DSBs mask the true baseline of KU70 
foci formation in MRE11-deficient cells.  Overall, my data show that the absence 
of MRE11 does not appear to affect accumulation of KU70 foci formation at DSBs 
after DNA damage induction.   
 
Phosphorylation of H2AX in the absence of DNA damage sensors 
 To further understand ATM recruitment in the absence of DSB sensors, I 
investigated one of the earliest events in the DSB response, which is 
phosphorylation of the histone variant H2AX (also known as γH2AX)[19, 20].  
Phosphorylation of H2AX occurs upon DNA DSB formation, as well as in response 
to replication stress, and is dependent on ATM.  Depending on cell type, H2AX is 
phosphorylated for megabase regions surrounding each side of a DSB and serves 
as a platform for more extensive chromatin changes, such as recruitment of DNA 
repair proteins to the chromatin, that are required to spread DNA-damage 
responses[21, 22].  Phosphorylated H2AX forms nuclear foci at sites of DNA 
DSBs, which can be visualized as punctate dots, using immunofluorescent 
microscopy.  Therefore, I set out to observe γH2AX foci formation in MRE11 and 
KU mutant MEFs, treated with irradiation to induce DSBs and with different 
combinations of PIKK kinase inhibitors.  
In each genotype, most cells (65-80%) contained ten or more γH2AX foci, 
and the morphologies of these foci were all similar (Figure2.4A).  In control cells, 
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the ATM inhibitor markedly decreased γH2AX foci formation, whereas DNA-PKcs 
inhibition had little effect on foci formation.  In contrast, I saw the opposite pattern 
in MRN-deficient cells, where the DNA-PKcs inhibitor reduced γH2AX foci 
formation to near-background levels.  These results are consistent with models in 
the literature depicting a requirement for MRN in ATM recruitment/activation under 
normal conditions, and it also demonstrates that DNA-PKcs can efficiently 
substitute for ATM in phosphorylating H2AX when MRN is absent[8, 9].  
Surprisingly, in Mre11-/-Ku70-/- cells, I observed substantial levels of γH2AX after 
ionizing radiation treatment and this phosphorylation event returned to being ATM-
dependent.  Thus, ATM is activated in the absence of both MRN and KU and is 
recruited to chromatin in the vicinity of DSBs to phosphorylate H2AX.  This data is 
consistent with western blot analysis done by Andrea Hartlerode comparing levels 
of phosphorylated H2AX (data not shown).  Quantitation of γH2AX 
immunofluorescent foci 30 minutes before and after ionizing radiation treatment 
was graphed from 3 independent experiments (Figure 2.4B).  
 
53BP1 localization to DSBs in the absence of DNA damage sensors 
To determine whether this sensor-independent ATM activity is restricted to 
H2AX phosphorylation, we examined other DNA damage response events.  
Additional ATM-dependent events such as phosphorylation of KAP1 and SMC1 
were also restored in Mre11-/-Ku70-/- cells (data not shown).  As with H2AX 
phosphorylation, the degree of phosphorylation was less than in control cells, but 
was fully ATM-dependent.  H2AX phosphorylation can also lead to recruitment of 
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p53-binding protein (53BP1), which, in turn, is important for recruiting other repair 
factors.  53BP1 is a key regulator of DSB repair pathway choice[23].  During G1 it 
promotes NHEJ mediated repair by antagonizing long-range DNA end resection 
which is essential for HR.  Interestingly, 53BP1 can still form foci in H2ax-/- cells 
and it has several pathways of recruitment to DSBs, all of which are not entirely 
dependent on ATM[23].  Thus, I examined the formation of 53BP1 foci in MRE11 
and KU70 mutant cells along with pharmacologic kinase inhibition after ionizing 
radiation treatment (Figure 2.5A).  Not surprisingly, I found that only a portion of 
53BP1 foci formation was dependent on the DNA damage kinases.  The graph 
shows quantitation of 53BP1 foci 30 minutes before and after ionizing radiation 
treatment from 3 independent experiments (Figure 2.5B).   
 
Rapid MDC1 recruitment in the absence of MRN and KU 
 After H2AX is phosphorylated, it is bound by the protein called mediator of 
DNA damage checkpoint 1 (MDC1)[24, 25].  MDC1 then promotes recruitment of 
DNA damage response and checkpoint proteins to the chromatin surrounding 
DSBs, ultimately leading to initiation of the G2-M checkpoint[26].  To gain further 
insight into the newly discovered MRN-independent ATM activation, Andrea 
Hartlerode and I examined GFP-tagged MDC1 recruitment with live-cell imaging 
after laser microirradiation[27].  This approach allows for visualization of 
recruitment within seconds to minutes after damage, which is much faster than 
timescales permitted with immunofluorescence-based experiments.  Thus, ATM 
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activation can be compared within the earliest timeframe of the DNA damage 
response.  
 In control cells, we found that MDC1 recruitment occurred by 15 seconds 
and this recruitment was dependent on ATM[24].  When MRN was deficient, MDC1 
accumulated as rapidly and intensely as control cells, but this recruitment switched 
to being dependent on DNA-PKcs.  Thus, even during the rapid events that occur 
immediately after DNA damage, DNA-PKcs can locally substitute for ATM when 
MRN is not there.  Mre11-/-Ku-/- cells exhibited recruitment of MDC1 similar to 
control cells, and this was, strikingly, ATM-dependent (Figure 2.6).  Therefore, 
even within the first minute of the DSB response, ATM can function in the absence 
of both DNA damage sensor complexes.  
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Discussion 
 We have shown in this study that when MRN is absent, removal of KU 
restores several ATM functions, including its ability to phosphorylate H2AX.  Other 
functions restored include ATM’s ability to relocate to chromatin and to activate the 
G2-M checkpoint (data not shown).  However, DNA-repair functions of MRN were 
not restored in the absence of KU (data not shown).  These findings indicate that 
MRN is not absolutely required for recruitment and activation of ATM, but perhaps 
instead it functions to maximize or sustain ATM-dependent DSB responses.  
Unlike a simple recruitment model previously believed in the field, activation of 
ATM appears to be strongly influenced by the complex interplay between MRN 
and KU occurring within seconds after DNA damage. 
 Studies in the past have shown that KU and MRN can compete for binding 
to DSBs in vitro and that KU must be removed from DNA ends to allow for HR to 
occur[28-30].  Together, these results suggest some level of competition between 
MRN and KU, however, our live-cell imaging studies suggest otherwise.   We show 
that both sensors bind DSBs rapidly, with KU binding first and MRN joining shortly 
after.  Neither complex appears to require the other for recruitment to DSBs.  
Importantly, the absence of one sensor does not measurably affect the recruitment 
of the other, even within the earliest time-points after DNA damage induction.  
These observations lead us to speculate that there is a level of opposition in the 
functions of MRN and Ku at DNA ends that does not just involve simple competition 
for initial binding. 
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 We also uncovered several instances of evidence that support the notion 
that MRN, although it is not absolutely essential for initial ATM activation, 
maximizes and sustains ATM-dependent responses.  Phosphorylation of ATM 
substrates KAP1 and SMC1 in MRN- and KU-deficient cells was not as robust as 
in control cells (data not shown).  Live-cell imaging of γH2AX-dependent MDC1 
recruitment demonstrated that MDC1 was rapidly recruited to sites of laser-
induced damage in cells of all the genotypes examined, but this recruitment was 
slightly decreased in MRN- and KU-deficient cells 15 seconds after damage.  This 
level of recruitment is near the limit of detection of the instrument used for this 
study, and thus interpretations must be considered with care.  Overall, western blot 
analysis of ATM substrates that measure responses over longer times suggested 
a more substantial delay than seen in the live-cell imaging, but still point to the 
conclusion that MRN works to maximize/sustain ATM functions. 
 For MRN to perform its ATM-dependent functions, it must be capable of 
overcoming the more rapid binding of KU, which protects the ends of DNA[28-30].  
The two KU subunits form a basket-shaped structure that threads onto DNA ends.  
Once bound, KU can slide down the DNA strand, allowing for more KU molecules 
to thread onto the end.  One hypothesis is that MRN could eject KU from the DSB 
by converting DSBs into ssDNA ends, which are a poor substrate for KU 
binding[29, 31].  The MRN complex possesses two activities that can generate 
ssDNA: the nuclease activities of MRE11 and ATP-dependent unwinding of DNA 
by RAD50[32].  While our studies point to the latter possibility over the first, future 
studies will need to investigate both questions (Figure 2.7).   
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The newly uncovered MRN-independent activation of ATM presented in this 
study represents a notable advance in our understanding of the early DSB 
response.  The ability of ATM to function in the absence of MRN helps to explain 
studies in mice that lack the critical ATM-interacting domain of Nbs1, which display 
astonishingly minimal AT-like phenotypes[33, 34].  The strong requirement for 
MRN only in the presence of KU suggests that a key function for MRN in ATM 
activation is to oppose KU at DSBs to expose DNA ends.  This idea is supported 
by previous in vitro studies, including one from Xenopus egg extracts that showed 
that ATM can be activated in the absence of MRN, but only when relatively higher 
levels of DNA ends were added[35-37].  Further studies will be needed to 
determine whether another unknown protein is required for recruitment and 
activation of ATM or to see if ATM is simply activated by the presence of DNA ends 
in vivo.    
The disease known as ataxia-telangiectasia-like disorder (ATLD) is caused 
by mutations in MRE11 and is phenotypically fairly similar to the disease ataxia-
telangiectasia (A-T) caused by mutations in ATM[38, 39].  ATLD is a rare disease 
characterized clinically by progressive cerebellar degeneration resulting in ataxia.  
Patient cells have defects in cell cycle checkpoints, increased sensitivity to 
radiation, and an in increase in chromosomal aberrations, all consistent with a 
defect in DNA repair[38-40].  Interestingly, our study proposes a novel way to treat 
patients with MRN deficiency.  Hypothetically, it could be possible to restore ATM 
activation in individuals with inherited MRN-deficiencies by pharmacologically 
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inhibiting KU function.  More studies will have to be conducted to test this intriguing 
hypothesis.   
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Materials and Methods 
Cell culture  
The following MEF genotypes were used in this study: Mre11+/-Ku70-/-, Mre11-/-
Ku70+/+, Mre11+/+Ku70-/-, and Mre11-/-Ku70-/-.  All MEFs were derived in house from 
day E13.5 embryos and grown in standard DMEM culture conditions.  MEFs were 
plated (5.0x105 cells) onto 10cm dishes, and 24 hours later, MEFs were infected 
with Adeno-Cre retrovirus at an MOI of 500 to delete endogenous Mre11.  MEFs 
were grown for 3 days after infection and split once before plating for experiments.  
 
Immunofluorescence microscopy 
MEF cells were plated and grown on glass cover slips in 6-well dishes, treated with 
10Gy irradiation (from a 137-cesium source), and allowed to recover for indicated 
times post-ionizing radiation.  Cells were then fixed in 3% paraformaldehyde/2% 
sucrose solution for 10 minutes at room temperature, followed by a 
permeabilization step in Triton-X-100 solution (0.5% Triton X-100; 20mM HEPES, 
pH 7.4; 50mM sodium chloride; 3mM magnesium chloride; and 300mM sucrose) 
for 3 minutes on ice.  For KU foci, the permeabilization step was coupled with a 
pre-extraction step in which 0.3mg/mL RNAse A (Roche Diagnostics) was added 
to the Triton-X-100 solution.  Fixed cells were incubated with the following 
antibodies in 5% goat serum/PBS solution for 20 minutes at 37 °C: anti-KU70 
monoclonal rabbit antibody at 1:100 (Cell Signaling, 4588s); anti-γH2AX 
monoclonal mouse at 1:1,000 (EMD Millipore, 05-636); and anti-53BP1 at 1:200 
(Novus Biologicals, NB100-904).  Cells were then incubated with goat anti-mouse 
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Alexa Fluor 488 antibody (1:800, Molecular Probes, A11001) or goat anti-rabbit 
Alexa Fluor 594 (1:800, Molecular Probes, A11012) antibody in 5% goat serum in 
PBS for 20 minutes at 37 °C. Stained coverslips were mounted with Prolong Gold 
anti-fade reagent with DAPI overnight at room temperature.   
Images were acquired using the Olympus BX61 microscope and the FISHview 
Software (Applied Spectral Imaging).  For KU70 foci, Mean Fluorescence Intensity 
was quantified using ImageJ64 software.  Nuclei were selected using the freehand 
selection tool.  Measurements were obtained for the following parameters: area, 
mean, standard deviation, mode, minimum, maximum, integrated density, median, 
and raw integrated density.  The Mean Fluorescence Intensity was obtained using 
data from the “mean” category and standard error of the mean (SEM) was then 
calculated.  Three independent experiments were conducted and analyzed for all 
foci experiments. 
 
Laser microirradiation and live-cell imaging 
MEFs were transfected with MDC1-BRCT-eGFP, KU70-GFP, KU80-GFP, or GFP-
NBS1 in glass-bottomed culture dishes (MatTek Corporation). Laser 
microirradiation damage was induced with an IX71 Microscope (Olympus) coupled 
with the MicroPoint Laser Illumination and Ablation System (Photonic 
Instruments).  Images were taken with the same microscope using CellSense 
software (Olympus) at the indicated times post-microirradiation damage.   
 
 
 93 
 
Western blotting 
Cells were harvested and lysed in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% 
C24H39O4Na, 0.1% SDS, and 50mM Tris-HCl, pH 8.0), resolved by SDS-PAGE, 
and transferred under standard conditions.  The following primary antibodies were 
used: MRE11 (Cell Signaling), RAD50 (Bethyl Laboratories), NBS1 (Novus 
Biologicals), KU70 (Cell Signaling), and TOPI (BD Biosciences).  Secondary 
antibodies for western blots were IRDye-conjugated goat anti-rabbit or anti-mouse 
(Li-Cor Biosciences).  Quantification of band intensities was performed with Li-Cor 
Odyssey 2.1 software.   
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Chapter III 
 
 
The MRE11 C-Terminus Regulates the Catalytic Activity of CDK2 in an S-
Phase Checkpoint Pathway† 
 
Abstract 
 DNA double-strand breaks (DSBs) are dangerous lesions that if not properly 
repaired lead to mutations, chromosomal aberrations, and tumorigenesis.  The 
MRE11/RAD50/NBS1 (MRN) complex, a sensor of DSBs, facilitates activation the 
ataxia-telangiectasia mutated (ATM) kinase, which in turn has roles in initiating 
DNA repair pathways, cell cycle checkpoints, and in some cases, apoptosis or 
senescence.  Hypomorphic mutations in MRE11 cause the rare disease ataxia-
telangiectasia like disorder (ATLD), which presents clinically with cerebellar 
degeneration, ataxia, and occasionally, cancer predisposition.  MRE11ATLD1 was 
the first MRE11 patient allele described and is caused by C-terminal truncation of 
the MRE11 protein.  MRE11ATLD1 patient cells have low levels of the MRN complex, 
defective ATM signaling, radio-sensitivity, and genomic instability.  Likewise, a 
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Mre11ATLD1/ATLD1 mouse model led to decreased maternal embryonic viability, ATM 
signaling defects, and chromosomal aberrations.  It is not known if the defects 
found in MRE11ATLD1 patient and Mre11ATLD1/ATLD1 mouse cells are due solely to 
low levels of the MRN complex, among other functions, or if loss of the MRE11 C-
terminus contributes.  We previously described a role for the MRE11 C-terminus 
in 2012, when our lab discovered that MRE11 interacts with cyclin dependent 
kinase 2 (CDK2).  We demonstrated that the MRE11 C-terminus is both required 
and sufficient for interaction with CDK2, and that this interaction has roles for 
homologous recombination in normally dividing cells.   
To further uncover functions of the MRE11 C-terminus, and to investigate 
roles for the MRE11-CDK2 interaction in the DNA damage response, we utilized 
MRE11-deficient, MRE11-nuclease deficient, and MRE11 C-terminal truncated 
expressing cells in experiments with DSBs induced by ionizing radiation (IR).  We 
found that IR caused dissociation of the MRE11-CDK2 interaction in an ATM-
dependent manner, as well as a reduction in activating phosphorylation of CDK2 
on Threonine 160 and in CDK2 catalytic activity.  Interestingly, genetic disruption 
of the MRE11-CDK2 interaction in MRE11-deficient and MRE11 C-terminal 
truncated expressing cells also resulted in reduced basal levels of CDK2 catalytic 
kinase activity and pCDK2Thr160 levels, mimicking IR-induced disruption of the 
interaction.  Deficiency of MRE11 nuclease activity did not affect CDK2 activity 
levels.  This data implies that MRE11, specifically its C-terminus, has roles in 
maintaining normal levels of CDK2 activity.  Interestingly, MRE11 C-terminal 
truncation did not cause defects in S-phase checkpoint functions, suggesting that 
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previously described defective S-phase checkpoint phenotypes in MRE11ATLD1 
patient and Mre11ATLD1/ATLD1 mouse cells are due to low levels of the MRN complex, 
and not due to loss of the MRE11 C-terminus alone.  Finally, we found that the 
MRE11-CDK2 interaction is not disrupted after IR in two human cancer cell lines, 
U2OS and HeLa.  From our studies, we conclude that the MRE11-CDK2 
interaction has roles in controlling CDK2 activity important for initiation of the S-
phase checkpoint, and this pathway appears to be altered in cancer cells.  Thus, 
MRE11 is a critical component of the cell cycle machinery through its interaction 
with CDK2.    
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Introduction 
 DSBs are among the most toxic forms of DNA lesions and are caused by 
exogenous sources such as chemicals, ionizing irradiation, and reactive oxygen 
species or can arise as a result of endogenous processes such as during 
replication[1].  Unrepaired DSBs lead to mutations and chromosomal aberrations 
that are essential in the transformation of normal cells into cancer cells[2, 3].  Thus, 
it is imperative that DSBs are fixed.  The two main DSB repair pathways are non-
homologous end-joining (NHEJ), a cut-and-paste method of DNA repair, and 
homologous recombination (HR), which repairs DSBs using a template sister 
chromatid[4].  Additionally, to combat the threat to the genome posed by DSBs, 
organisms have evolved complex networks of signaling pathways, termed the DNA 
Damage Response (DDR), that sense, signal, and repair DNA lesions[5].    
 MRN is a sensor protein complex important in recognizing and binding 
DSBs and is required for the recruitment and activation of the ATM kinase, the 
master regulator of the DDR[6-12].  Once activated, ATM phosphorylates a variety 
of proteins involved in DNA repair, cell cycle checkpoint control, and apoptotic 
responses, including checkpoint kinase 2 (CHK2), cellular tumor antigen p53 
(p53), breast cancer type 1 susceptibility protein (BRCA1), H2A histone family, 
member X (H2AX), structural maintenance of chromosome protein 1 (SMC1), 
ARTEMIS, and Nijmegen breakage syndrome 1 (NBS1)[13-19].  Phosphorylation 
of these and other substrates by ATM initiates cell cycle arrest at G1/S, intra-S, 
and G2/M checkpoints and promotes DNA repair.  Mutations in the ATM gene are 
responsible for the rare autosomal recessive disorder ataxia-telangiectasia (A-T), 
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which is characterized by cerebellar degeneration, immunodeficiency, and an 
increased risk of cancer[20].  Cells from individuals with A-T exhibit defects in DNA 
damage-induced checkpoint activation, radiation hypersensitivity, and an 
increased frequency of chromosomal aberrations[21]. 
 The functional relationship between ATM and MRN first became clear when 
it was discovered that patients with mutations in the MRN complex had similar 
clinical phenotypes as those found in A-T patients[22].  Loss of any of the individual 
components of the MRN complex results in embryonic lethality in mice[23-25].  
Because no known human disease alleles are null, MRN patient mutations must 
be hypomorphic to preserve functions of the MRN complex necessary for 
embryonic development.  Hypomorphic mutations in the NBS1 gene cause the 
disease Nijmegen breakage syndrome (NBS) which is characterized by cancer 
predisposition, immunodeficiency, and microcephaly, while hypomorphic 
mutations in RAD50 cause NBS-like disorder[26, 27].  Partial loss-of-function 
mutations in MRE11 cause ataxia-telangiectasia-like disorder (ATLD)[22].  
Interestingly, ATLD patient cells harbor low levels of mutant MRE11 protein, 
markedly reduced activation of ATM by DNA DSBs, and reduced ATM-dependent 
phosphorylation of downstream substrates[28, 29].  This observation supports the 
notion that MRN is required for optimal ATM activation following DNA DSB 
induction.    
Thus far, several ATLD patient alleles have been identified.  ATLD patient 
phenotypes include progressive cerebellar degeneration resulting in ataxia, 
developmental delay, and a varied predisposition to cancer[29].  MRE11ATLD1 was 
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the first reported ATLD patient allele and contains a nonsense mutation that 
truncates 76 amino acid residues from the C-terminus of MRE11[30].  MRE11ATLD1 
patient cells have low levels of the MRN complex, are radiosensitive, and have S-
phase checkpoint defects.  In 2003, mice with the Mre11ATLD1 allele (termed 
Mre11ATLD1/ATLD1) were derived to gain more insight into the in vivo functions of the 
MRN complex[31].  The mutation had a severe maternal effect on embryonic 
viability, and also resulted in low levels of the MRN complex and impaired ATM 
signaling, cell cycle checkpoint defects, and pronounced chromosomal instability 
in mouse-derived cells[31].  The mice, however, were not prone to cancer, 
suggesting that the defective cell cycle checkpoints and chromosomal instability 
were insufficient to initiate tumorigenesis[31].  While both MRE11ATLD1 patient and 
Mre11ATLD1/ATLD1 mouse cells exhibit similar phenotypes, it is unclear if these 
phenotypes are due to low levels of the MRN complex or due to loss of the MRE11 
C-terminus specifically.  
Interestingly, our lab discovered and published in 2012 that the MRE11 C-
terminus is required for interaction with CDK2, the kinase responsible for cell cycle 
progression in S-phase[32].  Binding of CDK2 with its regulatory partner, Cyclin A, 
promotes S-phase progression, the phase of the cell cycle where DNA replication 
takes place.  Problems during the replication process initiate the intra-s-phase 
checkpoint, which exists to delay progression through S-phase, allowing time for 
the DNA to be repaired before mitosis[33].  Buis et al., found that interaction of 
MRE11 with CDK2 is important for regulating homologous recombination in 
normally cycling cells[32].   
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This brought us to the question of how the MRE11-CDK2 interaction might 
function during the DDR in response to DSBs.  Taking all this knowledge together, 
we hypothesized that the MRE11 C-terminus, through interaction with CDK2, is a 
component of the intra-S-phase checkpoint.  To test our hypothesis, we utilized 
mouse embryonic fibroblast (MEF) cells in our lab harboring a conditional allele, 
which upon addition of Cre-adenovirus, confers MRE11-deficiency or MRE11-
nuclease deficiency[24].  Additionally, we generated an Mre11ATLD1-mutant 
expressing cell line from a cDNA in which endogenous MRE11 is deleted via the 
Cre/LoxP system[34].  We utilized these MRE11-deficient and MRE11 C-terminal 
truncated expressing cells as tools to study the MRE11-CDK2 interaction in vitro, 
with the addition of ionizing radiation to experimentally induce DSBs.  Through our 
studies, we have identified novel functions for the MRE11-CDK2 interaction in cell 
cycle checkpoint control in normal cells, which appears to be altered in two cancer 
cell lines.  First, we observed that IR-induced DNA damage led to disruption of the 
MRE11-CDK2 interaction in an ATM-dependent manner, as well as a reduction in 
CDK2 catalytic activity levels.   Interestingly, genetic disruption of the interaction in 
MRE11-deficient and MRE11 C-terminal truncated expressing cells also resulted 
in a reduction of CDK2 catalytic activity, mimicking IR-induced disruption of the 
interaction and this was independent of MRE11 nuclease activity.  Phosphorylation 
of CDK2 on Threonine 160, a phosphorylation event that promotes CDK2 activity, 
was decreased by both IR and by genetic disruption of the MRE11-CDK2 
interaction.  These data imply that MRE11 has roles in controlling CDK2 activity 
through its C-terminus.  Because a decrease in CDK2 activity is important for 
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stalling progression through S-phase, we hypothesize that IR-induced disruption 
of the MRE11-CDK2 interaction is a component of initiating this checkpoint 
response.  The decreased basal levels of CDK2 activity observed in the absence 
of the MRE11 C-terminus suggests that this checkpoint response is already 
activated in these cells.  Indeed, we observed slow proliferation in the MRE11 C-
terminal truncated expressing cells independent of dramatic genomic instability, a 
characteristic of MRN-deficiency.  Intriguingly, the MRE11-CDK2 interaction was 
not disrupted following IR treatment in two human cancer cells lines, U2OS and 
HeLa, implying the proposed S-phase checkpoint response initiated by disruption 
of the interaction is defective in these cancer cells.  Next, we analyzed S-phase 
checkpoint responses to IR in MRE11-deficient and MRE11 C-terminal truncated 
expressing cells.  MRE11-deficiency resulted in defects in S-phase cell cycle 
checkpoint function while MRE11 C-terminal truncation did not cause a defect, 
suggesting that previous S-phase checkpoint defects described in MRE11ATLD1 
patient and Mre11ATLD1/ATLD1 mouse cells are due to low levels of the MRN complex 
and defective ATM signaling, and do not appear to be caused by MRE11 C-
terminal truncation alone.  Taken together, our research has uncovered that 
MRE11, specifically the C-terminus, has roles in controlling CDK2 catalytic activity 
important for S-phase checkpoint function through interaction with CDK2.   
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Results 
Generation of mutant MRE11-expressing cell lines 
Past studies investigating the role of the MRN complex, specifically MRE11 
and its C-terminal domain, utilized MRE11ATLD1 patient and Mre11ATLD1/ATLD1 
mouse cells which result in not only C-terminal truncation, but also low levels of 
the entire MRN complex and defects in ATM signaling[30, 31].  These studies raise 
the question of whether phenotypes previously describing an S-phase checkpoint 
defect in patient and mouse cells are truly due to functions of the MRE11 C-
terminus or in fact to low levels of the MRN complex.  To further interrogate these 
mysteries, we utilized a mouse system previously generated in our lab in which 
mice lack MRE11 entirely, express an MRE11 nuclease-deficient allele, or express 
a cDNA for the Mre11ATLD1 mutation[24, 34]. 
To bypass the embryonic lethality conferred by MRE11-deficiency or 
defective MRE11-nuclease activity, we utilized immortalized MEFs from mice 
harboring a conditional Mre11 allele that is inactivated through Cre/LoxP-mediated 
recombination[24].  In this process, regions of the critical exon 5 of Mre11 are 
excised, resulting in MRE11 protein deletion.  Exposure of Cre-adenovirus to 
Mre11Cond/- MEFs in cell culture results in Mre11-/- cells, which also causes 
deficiency of the other components of the MRN complex (RAD50 and NBS1), most 
likely due to instability of the complex when MRE11 is absent[24].  Additionally, we 
used an allele containing a targeted single amino acid change (Mre11H129N) that 
eliminates both the endo- and exo-nuclease activities of MRE11 without disrupting 
MRN complex formation or its ability to sense DSBs and activate ATM[24].   
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To study the effects of C-terminal truncation of MRE11, we stably 
transfected Mre11Cond/- MEFs with pEF6-Mre11 constructs expressing the 
Mre11ATLD1 mutant from cDNA[34].  Clones were isolated, and cells exposed to 
cre-adenovirus in culture to delete endogenous MRE11 protein.  The clone used 
in this study was chosen because it expresses physiologic levels of the MRN 
complex[34].   
For experiments, MEF cells were split, cre-adenovirus was added, and after 
5 days in cell culture, cells were plated for experiments (Figure 3.1A).  Thus, 
genotypes used in this study are Mre11Cond/-, Mre11-/-, Mre11H129N/-, Mre11Cond/- + 
Mre11ATLD1 cDNA, and Mre11-/- + Mre11ATLD1 cDNA expressing MEFs (Figure 
3.1B).  Cdk2-/- and Atm-/- MEF cells were often used as controls in several 
experiments.  Loss of MRE11 or the MRE11 C-terminus was not found to affect 
levels of CDK2 protein.  Likewise, Cdk2-/- cells have normal levels of MRE11 
protein (Figure 3.1C).  Of note, all MEFs used in this study are SV40 large T-
antigen immortalized.    
  It is known that the MRN complex is required for recruitment and activation 
of ATM to DSBs[6-8, 12, 35, 36].  The activation of ATM is important during the 
DNA damage response as ATM phosphorylates and activates many proteins, 
which have roles in facilitating DNA repair, cell cycle checkpoints, and 
apoptosis[37].    Thus, I measured the ability of Mre11-/- and Mre11-/- + Mre11ATLD1 
cDNA expressing cells to activate ATM after DNA DSB induction by examining 
phosphorylation of the ATM substrates, KRAB [Kruppel-associated box domain]-
associated protein 1 (KAP1) and CHK2.  I induced DSBs with 10Gy ionizing 
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radiation and harvested cells 30 minutes post-treatment.  As expected, Mre11-/- 
cells exhibited defects in ATM signaling activation[24].  I confirmed that C-terminal 
truncation of MRE11 mimics controls and does not confer defects in ATM 
signaling, as previously described by our lab[34].  Phosphorylation of KAP1 looked 
similar to controls, as did phosphorylation of CHK2 (as detected by band shift after 
IR treatment) (Supplemental Figure 3.1).  Thus, any phenotypes found in the 
Mre11-/- + Mre11ATLD1 expressing cells can be attributed to C-terminal truncation of 
MRE11 and not due to low levels of the MRN complex or defects in ATM signaling.  
Additionally, I examined localization of MRE11 and CDK2 in MRE11 C-terminal 
truncated expressing cells in biochemical fractionation experiments.  Importantly, 
loss of the MRE11 C-terminus did not cause a defect in localization of MRE11 to 
chromatin as compared to its matched control.  CDK2 localization was restricted 
to the cytoplasmic and nuclear fractions in both control and Mre11-/- + Mre11ATLD1 
cDNA expressing cells (Supplemental Figure 3.2).    
 
The MRE11-CDK2 interaction is disrupted after DNA damage induced by 
ionizing radiation 
Previously, our lab discovered that the DNA repair protein MRE11 interacts 
with the cell cycle kinase CDK2 and found that this interaction is important for 
regulating homologous recombination in normally dividing cells[32].  MRE11 
interaction with CDK2 is necessary for CDK2 to phosphorylate DNA endonuclease 
RBBP8 (CTIP).  Phosphorylated CTIP can then bind BRCA1, and this tri-part 
interaction between MRN, CTIP, and BRCA1 facilitates resection in S and G2 
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phases of the cell cycle[24, 38-41].  This data shows that MRE11’s roles are not 
restricted to the DNA damage response, but that it also functions in cells under 
normal conditions through its interaction with CDK2.  
We next set out to investigate roles for the MRE11-CDK2 interaction in the 
DNA damage response.  First, we examined the interaction in immortalized 
Mre11Cond/- MEFs under normal conditions or treated with 10Gy ionizing radiation 
to induce DSBs.  Todd Festerling, a former graduate student in the lab, performed 
these initial immunoprecipitation experiments.  Cells were harvested at both early 
and late timepoints in a time-course of 15, 30, and 60 minutes after IR treatment.  
Co-immunoprecipitations were performed by immunoprecipitating CDK2 and 
blotting for the interaction with anti-MRE11 antibody.  Cyclin A antibody was used 
to confirm successful pulldown with CDK2.  The MRE11-CDK2 interaction was un-
altered at all time-points under normal conditions but was not detected post-IR 
treatment (Figure 3.2A).  Interestingly, Cyclin A still immunoprecipitated with CDK2 
after IR.  Thus, at both early and late timepoints, DNA DSBs cause the MRE11-
CDK2 interaction to dissociate in transformed MEFs.  However, DNA damage does 
not alter the interaction between CDK2 and Cyclin A.  
Next, we aimed to confirm the reciprocal co-immunoprecipitations of 
MRE11 and CDK2.  Therefore, in transformed MEFS, we immunoprecipitated 
MRE11 and blotted for CDK2.  NBS1 was blotted to confirm successful pulldown 
with MRE11.  MEF cells were either mock-treated or treated with 10Gy IR and 
harvested 30 minutes post-treatment.  As seen previously, the MRE11-CDK2 
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interaction was detected in normal cells, but not in irradiated cells, suggesting that 
DNA damage leads to disruption of this interaction (Figure 3.2B). 
Although we have confirmed this interaction is present in transformed 
MEFs, we thought it would be equally important to investigate whether the MRE11-
CDK2 interaction also exists in other cell types.  Therefore, we performed co-
immunoprecipitation experiments in primary MEFs and primary human cells.  For 
these experiments, we immunoprecipitated MRE11 and blotted for CDK2.  NBS1 
was blotted to confirm that MRE11 was indeed immunoprecipitated.  The cells 
were either mock-treated or treated with 10Gy IR and harvested 60 minutes post-
treatment.  Here, we show that the MRE11-CDK2 interaction is present in both 
primary MEFs and primary human cells under normal conditions and DNA damage 
by IR disrupts the MRE11-CDK2 interaction in both cell types (Figures 3.2C-D).  
This data implies that the MRE11-CDK2 interaction exists in several cell types and 
that disruption by IR appears to be universal in the cell types that we investigated.   
We have previously shown that the MRE11 C-terminus is required for 
interaction with CDK2[32].  To further interrogate the requirements of MRE11 
protein for its interaction with CDK2, I performed immunoprecipitations in cells 
lacking the MRN complex or the MRE11 C-terminus.  In these experiments, I 
immunoprecipitated CDK2 in either Mre11-/- or Mre11-/- + Mre11ATLD1 cDNA 
expressing MEFs compared to their matched control cell lines and blotted for 
MRE11 via western blot analysis.  CDK2 was probed to confirm successful CDK2 
pulldown.  MRE11 co-immunoprecipitated with CDK2 in Mre11Cond/- MEFs, but not 
in Mre11-/- MEFs (Supplemental Figure 3.3A).  This data demonstrates that the 
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MRE11-CDK2 interaction does not occur in MRE11-deficient cells, as expected.  
Likewise, CDK2 interacted with endogenous full-length MRE11 in Mre11Cond/- + 
Mre11ATLD1 cDNA expressing cell lines, but not with the truncated, C-terminal 
deleted version of MRE11.  There was no interaction present in Mre11-/- + 
Mre11ATLD1 cDNA expressing cells, where both endogenous MRE11 and the 
MRE11 C-terminus are deleted (Supplemental Figure 3.3B).  These data imply 
that, indeed, the MRE11 C-terminus is required for interaction with CDK2.  Thus, 
MRE11-deficiency and MRE11 C-terminal truncation genetically disrupt the 
MRE11-CDK2 interaction and can be used as tools in our studies to further 
investigate roles for the interaction during the DNA damage response. 
 Next, we were interested in further examining the requirement of the MRE11 
C-terminus for its interaction with CDK2 after ionizing radiation.  To this end, I 
transfected 293T cells with a FLAG-tagged MRE11 C-terminal construct (denoted 
C76) and an empty vector construct (EV) as a negative control.  After transient 
transfection, cells were either mock-treated or treated with 10Gy ionizing radiation 
and harvested 30 minutes after treatment.  Anti-FLAG antibody was used to detect 
expression of the MRE11 C-terminus and GAPDH was used as a loading control 
(Figure 3.2E).  I observed robust expression of C76 and no change in its 
expression after ionizing radiation treatment by western blot analysis.   
 Next, I performed co-immunoprecipitation experiments in 293T cells 
expressing EV or C76 constructs.  Cells were either mock or IR treated and 
harvested 30 minutes post-IR.  The FLAG-tagged MRE11 C-terminus was 
immunoprecipitated with anti-FLAG antibody.  Western blots were probed with 
 111 
 
either anti-FLAG antibody to confirm pulldown or anti-CDK2 antibody to examine 
co-immunoprecipitation.  As expected, I found that the FLAG-tagged MRE11 C-
terminus is sufficient to pulldown CDK2[32].  However, after IR treatment, CDK2 
no longer co-immunoprecipitated with the MRE11 C-terminus (Figure 3.2F).  This 
data implies that the MRE11 C-terminus contains the faculties necessary for 
control of the IR-dependent disruption of the MRE11-CDK2 interaction.   
 
Disruption of the MRE11-CDK2 interaction after DNA damage is ATM-
dependent 
 ATM kinase is the master regulator of the DNA damage response.  Its 
activation is important for initiating cellular responses to DSBs, including DNA 
repair, cell cycle checkpoints, transcription, and cell death[1].  Because of ATM’s 
roles in response to DSBs, we hypothesized that ATM may regulate the 
dissociation of the MRE11-CDK2 interaction after DNA damage.  To test this 
hypothesis, I co-immunoprecipitated CDK2 from control and Atm-/- MEFs and 
analyzed the interaction status by blotting for MRE11.  Cells were either mock-
treated or treated with 10Gy IR and harvested 30 minutes post-treatment.  I found 
that the MRE11-CDK2 interaction was disrupted after treatment with IR in control 
cells, but not in Atm-/- cells (Figure 3.3A). 
 Next, I analyzed the MRE11-CDK2 interaction in transformed Mre11Cond/- 
MEFs, either untreated or treated with KU-55933 (a potent and selective inhibitor 
of ATM) in response to IR (10Gy and 30-minute recovery)[42].  Cells were treated 
 112 
 
with 10µM ATM inhibitor for 1 hour before IR treatment.  CDK2 was 
immunoprecipitated from cells and western blots were probed with anti-MRE11 
antibody.  Like the co-immunoprecipitations in Atm-/- cells, I found that the MRE11-
CDK2 interaction was not disrupted when cells were treated with the ATM inhibitor 
after IR (Figure 3.3B).  Together, these results suggest that the dissociation of the 
MRE11-CDK2 interaction after DNA damage is dependent on the ATM kinase.   
 
Ionizing radiation and genetically-induced disruption of the MRE11-CDK2 
interaction cause reduction in phosphorylation of CDK2 on Threonine 160 
and in CDK2 catalytic activity  
Previous studies have reported that DNA damage induced by ionizing 
radiation causes reduction in CDK2 catalytic activity and that this reduction in 
activity is important for initiating the S-phase checkpoint, in which S-phase 
progression is halted, allowing for DNA to be repaired before the cell divides in 
mitosis[43, 44].  In fact, several S-phase checkpoint pathways have been 
described.  One pathway involves ATM-dependent phosphorylation of CHK2, 
degradation of the phosphatase CDC25A, inhibitory phosphorylation of CDK2, and 
a reduction in CDK2 activity which inhibits chromatin-associated loading of 
CDC45, a member of the pre-replication complex, thus stalling replication and 
progression of S-phase[43, 45].  Another S-phase checkpoint pathway previously 
described involves ATM-mediated phosphorylation of NBS1 and 
SMC1[46].  Mutations of ATM phosphorylation sites on NBS1 (Serine 343) and 
SMC1 (Serines 957 and 966) result in S-phase checkpoint defects[46].  It is 
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possible that other mechanisms for inducing the S-phase checkpoint through 
reduction in CDK2 activity exist.  Therefore, we hypothesized that dissociation of 
the MRE11-CDK2 interaction causes reduction in CDK2 activity after IR, implying 
that the MRE11-CDK2 interaction is a component of an S-phase checkpoint 
pathway.  To test this hypothesis, I performed an in vitro CDK2 kinase assay to 
examine the enzymatic catalytic activity of CDK2 in conjunction with 
association/dissociation of MRE11-CDK2 interaction in a time-course after IR.  In 
the kinase assay, CDK2 antibody was used to isolate CDK2 complexes which are 
subsequently incubated with histone H1 protein substrate in the presence of 
radioactive ATP.  After the termination of the kinase reaction, the amount of 
radioactively labeled substrate, which reflects the extent of kinase activity, can be 
visualized on a polyacrylamide gel and exposed to film[47].  
I simultaneously examined CDK2 activity at the same time as MRE11-CDK2 
interaction 15, 30, 60, and 120 minutes after ionizing radiation treatment (Figure 
3.4A).  CDK2 activity was highest in normal cells and this corresponded to an intact 
MRE11-CDK2 interaction.  After IR, I observed a steady decrease in CDK2 kinase 
activity and disruption of the MRE11-CDK2 interaction.  KAP1 phosphorylation was 
measured to analyze ATM activation kinetics in the cells in response to IR.  It is 
important to note that there was intermittent variability of either the interaction 
status of MRE11-CDK2 or reduction in kinase activity at 15 minutes post-IR 
treatment.  This could be due to the technical difficulty of harvesting cells at such 
an early time-point after IR.  In the figure presented here, I did not observe 
dissociation of the MRE11-CDK2 interaction until 30 minutes after IR, whereas, in 
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other experiments, we have seen dissociation as early as 15 minutes.  Thus, our 
data cannot confirm whether the MRE11-CDK2 dissociation after IR causes CDK2 
activity to decrease and to initiate the S-phase checkpoint.  Instead, our data 
implies that ionizing radiation causes a reduction of CDK2 kinase activity and 
disruption of MRE11-CDK2 interaction in cells at the same time.     
Phosphorylation of CDK2 on Threonine 160 by CDK-activating (CAK) 
kinases promotes CDK2 activity, along with binding to Cyclin A or E[48, 49].  
Jeffrey Buis, a former post-doctoral fellow in the lab, examined pCDK2Thr160 in 
control (Atm+/+) cells on a time-course of 15, 30, 60, and 240 hours after 10Gy IR 
treatment.  Phosphorylation of the histone variant H2AX (denoted as γH2AX) was 
used as a marker for activation of the DNA damage response[14].  We observed 
lower levels of pCDK2Thr160 in cells at all time-points after IR and most strikingly at 
15 and 30 minutes post-DSB induction (Figure 3.4B).  This data mirrors the 
reduction in CDK2 activity we observed in control cells after IR and offers a 
mechanism for reduction in CDK2 catalytic activity.  Jeffrey Buis next examined 
phosphorylation of CDK2 on Threonine 160 in Atm-/- cells on a time course of 15, 
30, 60, and 120 minutes after IR.  Notably, we observed a delayed response in 
phosphorylation of H2AX after IR in Atm-/- cells as compared to controls.  
Moreover, IR did not cause a decrease in phosphorylation of CDK2 on Threonine 
160 in Atm-/- cells after IR (Figure 3.4C).  This data suggests that inhibition of CDK2 
activity via dephosphorylation of Threonine 160 on CDK2 after DNA damage is an 
ATM-dependent process.   
 115 
 
We next investigated how loss of the MRN complex or loss of the MRE11 
C-terminus effects levels of CDK2 activity.  Thus, I conducted in vitro CDK2 kinase 
assays in Mre11Cond/-, Mre11-/-, Mre11Cond/- + Mre11ATLD1 cDNA, and Mre11-/- + 
Mre11ATLD1 cDNA expressing MEFs.  CDK2 was purified from lysates using anti-
CDK2 antibody and Cdk2-/- MEFs were used as a negative control.  Inputs show 
successful deletion of endogenous MRE11 using adeno-cre virus.  Interestingly, 
loss of MRN and the MRE11 C-terminus both resulted in decreased basal levels 
of CDK2 catalytic activity compared to matched controls (Figure 3.4D).  At least 
three independent experiments were conducted, and activity was quantified using 
ImageJ software.  Data is graphed by pixel density (Figure 3.4E).  Additionally, 
Jeffrey Buis analyzed the impact of MRE11 nuclease deficiency on CDK2 catalytic 
activity, and saw no effect, suggesting that the nucleolytic activities of MRE11 are 
not important for control of CDK2 activity (Figure 3.4F).  From this data, we 
conclude that MRE11, specifically the C-terminus, is required for maintaining 
normal levels of CDK2 catalytic activity.   
Jeffrey Buis next analyzed basal levels of phosphorylation of CDK2 on 
Threonine 160 in Mre11Cond/-, Mre11-/-, Mre11H129N/-, and Mre11-/- + Mre11ATLD1 
expressing cells (Figure 3.4G).  As expected, we observed lower levels of 
pCDK2Thr160 in MRE11-null and MRE11 C-terminal truncated mutant MEFs, 
mirroring our previous observations of reduced basal CDK2 activity in these mutant 
cells.  Loss of MRE11 nuclease activity did not impact pCDK2Thr160 levels.  Taken 
together, we demonstrate that genetic disruption of the MRE11-CDK2 interaction 
mimics IR-induced disruption of the interaction, both of which result in lower 
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catalytic CDK2 activity and pCDK2Thr160 levels.  This data implies that the MRN 
complex, specifically the MRE11 C-terminus, regulates levels of CDK2 activity 
through phosphorylation of CDK2 on Threonine 160, independent of MRE11 
nuclease activity.     
 
MRE11 C-terminal truncation results in slow proliferation equivalent to that 
of MRE11-deficiency, but only a mild genomic instability phenotype 
 Because CDK2 is the central cell cycle kinase that regulates S-phase 
progression, I decided to investigate whether lower basal CDK2 activity levels 
impact proliferation rates in cells lacking the MRE11 C-terminus.  Loss of the MRN 
complex has previously been shown to cause proliferation defects in cells, and so 
I utilized this cell line as a control for slow cell growth, along with DNA ligase IV-/- 
and Atm-/- MEFs[24, 50, 51].  Consequently, I examined proliferation of all 
genotypes over the course of a five-day period in cell culture.  Surprisingly, I 
observed slow cell growth in the MRE11 C-terminal truncation mutant, which was 
comparable to the slow growth observed in MRE11-null cells (Figure 3.5A).  
Importantly, the addition of cre-adenovirus to Mre11+/+ cells did not affect cell 
proliferation, demonstrating that the virus did not have any off-target effects that 
might confound our results (Supplemental Figure 3.4).  This data complements our 
earlier experiments demonstrating equally low levels of CDK2 catalytic activity in 
both MRE11-mutants. This brought us to two possibilities:  1) Genetic disruption 
of the MRE11-CDK2 interaction causes lower levels of CDK2 activity, mimicking 
initiation of the S-phase checkpoint and leading to slower proliferation rates in the 
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cells or 2) The slower proliferation rates are not due to disruption of the MRE11-
CDK2 interaction, but rather to increased DNA damage in the cells. 
Next, I tested the hypothesis that the slower proliferation rate in Mre11-/- + 
Mre11ATLD1 cDNA expressing cells is due to genomic instability.  First, cells were 
stained with the fluorescent intercalating agent Propidium Iodine (PI), which binds 
to DNA, to evaluate DNA content in cell cycle analysis via flow cytometry.  Cell 
cycle analysis revealed normal cell cycle profiles for control cell lines, as expected.  
MRE11-deficiency, on the other hand, resulted in a small sub-G1 peak that most 
likely signifies DNA fragmentation and loss of DNA content due to dramatic 
genomic instability.  MRE11 C-terminal truncation did not result in a sub-G1 peak, 
although an increase of cells in G1 and a decrease of cells in S-phase was 
observed (Figure 3.5B).  This data hints at a severe genomic instability phenotype 
in the absence of the MRN complex, but not in the absence of the MRE11 C-
terminus. 
Cytogenetics, or the analysis of chromosomes, is the gold standard for the 
identification of the chromosomal anomalies that define genomic instability.  To 
examine chromosome anomalies, cells were treated with the drug Colcemid which 
prevents spindle formation during mitosis, causing cells to arrest in mitosis so that 
chromosomes can be separated for cytogenetic analysis.  The bar graph shows 
the number of chromosomal anomalies per metaphase with the types of anomalies 
listed in the key.  The table shows proportions of anomalies scored for each 
genotype (Figure 3.5C).  The anomalies identified include fragments, breaks, 
dicentrics, Robertsonian translocations, circular chromosomes, and radial 
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structures (Supplemental Figure 3.5).  Loss of MRE11, as expected, led to 
dramatic genomic instability, as seen previously[24].  ATM-deficiency also led to 
increased chromosomal anomalies, but not to the same extent as MRE11-
deficiency, consistent with studies demonstrating that MRE11-defiency leads to 
the more severe phenotype of embryonic lethality in mice, while ATM-deficiency 
does not[24, 51].  MRE11 C-terminal truncation resulted in an increase in 
chromosomal anomalies compared to its matched control, but this phenotype was 
not as severe as the genomic instability observed in either MRN or ATM 
deficiencies.  From this data, we can conclude that the dramatic genomic instability 
due to loss of the MRN complex is a major contributor to slow proliferation and low 
levels of CDK2 activity in these cells.  However, MRE11 C-terminal truncation, 
which supports ATM activation and MRN complex formation, exhibited only a mild 
genomic instability phenotype not likely severe enough to cause the slow growth 
and low CDK2 activity levels observed in these cells[34].  Together, these studies 
support the notion that genetic disruption of the MRE11-CDK2 interaction due to 
loss of the C-terminus mimics IR-induced disruption of the interaction, 
constitutively activating the S-phase checkpoint in these cells, leading to lower 
CDK2 activity levels and slow proliferation.   
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Examination of inhibitory phosphorylation of CDK2 on Tyrosine 15 and 
inhibition of CDK2 kinase activity after ionizing radiation treatment in 
MRE11-mutants 
Previous studies have shown that MRE11ATLD1 patient cells and 
Mre11ATLD1/ATLD1 mouse cells have defects in cell cycle checkpoints, including the 
intra-s-phase checkpoint[22, 31].   Because we found that the MRE11-CDK2 
interaction is disrupted after IR in an ATM-dependent manner, and CDK2/Cyclin A 
regulate progression in S-phase of the cell cycle, we set out to analyze the effects 
of IR-induced DNA damage on S-phase checkpoint functions in the absence of 
either the MRN complex or the MRE11 C-terminus.   
I utilized MRE11-deficient and MRE11 C-terminal truncated expressing 
cells, which genetically disrupt the MRE11-CDK2 interaction, in our experiments.  
As mentioned previously, studies have reported that inhibition of CDK2 activity 
after IR is important for induction of the S-phase checkpoint, and this pathway is 
deregulated in ATM-deficient cells[43, 44].  Therefore, I began by measuring 
catalytic CDK2 activity in control Mre11Cond/- and Atm-/- MEFs in response to DNA 
damage (Figure 3.6A).  CDK2 was immunoprecipitated and kinase assay reactions 
performed from cells mock-treated or IR-treated and harvested 30 minutes post-
treatment.   I observed inhibition of CDK2 activity after IR in control cells, but not 
in Atm-/- cells.  This data confirms that S-phase checkpoint induction by inhibition 
of CDK2 activity after IR is ATM-dependent, as previously described[43].  Next, I 
examined CDK2 catalytic activity in response to IR in Mre11Cond/-, Mre11-/-, 
Mre11Cond/- + Mre11ATLD1 cDNA, and Mre11-/- + Mre11ATLD1 cDNA expressing MEFs 
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(Figure 3.6B).  10Gy IR was used to induced DSBs and cells were harvested 30 
minutes after treatment.  Control cells showed a reduction in CDK2 catalytic activity 
after IR.  However, Mre11-/- cells, like Atm-/- cells, did not inhibit CDK2 activity 
following DSB induction, while MRE11 C-terminal truncation still allowed for 
inhibition of CDK2 activity after IR.  These data are graphed as a +IR/-IR ratio in 
which at least 3 independent kinase assays were performed per genotype and 
quantified using ImageJ software (Figure 3.6C).  Our results suggest that inhibition 
of CDK2 activity after IR depends on full-length MRE11, but not’s its C-terminus.   
The catalytic activity of CDK2 is regulated in numerous ways, including 
binding of Cyclins A or E, activating phosphorylation of CDK2 on Threonine 160, 
or inhibitory phosphorylation of CDK2 on Tyrosine 15 or Threonine 14[52].  
Inhibitory phosphorylation of CDK2 plays important roles in regulating the activity 
of CDK2 during the DNA damage response, whereby inhibitory phosphorylation of 
CDK2 on Tyrosine 15 and Threonine 14 contributes to inhibition of CDK2 activity, 
and eventually a halt of S-phase progression[43].  Thus, I examined inhibitory 
phosphorylation of CDK2 on Tyrosine 15 as a readout for CDK2 catalytic activity 
in response to ionizing radiation in MRE11-deficient or MRE11 C-terminal 
truncated cells.  As a control experiment, I analyzed levels of pCDK2Y15 in control 
and Atm-/- MEFs (Figure 3.6D).  Cells were either mock-treated or IR-treated with 
10Gy and harvested after 30 minutes post-treatment.  CDK2 complexes were 
immunoprecipitated using anti-CDK2 antibody, and western blots were probed 
with anti-pCDK2Y15 antibody.  Cdk2-/- cells were used as negative control.  As seen 
previously in the literature, CDK2 was phosphorylated on Tyrosine 15 after IR 
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(indicating inhibition of CDK2 activity) in control cells, but not in Atm-/- cells[43].  
Thus, inhibitory phosphorylation on CDK2 Tyrosine 15 is ATM-dependent after IR.  
Next, I examined pCDK2Y15 levels in Mre11Cond/- and Mre11-/- MEFs before and 
after IR treatment (Figure 3.6E).  Mre11-/- cells, similar to Atm-/-, was not 
phosphorylated on Tyrosine 15 to the same extent as matched Mre11Cond/- 
controls.  This data supports our findings demonstrating that the MRN complex 
contributes to the inhibition of CDK2 activity after IR and inhibitory phosphorylation 
on CDK2 Tyrosine 15 after IR provides a mechanism for this.  In contrast, cells 
lacking the MRE11 C-terminus exhibited phosphorylation on CDK2 Tyrosine 15 
after IR to the same extent to its matched control (Figure 3.6F).  This data implies 
that the MRE11 C-terminus is not necessary for inhibition of CDK2 activity or 
inhibitory pCDK2Y15 after IR.  It should be noted that I attempted to analyze 
CDC25A in our experiments but was unable to successfully detect its degradation 
following IR (data not shown). 
 
MRE11-deficient cells display an intermediate radio-resistant DNA synthesis 
phenotype while MRE11 C-terminal truncated expressing cells inhibit DNA 
synthesis after ionizing radiation treatment similar to controls 
 Defects in the intra-s-phase checkpoint result in the inability of cells to 
reduce their rate of replication after IR.  This phenomenon, known as radioresistant 
DNA synthesis (RDS), was first observed in cells derived from patients with ataxia-
telangiectasia, who have mutations in the ATM gene[53].  The assay for measuring 
RDS (known as the RDS assay) is considered the gold standard in the DNA repair 
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field.  In this assay, the rate of replication is measured by incorporation of 
radioactively labeled thymidine, followed by quantification using a liquid 
scintillation counter[54].  I performed the RDS assay on our MRE11-mutant 
genotypes to determine if either loss of the MRN complex or the MRE11 C-
terminus cause defects in inhibition of DNA synthesis after IR (Figure 3.7).  Cells 
were treated with 10Gy IR and harvested for the experiment 4 hours post-
treatment.  Atm-/- cells were used as a positive control for the radioresistant DNA 
synthesis phenotype.  At least 3 independent experiments were conducted, and 
data is graphed as a +IR/-IR ratio.  Atm-/- MEFs were found to exhibit the classic 
RDS phenotype whereas control cells displayed a low +IR/-IR ratio, indicating 
inhibition of DNA synthesis after IR.  Mre11-/- MEFs displayed an intermediate 
phenotype, which has been seen previously in hypomorphic ATLD- and NBS-
mutated patient cells[44].  This data was surprising, as one might expect MRE11-
deficiency to mimic the severe RDS phenotype caused by ATM-deficiency.  This 
data suggests in the absence of MRE11, inhibition of DNA synthesis after IR might 
become dependent on other DNA repair kinases, such as ATR or DNA-PKCs.  
Surprisingly, Cdk2-/- cells inhibited DNA synthesis after IR comparable to controls, 
also implying other CDKs might facilitate S-phase checkpoint function in the 
absence of CDK2.  Loss of the MRE11 C-terminus did not cause a defect in 
inhibition of DNA synthesis after IR.  Together, our data demonstrates that the 
MRN complex has roles for inhibiting DNA synthesis after IR, but not specifically 
through the MRE11 C-terminus.  
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Inhibition of CDC45 loading onto chromatin is thought to be important for 
stalling replication in response to DNA damage as part of an S-phase checkpoint 
pathway[44, 55, 56].  Therefore, I analyzed loading of the replication factor CDC45 
onto chromatin after DSB induction in control cells and cells lacking either the MRN 
complex or the MRE11 C-terminus.  In control cells following IR, I did not observe 
the expected decrease in loading of CDC45 onto chromatin[44].  I also examined 
CDC45 chromatin loading on a time-course of several hours after IR in control cells 
and in MRE11-mutants, but again, no decrease in loading was detected 
(Supplemental Figures 3.6A-C).  Therefore, I did not use chromatin-associated 
loading of CDC45 as a marker for replication in our experiments. 
 
The MRE11-CDK2 interaction is not disrupted after DNA damage in the 
human U2OS and HeLa cancer cells lines  
 It is known that cell cycle checkpoints and DNA repair mechanisms are 
deregulated in cancer cells, leading to genomic instability and uncontrolled cell 
growth[33].  To further understand roles for the MRE11-CDK2 interaction in 
cancer, I performed co-immunoprecipitations after DNA damage in a panel of 
cancer cells lines (Figure 3.8).  Control MEFs, HeLa (human cervical cancer), and 
U2OS (human bone osteosarcoma) cells were either mock-treated or IR treated 
with 10Gy and harvested 30 minutes after treatment.  CDK2 was 
immunoprecipitated from cells using anti-CDK2 antibody and western blots were 
probed with anti-MRE11 antibody to detect the interaction.  In control MEFs, the 
MRE11-CDK2 interaction was disrupted after IR, as seen in previous experiments.  
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However, in both cancer cell lines, the MRE11-CDK2 remained unaltered after 
induction of DNA DSBs.  This data supports the notion that cancer cells, like Atm-
/- cells, may be unable to initiate S-phase checkpoint pathways after DNA damage 
and that disruption of the MRE11-CDK2 interaction is needed for that to occur.   
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Discussion 
 In this study, we sought to further understand how the MRE11-CDK2 
interaction functions in the DNA damage response and to decipher the biological 
functions of the MRE11 C-terminus.  We have previously described how the 
MRE11-CDK2 interaction has roles in homologous recombination in normally 
dividing cells[32].  Our most recent research reveals that the MRE11-CDK2 
interaction, though intact in normal cells, is disrupted after DSB induction in an 
ATM-dependent manner.  While ATM is the master kinase of the DNA damage 
response, other DNA repair kinases could also be involved in regulating this 
interaction (i.e. ATR or DNA-PKcs), which warrants further investigation.  Likewise, 
we only tested the interaction status after DSB induction caused by ionizing 
radiation.  Future studies will need to investigate how other forms of damage, such 
as replication stress caused by the drug aphidicolin, effect the interaction between 
MRE11 and CDK2.  Intriguingly, we did not observe disruption of the MRE11-
CDK2 interaction after ionizing radiation treatment in human cancer cells, which 
leads us to speculate that the disruption after IR could be a mechanism to control 
CDK2 activity.  It makes sense that this pathway would be altered in cancer cells 
– cells that bypass cell cycle checkpoints, accumulate DNA damage, and 
proliferate uncontrollably to form tumors.  While we investigated this interaction in 
several human, mouse, and cancer cell lines, it remains to be seen if the MRE11-
CDK2 interaction exists in cell lines we did not test.  
 Our lab has previously shown that the MRE11 C-terminus is both sufficient 
and required for interaction with CDK2[32].  In this recent study, we demonstrate 
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that the MRE11 C-terminus appears to regulate the disruption between MRE11 
and CDK2 following IR treatment.  However, the mechanism for IR-induced, ATM-
dependent disruption of the MRE11-CDK2 interaction remains unclear.  Previous 
studies demonstrated that the MRE11 C-terminus contains 5 ATM (and/or ATR) 
phosphorylation sites and that ATM phosphorylates these SQ/TQ sequences after 
IR[57, 58].  A phosphosite-mutant cell line in one of these reports exhibited 
decreased cell survival and increased chromosomal aberrations after radiation 
exposure, indicating these phoshosites have roles in DNA repair[59].  Here, we 
propose the mechanism for MRE11-CDK2 disruption after IR is ATM-dependent 
phosphorylation on one or many of the SQ/TQ sites on the MRE11 C-terminus.   
To test this hypothesis, we could mutate the Serines in the SQ/TQ sites to Alanines 
on the MRE11 C-terminus, making the protein non-phosphorylatable, and test its 
ability to interact with CDK2 before and after irradiation treatment.  While this would 
be an exciting avenue to explore, our data counteracts this theory as we did not 
observe a band-shift (indicating phosphorylation) on a FLAG-tagged MRE11 C-
terminal expressing construct treated with ionizing radiation.  It is possible, 
however, that western blot analysis is not sensitive enough to detect this post-
translational modification.  To further investigate these questions, it would be 
interesting to utilize mass spectrometry, a more powerful technique, to examine 
post-translational modifications of the MRE11 C-terminus before and after DNA 
damage.   
In this study, we demonstrate that ionizing radiation leads to disruption of 
the MRE11-CDK2 interaction, a reduction in catalytic CDK2 levels, and a decrease 
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in activating phosphorylation of CDK2 on Threonine 160.  Next, we set out to 
determine how genetic disruption of the MRE11-CDK2 interaction effects CDK2 
catalytic activity by examining basal levels of CDK2 kinase activity in MRE11-
deficient and MRE11 C-terminal truncated cells compared to their matched 
controls.  We observed lower levels in both MRE11-mutant genotypes.  
Additionally, we observed reduced levels of pCDK2 Threonine 160 in the MRE11-
mutants.  Together, this data suggests that genetic disruption of the MRE11-CDK2 
interaction mimics IR-induced disruption of the interaction, both leading to reduced 
levels of CDK2 activity via decreased phosphorylation on CDK2 Threonine 160.  
We conclude that MRE11, specifically the C-terminus, has roles in controlling 
levels of CDK2 activity.  Interestingly, MRE11-nuclease deficiency did not impact 
basal levels of CDK2 activity or activating CDK2 Threonine 160 phosphorylation, 
suggesting that MRE11’s control over CDK2 activity in S-phase checkpoint 
functions is separate from its roles in DNA repair.  
We hypothesize that disruption of the interaction is important for initiating 
an S-phase checkpoint pathway.  Because the interaction is genetically disrupted 
in the MRE11 C-terminal truncation mutant, we predict that the S-phase checkpoint 
is always “on” on these cells.  A constitutively active S-phase checkpoint would 
likely cause cells to proliferate slowly, independent of massive genomic instability.  
Indeed, we observed slow proliferation in cells lacking the MRE11 C-terminus, 
equivalent to the slow proliferation characteristic of MRE11-deficient MEFs[24].  
Additionally, there was an increase in chromosome anomalies in the absence of 
the MRE11 C-terminus, but not to the same extent as those in cells lacking the 
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entire MRN complex.  This data suggests that the mild genomic instability in the 
MRE11 C-terminal truncation mutant is insufficient to cause the slow proliferation 
phenotype and is instead due to low levels of CDK2 activity caused by genetic 
disruption of the MRE11-CDK2 interaction.    
Next, we investigated how MRE11-deficiency and MRE11 C-terminal 
truncation impact responses to ionizing radiation during the S-phase checkpoint 
pathway.  The S-phase checkpoint is an important anti-cancer barrier which 
detects DNA damage and replication stress and arrests cell cycle progression until 
the damage is repaired[33].  Previous studies have shown that normal cells inhibit 
CDK2 activity after IR as a mechanism for induction of the S-phase checkpoint[43, 
44].  This process is defective in A-T patient cells,  demonstrating that reduction in 
CDK2 activity after IR is ATM-dependent[43].   We found that complete loss of the 
MRN complex led to defects in inhibition of CDK2 activity after IR, while MRE11 
C-terminal truncation still allowed for CDK2 inhibition in response to DNA damage.  
This data suggests that the MRN complex contributes to the inhibition of CDK2 
activity after DNA damage, but not specifically through the MRE11 C-terminus.   
Inhibitory phosphorylation of CDK2 on Tyrosine 15 mirror these results as well. 
 The hallmark of the S-phase damage checkpoint is the slowing of 
replication in response to DNA damage.  A-T patient cells exhibit radioresistant 
DNA synthesis, the inability to inhibit DNA replication in response to ionizing 
radiation[53].  Patient cells derived from individuals with ATLD and NBS have been 
found to exhibit an intermediate radioresistant DNA synthesis phenotype, while 
Mre11ATLD1/ATLD1 mice, which express a patient allele causing truncation of the 
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MRE11 C-terminus, exhibited a severe radioresistant DNA synthesis 
phenotype[31, 44].  In our studies, MRE11-deficiency caused an intermediate 
radioresistant DNA synthesis phenotype, reminiscent of the studies in ATLD and 
NBS patients[44].  Loss of the MRE11 C-terminus, however, allowed for inhibition 
of DNA synthesis after IR.    Patient and mouse ATLD cells have low levels of the 
MRN complex and loss of ATM-signaling, while our cell model for MRE11  C-
terminal truncation has physiologic levels of the MRN complex and intact ATM 
signaling[30, 31].  Thus, we show that the S-phase checkpoint defects previously 
seen in MRE11ATLD1 human and Mre11ATLD1/ATLD1 mouse cells must be due to low 
levels of the MRN complex, and not due to loss of the MRE11 C-terminus 
specifically.  Intriguingly, this data supports our hypothesis of a constitutively active 
S-phase checkpoint in MRE11 C-terminally truncated cells, where we would not 
expect to observe S-phase checkpoint defects in response to IR.  
Cell cycle checkpoint control is a universal mechanism in cells to prevent 
tumorigenesis[33].  The S-phase checkpoint is especially important because of its 
role in stalling replication to allow for damaged DNA to be repaired before cells 
divide in mitosis.  Here we show that MRE11, a DNA repair protein, regulates 
CDK2’s activity through its interaction with CDK2.  Loss of the MRE11 C-terminus, 
which disrupts the interaction, results in lower levels of basal CDK2 activity, 
suggesting the C-terminus has specific roles in controlling CDK2 activity levels.  
Our proposed model is that disruption of the MRE11-CDK2 interaction after IR 
initiates an S-phase checkpoint pathway by reducing CDK2 catalytic activity.  
Therefore, our studies have revealed a novel S-phase checkpoint pathway 
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regulated by the MRE11 C-terminus.  Future studies should further investigate the 
role of the MRE11-CDK2 interaction in cancer cells.  If disruption of the interaction 
after DNA damage is important for initiating S-phase checkpoint function, one 
intriguing possibility is that disrupting the interaction synthetically in cancer cells 
using a small molecule inhibitor could restore S-phase checkpoint functions in 
these cells.  
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Materials and Methods 
DNA constructs 
The Mre11ATLD1 mutation was introduced into pEF6-MmMre11a using site directed 
mutagenesis (Stratagene).  Mre11Cond/- MEFs were transfected (Lipofectamine 
2000, Life Technologies) with the mutant MRE11-expressing construct and clones 
were then isolated and grown under blasticidin selection.   
 
MEF engineering and cell culture 
MEFs were derived in house as previously described[24].  Cells (MEFs, 293T, 
HeLa, and U20S) were grown in DMEM media (Invitrogen) supplemented with 
10% FBS, 20mM HEPES (Corning), non-essential amino acids (Invitrogen), 1mM 
sodium pyruvate (Invitrogen), 2mM L-glutamine (Invitrogen), and β-
mercaptoethanol.  For deletion of endogenous MRE11 protein, MEF cells were 
infected with Adeno-Cre retrovirus at an MOI of 500, grown for 5 days, split once, 
and then plated for experiments.  Cells were exposed to a 137 Cesium source for 
ionizing radiation treatment when indicated.   
 
Transient transfection of 293T cells 
293T cells were plated onto 10 cm dishes and grown for 24 hours until 80-90% 
confluency.  Cells were transfected with either empty vector or MRE11 C-terminal-
Flag tagged cDNA, Lipofectamine 2000 (Thermo Fisher Scientific), and Optimem 
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(Thermo Fisher Scientific) according to the manufacturer’s instructions.  
Transfections were confirmed by western blot analysis. 
 
Western blot analysis 
Cells were lysed in RIPA buffer (150mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 0.1% SDS, and 50mM Tris, (pH 8.0)) or CSK buffer (50mM Tris- 
HCL, (pH 7.5), 150mM NaCl, 1% NP-40, and 10% Glycerol) containing protease 
and phosphatase inhibitors (Halt -Thermo Scientific Fisher) and spun down at high 
speed for 20 minutes, 4°C.  Protein concentrations were determined using the 
Pierce Protein BCA Assay kit (Thermo Fisher Scientific).  Denatured samples were 
resolved by SDS-PAGE and transferred to PVDF membranes (Immobilin). 
 
Immunoprecipitation 
Cells were harvested and lysed on ice in lysis buffer containing 50mM Tris- HCL 
(pH 7.5), 150mM NaCl, 1% NP-40, and 10% Glycerol supplemented with protease 
and phosphatase inhibitors (Halt – Thermo Fisher Scientific).  Protein lysates were 
then incubated on ice for 30 minutes and spun down at 4°C for 20 minutes at high 
speed.  Lysates were precleared with 10µL Protein A Agarose beads (Roche) for 
20 minutes at 4°C on a rotator.  Pierce BCA Protein Assay kit (Thermo Fisher 
Scientific) was used to calculate protein concentrations.  1.5 to 3 mg of protein 
were incubated with anti-CDK2 antibody or anti-Mre11 antibody overnight at 4°C 
on a rotating block.  Approximately 18 hours later, 100µL of Protein A Agarose 
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beads (washed 3 times with lysis buffer) were added to the protein-antibody 
conjugates and allowed to mix for 1 hour at 4°C.  Beads were then washed 3-5 
times with lysis buffer.  Immunoprecipitates were eluted with 2x Laemmli buffer 
(Bio-Rad) at 95°C for 10 minutes.  Samples were resolved on SDS-PAGE and 
transferred under normal conditions.    
 
Antibodies  
Primary antibodies used in this study are as follows: Cyclin A (Santa Cruz), CDC45 
(Santa Cruz), CDK2 (Cell Signaling), pCDK2Thr160 (Cell Signaling), pCDK2Y15 
(Abcam), CHK2 (Cell Signaling), CTIP (Santa Cruz), FLAG (Santa Cruz), GAPDH 
(Santa Cruz), H2AX (Cell Signaling), γH2AX (Millipore), KAP1 (Cell Signaling), 
pKAP1 (Bethyl), MRE11 (Cell Signaling), NBS1 (Novus), and TOP1 (BD 
Pharmingen).  Secondary antibodies for western blot analysis were: 
IRDye800CW-conjugated goat anti-rabbit/anti-mouse (Li-Cor Biosciences) or 
peroxidase goat anti-rabbit/anti-mouse (Jackson Immunolabs).   
 
Kinase Assay 
1x106 cells were plated onto 10cm dishes and allowed to grow for 48 hours.  Cells 
were treated with 10Gy of ionizing radiation and allowed to recover for indicated 
timepoints post-irradiation.  Next, cells were harvested and lysed on ice in lysis 
buffer containing 20mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
(w/v) Triton X-100, 2.5mM sodium pyrophosphate, 1mM B-glycerophosphate, 
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1mM Na3VO4, and 1mM leupeptin.  Protein extracts were spun down for 20 
minutes at 4°C at high speed and protein concentrations were measured using the 
Pierce BCA kit (Thermo Fisher Scientific).  Protein A Agarose beads (Roche) were 
washed 3 times in lysis buffer (5 minutes each).  1.5-3 mg of protein was loaded 
onto 100µL of washed beads, along with anti-CDK2 antibody (Cell Signaling), and 
incubated together overnight at 4°C while rotating.  18 hours later, the beads were 
washed 3 times in lysis buffer.  Beads were then equilibrated and washed 3 times 
in kinase buffer containing 50mM Tris-HCL (pH 7.5), 150mM NaCl, 10mM MgCl2 
and 1mM DTT (dithiothreitol; stock is 1M in H2O).  Next, the kinase reactions were 
performed whereby the kinase reaction mix was added to the purified CDK 
complexes.  Each reaction contains the purified CDK complex with antibody, 
protein A-agarose beads mixed with 2ug Histone H1 protein (Roche), 50uM “cold” 
ATP (Roche), 10µCi γ-32P-ATP (Perkin Elmer), in a total of 25µL kinase buffer.  
The reactions were mixed well and were incubated for 45 minutes in a 37°C 
incubator.  Samples were denatured in 2x Laemmli buffer (Bio-Rad) for 10 minutes 
at 95°C and resolved on acrylamide gels under normal conditions.  Kinase activity 
was evaluated using autoradiography using film and/or a 9400 Typhoon Scanner 
(GE Healthcare).  Steps using radioactivity were performed behind a β-shield to 
protect the experimenter from harmful radiation.  
 
Metaphase analysis 
1x106 cells per genotype were plated onto 10 cm dishes and allowed to grow for 
48 hours.  Colcemid (KaryoMAX) solution (20µL colcemid per mL of media) was 
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added to the cells for an incubation time of 4 hours at 37°C.  The cells were then 
trypsinized, pelleted, and washed 2 times with PBS.  0.4% KCL solution was 
prewarmed at 37°C and added slowly to the cells with gentle agitation to disrupt 
any clumps and then incubated at 37°C for 15 minutes.  Cells were then fixed with 
fresh ice-cold fixative (3:1 methanol: glacial acetic acid).  After fixing, cells were 
dropped onto glass slides and dried on a slide warmer at 65°C.  Nuclei were 
stained with DAPI (Invitrogen).  Metaphases were viewed on an Olympus 
microscope under 100X objective and analyzed with SKYview Software (Applied 
Spectral Imaging).  
 
Radioresistant DNA Synthesis Assay 
Cells were seeded onto 6 well dishes at a density of 1x105 cells/well (unirradiated 
controls and irradiated samples in duplicate) and cultured for 48 hours in 
thymidine-free media (RPMI1640).  After 48 hours, cells were irradiated or mock-
irradiated at a dose of 10Gy.  The media was immediately changed to tritiated 
HEPES media (methyl-3H Thymidine at 2.0uCi/mmol [Perkin Elmer]), along with 
unlabeled thymidine to final molar concentration of 1µM, and the cells were 
allowed to recover for 4 hours.  Next, the media was removed, and the cells were 
washed with warm PBS.  The cells were then incubated at 37°C in unlabeled media 
for an additional 20 minutes to chase the labeled precursor pool.  After 20 minutes, 
the media was removed, and the cells were again washed with PBS.  500µL of 
fresh 0.25M NaOH was used to lyse the cells which were mixed with a pipette and 
transferred to scintillation vials filled with 7.5mL of scintillation cocktail suitable for 
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alkaline solutions (Hionic Fluor from Packard).  Samples were immediately taken 
to a scintillation counter for counting and analysis. 
 
Proliferation Assay 
Cells were plated in 6 well dishes at a density of 2x104 cells/well and counted every 
day for 5 days using a hemocytometer and trypan blue exclusion. 
 
Cell cycle profiles 
Cells were harvested, fixed with 70% ethanol, and stained with 50µg/mL propidium 
iodide (PI), 50µg/mL RNase A, 0.1% Triton-X solution for 20 minutes and then 
analyzed by FACs analysis on an Accuri C6 flow cytometer.  FlowJo software was 
used to analyze cell cycle profiles.   
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Chapter IV 
 
MRE11 Promotes Tumorigenesis by Facilitating Resistance to Oncogene-
Induced Replication Stress‡ 
 
Abstract 
Hypomorphic mutations in the genes encoding the MRE11/RAD50/NBS1 
(MRN) complex lead to human syndromes associated with cancer.  MRN is a 
sensor of DNA double-strand breaks (DSBs) and is required for recruitment and 
activation of the ataxia-telangiectasia mutated (ATM) kinase, which triggers DNA 
repair pathways and cell-cycle checkpoints.  To gain a deeper understanding of 
the roles of the MRN complex in cancer, our lab engineered mice with B-
lymphocytes lacking either the entire MRN complex or lacking the nuclease 
activities of MRE11.  Both forms of MRN deficiency led to characteristics of cancer, 
including oncogenic translocations between C-MYC and the immunoglobulin locus 
                                                          
‡ Contents of this chapter have been published in the following paper and have been modified for this thesis: 
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(Ig).  Interestingly, these preneoplastic B lymphocytes did not progress to 
detectable B-cell lineage lymphoma, even in the absence of the tumor suppressor, 
p53.  In addition, MRE11 deficiencies prevented tumorigenesis in a mouse model 
strongly predisposed to spontaneous B-cell lymphomas.  These findings indicate 
that MRN is not a classic tumor suppressor and instead imply that the nuclease 
activities of MRE11 are required for oncogenesis.  Inhibition of MRE11 nuclease 
activity increased DNA damage and selectively induced apoptosis in cells 
overexpressing the C-MYC and N-MYC oncogenes, suggesting that MRE11 
serves an important role in countering oncogene-induced replication stress.  
Together, these data imply that MRE11, specifically its nuclease activities, could 
serve as a therapeutic target in cancers overexpressing the oncogene MYC. 
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Introduction 
Inherited syndromes that cause cancer-predisposition often arise from 
mutations in genes involved in the cell cycle checkpoints and DNA repair.  DNA 
DSBs are highly toxic lesions and failure of cellular responses to DSBs cause 
diseases with diverse pathological symptoms, including cancer pre-disposition[1].  
One example is Li-Fraumeni syndrome, caused by germline mutations in the TP53 
gene, which plays important roles in cell cycle regulation upon DNA damage.  
These patients present with clinical phenotypes such as sarcomas, leukemias, 
adrenal cortical carcinomas, and other cancers[2].  Similarly, inherited deficiencies 
in the ATM gene cause the disease ataxia-telangiectasia (A-T), which also leads 
to lymphomas and other cancers in patients[3].  
ATM, a serine/threonine kinase, is activated in response to DSBs and 
initiates signaling cascades that elicits DNA repair mechanisms, cell-cycle 
checkpoints, and apoptosis.  The recruitment and activation of ATM primarily 
depends on the MRN complex[4, 5].  MRE11’s nuclease activities initiate end-
resection during repair by homologous recombination (HR)[6-8].  The functional 
relationship between MRN and ATM is highlighted by the fact that mutations in the 
MRN complex cause inherited genetic syndromes with phenotypes like those 
found in A-T patients.  Partial loss-of-function mutations in MRE11 cause the 
disease ataxia-telangiectasia-like disorder (ATLD), which is characterized by 
cerebellar ataxia and variable predisposition to cancer[9, 10].  Hypomorphic 
mutations in the NBS1 gene lead to Nijmegen breakage syndrome (NBS) and 
mutations in RAD50 lead to NBS-like disorder.  Patients with NBS exhibit severe 
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predisposition to cancer, immunodeficiency, mental retardation, and 
microcephaly[11, 12].   
The cancer-prone phenotypes associated with MRN syndromes suggest 
the complex functions as a tumor suppressor.  Two Japanese brothers with ATLD 
reportedly died of pulmonary adenocarcinoma at ages 9 and 14 and were shown 
to have two distinct MRE11-mutant alleles[10].  Furthermore, mouse models 
harboring NBS or ATLD disease alleles are commonly prone to cancer, which 
reinforces the notion that MRN acts as a tumor suppressor[13-15].  However, 
complete knockout of any of the components of the MRN complex results in early 
embryonic lethality in mice[16-18].  This is likely the same for humans as no known 
disease alleles are null.  Thus, human disease alleles must preserve some 
functions of the MRN complex necessary for mammalian development.  
Our lab has previously generated a germline mouse allele in which Mre11 
can be conditionally deleted, leading to deficiency of the entire MRN complex[16].  
In addition, we have targeted a single amino acid change in the endogenous Mre11 
locus that expresses a mutant MRE11 (Mre11H129N) deficient in DNA nuclease 
activities, while preserving the integrity of the MRN complex[16].  Studies of mice 
and cells with combinations of these alleles have demonstrated that the nuclease 
activity of MRE11 is essential for embryonic development and for DSB repair[16, 
19].  However, the nuclease activity of MRE11 is not required for ATM activation, 
thus providing a clear separation of function between involvement in DNA repair 
and ATM-dependent damage and cell cycle checkpoint responses.  
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In this study, we utilized our engineered Mre11 mouse alleles in 
combination with p53 deficiency to further understand roles for MRN in cancer.  
Mice were generated in which mature B lymphocytes were either deficient for the 
entire MRN complex, or MRE11 nuclease activity, which preserves functions of the 
rest of the complex.  Surprisingly, MRE11 deficiency and MRE11 nuclease 
deficiency did not predispose mice to detectable B-cell malignancy.  Furthermore, 
MRE11 deficiency prevented the formation of tumors in a genetic background 
highly prone to early B-cell lymphomas.  From this data, we conclude that MRN is 
not a classic tumor suppressor.  It appears, instead, that certain functions of the 
complex, such as MRE11 DNA nuclease activity, may be required for oncogenesis.      
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Results 
Establishing MRE11 deficiencies in the murine B-lymphocyte lineage 
 The programmed DSBs and rearrangements that exist in B-lymphocytes 
makes this cell lineage ideal to study roles of aberrant DSB repair in cancer 
initiation and progression.  These mistakes in DSB repair are directly responsible 
for oncogenic translocations between the immunoglobulin heavy chain locus (IgH) 
and proto-oncogenes, such as C-MYC[20].  In mice, B lineage tumors harbor 
IgH:MYC translocations.  Therefore, we generated mice that lack MRE11 entirely, 
or express an MRE11 nuclease-deficient allele, in the B-lymphocyte lineage to 
evaluate the impact on the initiation or progression of lymphomagenesis[16, 19].   
 In order to overcome the embryonic lethality conferred by absence of 
MRE11 (Mre11-/-) or defective MRE11 nuclease activity (Mre11H129N/-), we utilized 
a conditional allele (Mre11cond) that can be inactivated through cre-mediated 
recombination of two LoxP sites flanking a conserved exon within the endogenous 
Mre11 locus.  Through breeding, we generated Mre11+/cond, Mre11-/cond, and 
Mre11H129N/cond mice, each containing one allele of CD19-cre, which expresses cre 
recombinase in bone marrow B-lymphocyte progenitors[16, 19].  Cre expression 
can be detected in pro-B cells in bone marrow, prior to class switch recombination 
(CSR), which takes place in mature B-cells in peripheral lymphoid organs[21].  This 
breeding scheme resulted in mice with B cells of the following genotypes:  Mre11+/-
, Mre11-/-, and Mre11H129N/- (Figure 4.1A).   
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Examination of survival and tumorigenesis in mice with deficiencies in 
MRE11 and P53 
 Elizabeth Spehalski and I aged mice with B-cell genotypes Mre11+/- 
(control), Mre11-/-, and Mre11H129N/-, with and without p53, to evaluate survival and 
tumor development.  p53 wild-type mice with B-cell-specific MRE11 deficiencies 
were found to have a normal life span with a median survival of 27.5 months 
(compared with 29 months for the controls) (Figure 4.1B).  Mice with p53-/-Mre11-
/- and p53-/-Mre11H129N/- B-cell genotypes died at about 16 to 18 weeks of age 
(Figure 4.1C).  Upon necropsy, the majority of p53-/- mice presented with an 
enlarged thymus that was negative for the B-cell marker B220 (data not shown).  
Additional flow cytometry analyses of these tumors indicated that the masses were 
thymic lymphomas of T-cell origin, which is a common outcome of murine p53 
deficiency[22, 23].  A smaller percentage of mice had non-lymphoid tumors.  This 
data suggests that B lymphocyte-specific deficiency of MRE11, or MRE11 
nuclease activity, does not significantly impact the survival of mice.  Furthermore, 
these studies imply that there is no predisposition to B-cell malignancy in these 
mice despite the presence of genome instability and defective p53-dependent cell-
cycle checkpoints (Figure 4.1D).    
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MRE11 B-cell specific mutation suppresses pro-B lymphoma in an 
Artemis/p53 double-null background 
 Next, to further assess the roles of MRE11 in tumorigenesis, we examined 
the impact of MRE11 deficiencies in a mouse model that is strongly predisposed 
to B-cell lineage lymphomas[24].  Cheryl Jacobs Smith performed these 
experiments.  The ARTEMIS DNA nuclease is required for processing of DNA 
ends during V(D)J recombination, a lymphocyte-specific DNA rearrangement that 
generates antibody diversity[20].  V(D)J recombination is required for lymphocyte 
development and mutations in ARTEMIS cause immunodeficiency disorders and 
in some patients, cancer predisposition[25].  Previous studies have demonstrated 
that Artemis-null mice, when combined with p53 mutation, succumb to lymphoid 
tumors that display clonal translocations involving IgH and C-Myc or N-Myc 
genomic loci[24].  In this study, we used the Artemis-/-p53-/- mouse model of 
spontaneous pro-B lymphomagenesis to determine the impact of MRE11 
deficiency or MRE11 nuclease deficiency on tumor development.       
 We introduced the target Mre11 mutant alleles into the Artermis/p53 double-
null background through a complex mouse breeding scheme and obtained 
Artemis-/-p53-/-Mre11-/cond and Artemis-/-p53-/-Mre11H129N/cond mice harboring the 
CD19-cre transgene.  We observed that the Artemis-/-p53-/- mice expressing wild-
type MRE11 in B cells had a median survival of 14 weeks (Figure 4.2A).  In 
comparison, mice with B-cell genotypes of Artemis-/-P53-/-Mre11-/- and Artemis-/-
p53-/-Mre11H129N/- exhibited median survival times of 17 and 19 weeks, respectively 
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(Figure 4.2A).  These studies show that B-cell-specific loss of MRE11 or MRE11 
nuclease activity did not markedly alter survival of these tumor-prone mice. 
 The majority of Artemis-/-p53-/- mice analyzed succumbed to progenitor B-
lymphoma, and smaller subsets had thymic lymphoma of progenitor T-cell origin 
or other tumor types, which are consistent with previous studies[24, 26].  Analyses 
of the pro-B tumors confirmed that they had clonal IgH rearrangements and 
amplifications of the IgH and C-Myc or N-Myc loci (data not shown).  We observed 
that nearly all of the mice analyzed harboring B-lineage MRE11 deficiencies also 
succumbed to tumors.  One Artemis-/-p53-/-Mre11H129N/- mouse became moribund 
and died with no obvious cause of death upon analysis.  Surprisingly, no pro-B-
cell lymphomas arose in Artemis-/-p53-/- mice with either the Mre11-/- (n=11) or 
Mre11-/H129N (n=11) B cell genotypes.  The mice in these cohorts primarily 
developed thymic lymphomas, and in one Artemis-/-p53-/-Mre11-/H129N case, a pre-
B cell tumor.  Importantly, this tumor as well as all of the other lymphoid tumors 
analyzed retained the Mre11 conditional allele and expressed MRE11 protein.  
These results indicate that MRE11 mutation suppresses pro-B-cell lymphomas in 
tumor-prone mice where they normally arise (Figure 4.2B).   
 
Detection of translocations in MRE11-deficient cells 
 
We next investigated the broader roles of the MRN complex in generating 
chromosomal translocations by examining sites outside of the rearranging IgH 
locus.  Because the MRN complex has been implicated in all known DSB repair 
pathways, it is possible that translocations cannot be generated in the absence of 
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MRE11.  To answer this important question, Elizabeth Spehalski stably integrated 
a plasmid (DR-GFP) harboring an 18 base pair target site for the rare cutting 
endonuclease I-SceI in Mre11-/cond MEFs.  The conditional Mre11 allele was 
deleted by the addition of cre adenovirus to generate Mre11-/- cells[16].  Mre11H129N 
cDNA was also stably expressed in cells to analyze the impact of MRE11 nuclease 
deficiency in translocation formation.  I-SceI can cleave the mouse genome at 
cryptic sites that diverge 1-5 nucelotides from the consensus sequence[27].  
Erroneous repair between the I-SceI induced DSB in the integrated substrate and 
cryptic sites results in translocation between the two loci, which can be detected 
by PCR amplification.  After introduction of I-SceI via adenovirus, we detected 
translocations between the stably integrated I-SceI substrate and the endogenous 
Mmp24 gene on chromosome 2, which contains a cryptic cut site in control 
cells[27].  PCR products were cloned and sequenced to confirm the presence of 
translocations (data not shown).  In Mre11-/- MEFS and Mre11-/- MEFs expressing 
the Mre11H129N cDNA, we also detected PCR products that were confirmed to be 
translocations (Figure 4.3A).  This data demonstrates that translocations can be 
generated in fibroblasts that lack either MRE11 entirely or lack MRE11 nuclease 
activity.  
We next examined the spontaneous chromosomal anomalies that arise in 
Mre11-/- and Artemis-/-Mre11-/- MEFs for the presence of fusions and translocations 
by analyzing metaphase spreads.  This experiment was performed by Kayla 
Capper.  Upon adeno-cre deletion of MRE11, we observed a marked increase in 
chromosomal anomalies in Mre11-/- MEFs in comparison with control cells, 
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consistent with previous studies[16].  We found that combined mutation of 
ARTEMIS and MRE11 resulted in a moderate increase in chromosomal anomalies 
as compared to MRE11 deficiency alone.  It is worthy to note that MRE11 
deficiency alone or in combination with ARTEMIS deficiency displayed elevated 
levels of chromosome and chromatid fusions, including dicentrics, ring 
chromosomes, and Robertsonian translocations as compared to controls.  These 
observations provide evidence that chromosomal translocations can be generated 
in the absence of MRE11 in nonlymphoid cell types at loci outside of the 
rearranging IgH locus, and also in cells lacking the ARTEMIS DSB repair nuclease.  
 
DNA damage responses in MYC oncogene overexpressing cells 
 Many activated oncogenes drive inappropriate entry into and progression 
through S-phase of the cell cycle, which can lead to replication stress in the form 
of collapsed replication forks that result in the generation of DSB intermediates[28].  
The presence of DSBs activates DNA damage responses that can be detected in 
some tumors[28].  The DNA damage response reflects an attempt to maintain 
genome stability, but has the unintended consequence of preserving the viability 
of cancerous cells. We therefore examined the DNA damage responses triggered 
by overexpression of the oncogene MYC.   
 To induce MYC function in the nucleus, Kayla Capper generated human 
U2OS cell lines stably expressing the human MYC cDNA fused to the hormone-
binding domain of the estrogen receptor (MYC-ER)[29].  Upon 4-hydroxytamoxifen 
(4-OHT) treatment, MYC translocates to the nucleus where it becomes active and 
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leads to increased accumulation of cells in the S-phase (data not shown)[30].  We 
examined the localization of DNA repair proteins to sites of damage, which can be 
detected as punctate subnuclear foci by immunofluorescence microscopy.  Key 
DNA repair proteins, including phosphorylated H2AX (γH2AX) p53-binding protein 
1 (53BP1), single strand DNA-binding protein (RPA), Fanconi anemia group D2 
protein (FANCD2), and breast cancer 1, early onset (BRCA1), localize to stalled 
replication forks and facilitate their restart and/or repair.  We observed that MYC 
overexpression induced increased foci formation of γH2AX (among others) 
compared with controls (Figure 4.4A).  Importantly, we also observed increased 
localization of the NBS1 component of MRN to sites of damage in response to 
MYC oncogene overexpression (Figure 4.4B).  These findings indicate that MYC 
overexpression induces genomic damage that triggers recruitment of the MRN 
complex to DNA DSBs. 
  
MRE11 deletion or inhibition in oncogene-overexpressing cells reduces 
cellular survival 
 Findings not shown here indicate that loss of MRE11 results in decreased 
proliferation in cells overexpressing MYC.  To selectively examine the importance 
of MRE11 nuclease activity in MYC overexpressing cells, Kayla Capper utilized 
Mirin, a well-characterized small molecular inhibitor of MRE11.  Mirin was first 
identified in 2008 in a forward genetic screen of 10,000 compounds[31].  Studies 
have shown that Mirin specifically inhibits MRE11 exonuclease activity, while 
maintaining the integrity of MRN complex formation and ATM signaling[31].  First, 
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the impact of inhibition of MRE11 nuclease activity by Mirin on survival of the 
human U2OS cell line overexpressing MYC was assessed.  Upon 4-OHT 
treatment, exposure to Mirin resulted in markedly reduced survival at 
concentrations of the inhibitor that had minimal impact on survival of control cells 
(Figure 4.5A).  To determine the cause of reduced viability of cells overexpressing 
MYC, the extent of apoptosis in the cells induced by Mirin was examined.  We 
observed that the percentage of cells undergoing apoptosis as measured by 
Annexin V staining was significantly increased in Mirin-treated cells 
overexpressing MYC in a dose-dependent manner.  In contrast, at similar doses 
of the MRE11 nuclease inhibitor, control cells were mostly unaffected (Figure 
4.5B).  These results indicated that the nuclease activity of MRE11 is important for 
survival of cells overexpressing oncogenes, and a small molecular inhibitor of 
MRE11 nuclease activity can induce selective killing of MYC-expressing cells.     
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Discussion 
 In this study, we sought to further understand roles of the MRN complex in 
cancer development.  To this end, we generated mice with MRE11 deficiency or 
MRE11 nuclease deficiency in the B-lymphocyte lineage.  Splenic B cells displayed 
hallmarks of cancer, such as genome instability and the formation of oncogenic 
IgH:Myc translocations.  Despite these observations, and the defective ATM-
dependent checkpoint responses inherent to loss of MRN, there was a striking 
absence of B-lymphocyte malignancy, even in a p53 null background.  This data 
implies that partial loss of the MRN complex in inherited patient alleles retains 
functions of the complex necessary for tumor formation.  The nuclease activities 
of MRE11 appear to be one such function.  In support of this notion, we found that 
loss of the MRN complex or MRE11 nuclease activity prevents pro-B 
lymphomagenesis in the Artemis-/-p53-/- tumor-prone mouse model.   
 The lack of tumors was even more surprising when compared with 
deficiencies of other factors involved in DSB repair.  When XRCC4 was absent in 
mature mouse B-lymphocytes, persistent chromosome breaks in IgH were 
observed at about the same frequency we observed with MRE11 deficiency.  In 
this case, however, mature B-lineage lymphomas did form when XRCC4 
deficiency was combined with germline p53 deficiency[32].  Furthermore, mouse 
models harboring targeted germline null mutations in DNA ligase IV, Xrcc4, or 
Artemis, combined with p53 deficiency, were predominately predisposed to pro-B-
cell lymphomas characterized by translocation and co-amplification of the IgH and 
Myc loci (and IgH:N-MYC) translocations in the case of ARTEMIS deficiency)[24, 
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33, 34].  This is in striking contrast to deficiency of the MRN complex or MRE11 
nuclease activities, where we found a noticeable absence of these tumors.  We 
cannot entirely exclude the possibility that the p53-deficient mice succumb to 
thymic lymphomas before B-cell lymphomas can be detected.  However, tissues 
from Mre11/p53-mutant mice at ages beyond development of tumors in the 
Xrcc4/p53-deficient mice showed no sign of malignancy. 
 One hypothesis for the absence of B-cell tumors in MRE11 deficiency is that 
oncogenes, like MYC, play a role in tumor development in conjunction with 
MRE11.  Previous studies have shown that overexpression of MYC deregulate S-
phase, which increases replication stress and generates significant genomic 
instability[28].  Secondly, MRE11 and its nuclease activities are required for 
cellular survival in response to replication stress[16, 35, 36].  Thus, it is possible 
that overexpression of oncogenes coupled with defective cellular responses to 
replication stress is incompatible with the cellular proliferation and survival required 
for tumor growth[37].  To this end, we demonstrate that cells overexpressing 
oncogenes exhibit enhanced DNA damage responses, decreased survival, and 
increased apoptosis upon inactivation of MRE11 nuclease activity.  Together, 
these findings suggest that although inherited hypomorphic mutations of MRN 
components lead to cancer predisposition, complete loss of MRN may not be 
compatible with malignancy.  Thus, the hypomorphic mutations of MRN must retain 
specific functions of the complex, likely MRE11 nuclease activity, that support 
cancer development.   
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 Our studies raise the possibility that pharmacologic inhibition of MRE11 
nuclease activity could represent a promising new avenue in cancer therapeutics 
(Figure 4.6).  Consistent with this notion, we demonstrate that inhibition of MRE11 
nuclease activity by the small-molecule inhibitor, Mirin, selectively decreases 
survival of oncogene expressing human cells.  Specifically targeting the nuclease 
activities of MRE11 would disable the ability of tumor cells to endure oncogene-
induced replication stress, while maintaining responses controlled by the ATM 
kinase.  This approach warrants further study, especially in light of the 
development of the next generation of selective MRE11 nuclease inhibitors[6].  
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Materials and Methods 
 
Mouse Models 
Mre11cond/+, Mre11cond/−, and Mre11cond/H129N mice with CD19-Cre expression were 
generated in our lab.  P53 mice were obtained from The Jackson Laboratory.  The 
gene targeted Artemis-null mice are as previously described[38].  Mice were 
housed in a pathogen-free facility.  
 
Derivation and transformation of murine embryonic fibroblasts 
Primary murine embryonic fibroblasts (MEF) of less than 4 passages were 
immortalized with SV40 large T antigen or MYC using pLenti-Myc T58A (generous 
gift from Dr. David Lombard, University of Michigan).  Primary MEFs were derived 
in our laboratories and confirmed by PCR-based genotyping, sequencing, and 
Western blot analyses.  Experiments were performed on cells ranging from 5 to 10 
passages after immortalization.  
 
Translocation PCR 
DR-GFP:Mmp24 translocations were identified by a nested PCR reaction using 
Expand Long Template PCR System (Roche).  
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MRE11 inhibitor treatment of MYC-overexpressing cells 
U2OS cells were originally obtained from the ATCC.  U2OS-pBABE and U2OS-
cMycER cell lines were generated by infecting the human U2OS cell line with the 
retroviral vector pBABE-PURO or pBabepuro-MYC-ER (Addgene plasmid 
#19128) expressing human c-MYC cDNA fused to the hormone-binding domain of 
the estrogen receptor (ER), then selected in puromycin (2.5 mg/mL). For cellular 
survival assays, U2OS-pBABE and U2OS-cMycER cells were plated in triplicate 
in 96-well plates 24 hours before treatment with 200 nmol/L 4-OHT (Sigma).  After 
72 hours, cells were treated with mirin (Cayman Chemical) or DMSO for 24 hours, 
and survival was determined by fixing and staining cells with Crystal Violet then 
measuring absorbance of solubilized dye at 595 nm.  Percent survival was 
calculated relative to vehicle-treated controls. Three or more independent 
experiments were performed. 
 
Apoptosis Assay 
U2OS-pBABE and U2OS-cMycER cells were plated in 6-well plates 24 hours 
before treatment with 200 nmol/L 4-OHT (72 hours) and then treated with mirin for 
24 hours. After 48 hours, cells were harvested and stained with FITC Annexin V 
antibody (BD Pharmingen 556419) and propidium iodide and then analyzed by 
flow cytometry (BD Accuri C6 Flow Cytometer).  Data were analyzed using FlowJo 
software. 
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Metaphase spread analyses 
Mre11Cond/− and Artemis−/−Mre11Cond/− MEFs were infected with adeno-empty or 
adeno-cre viruses at an MOI of 500. Cells were grown for 3 days, split, doubly 
infected then incubated with colcemid (KaryoMAX) for 8 hours. DAPI-stained 
chromosomes were imaged on an Olympus BX61 microscope using 60× objective 
(SKYview software; Applied Spectral Imaging). Chromosomal anomalies were 
scored in a blinded manner from at least three independent experiments. 
 
Immunofluorescence microscopy 
U2OS-pBABE and U2OS-cMycER cells were plated on coverslips (4 × 104) in a 
12-well dish (24 hours) and then treated with 200 nmol/L 4-OHT for 72 hours. Fixed 
cells were stained with primary antibodies (45 minutes), and then secondary 
antibodies, Alexa Fluor 488 or 594 (45 minutes). Foci were visualized using an 
Olympus BX61 microscope using 100× objective.  
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Chapter V 
 
Discussion 
 
Roles for MRN in DNA damage kinase activation 
 
Summary and Insights 
 In this thesis, I investigated roles for the MRN complex in DNA damage 
kinase activation, cell cycle checkpoint control, and tumorigenesis.  In Chapter II, 
I sought to further understand the interplay between the two main double-strand 
break (DSB) sensors, the MRE11/RAD50/NBS1 (MRN) complex and the 
KU70/KU80 heterodimer, and activation of their respective kinases, ataxia-
telangiectasia mutated (ATM) and DNA-dependent protein kinase, catalytic 
subunit (DNA-PKcs).  MRN senses and directly binds DSBs and is primarily 
responsible for the recruitment and activation of ATM[1-4].   KU also binds DSBs 
and activates the DNA-PKcs kinase, which has roles in the non-homologous end-
joining (NHEJ) repair pathway and V(D)J recombination[5, 6].  It is not known why 
there are two DSB sensors needed in the mammalian DSB response.   
 To gain mechanistic insight into the early DSB response, we examined cells 
lacking one or both DNA damage sensors and used pharmacological inhibitors to 
inhibit the activity of either ATM, DNA-PKcs, or both.  We disabled the MRN 
complex in mouse embryonic fibroblast cells (MEFs) derived from mice that 
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contained one Mre11 null allele and one Cre/LoxP conditional allele[7].  Cre 
recombinase was added to the cells in tissue culture to convert them to Mre11-/-, 
which also causes deficiency of the entire MRN complex[7].  Through mouse 
breeding, we also generated MEFs of MRN genotypes combined with Ku-
deficiency (Ku70-/-)[8].  
 We first set out to investigate how loss of both sensors affects one of the 
earliest events in the DSB response: phosphorylation of the histone variant H2AX 
(phosphorylated H2AX is denoted as γH2AX)[9].  After DSB induction, repair 
proteins are recruited to the sites of damage and can be visualized as punctate 
dots called foci[10].  Therefore, we analyzed γH2AX foci formation in cells deficient 
for MRE11, KU70, or both following DNA damage induced by ionizing radiation 
(IR).  Cells were also treated with ATM and DNA-PKcs inhibitors.  We found that 
in control cells, γH2AX foci formation is ATM-dependent.  In Mre11-/- cells, γH2AX 
foci formation is dependent on DNA-PKcs.  In the absence of KU70, γH2AX foci 
formation became ATM-dependent.  Finally, to our surprise, we observed γH2AX 
foci formation in the absence of both DNA damage sensors, which was dependent 
on ATM.  This data was also supported by western blot analysis of phosphorylated 
H2AX.  In addition, we found several other ATM-dependent responses restored in 
the absence of both MRN and KU following DNA damage, including early 
recruitment of MDC1 to DSBs and the G2-M checkpoint[11, 12].  However, 
Mre11/Ku70-deficiency in mice did not allow for embryonic survival, DNA repair by 
homologous recombination, or normal IR sensitivity.  These findings indicate that 
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MRN is not absolutely required for the activation of ATM, as previously believed in 
the DNA repair field.   
 While our data shows that MRN is not required for initial ATM activation, it 
might be important for maximizing and sustaining ATM-dependent responses.  We 
noticed that phosphorylation of the ATM substrates KAP1 and SMC1 in MRN/KU-
deficient cells was not as robust as in control cells.  Furthermore, MDC1 
recruitment to DSBs was slightly decreased in cells lacking both DNA damage 
sensors as compared to control cells.  This data would suggest that MRN is needed 
for maximal ATM activation.  This conclusion is further supported by the fact that 
patients with mutations in MRE11 (ataxia-telangiectasia-like disorder) have similar 
clinical phenotypes as to those with mutations in ATM (ataxia-telangiectasia)[13, 
14].  Furthermore, ataxia-telangiectasia-like disorder (ATLD) patient cells have low 
levels of the MRN complex, reduced activation of ATM by DSBs, and reduced 
ATM-dependent phosphorylation of downstream substrates[15].    
To gain a better understanding of how MRN and KU function with or without 
the other in the early DSB response, we analyzed the localization of GFP-tagged 
NBS1 or KU to DNA DSBs using laser-induced microirradiation and live-cell 
imaging.  We found that MRN was recruited to breaks within 15 to 30 seconds and 
that KU-deficiency did not affect its recruitment.  Moreover, we found that KU was 
recruited to breaks within 1 second after DNA damage and the absence of MRN 
did not affect its recruitment.  I also examined the formation of KU70 foci in the 
absence of MRE11 at later time-points following IR treatment[16].  I observed 
KU70 foci formation within 5 minutes after DNA damage in both control and 
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MRE11-deficient cells.  Control and Mre11-/- cells reached the same maximal peak 
of KU70 foci formation at 5 minutes post-IR.  From these experiments, we learned 
that 1) KU70 is recruited to DSB breaks before MRN and 2) the absence of either 
sensor does not affect the overall accumulation of the other.  These findings 
suggest that MRN and KU do not compete at DSBs for initial DSB binding.  
However, it remains unclear as to how they oppose each other at DSBs. 
 
Future Directions 
 The MRN complex must somehow overcome the rapid binding of KU to 
DSBs for it to perform its ATM-dependent functions.  This leads us to the question 
of how exactly KU is removed from DNA following the ligation of DSBs.  We know 
that KU is rapidly recruited to DNA breaks before MRN.  Studies have also shown 
in laser micro-irradiation experiments that KU signal steadily depletes within hours 
after the initial damage, suggesting that KU is somehow being removed from the 
DNA[17].  KU differs from other DNA repair proteins in that it has a ring-like 
structure that encircles the DSB, suggesting that once the DSB is ligated, it 
becomes trapped[18, 19].  One possible mechanism for KU removal is through 
the protein degradation pathway.  A previous study found that poly-ubiquitination 
of KU80 Lysine 48 leads to its degradation by SKP1-CUL1-FBXL12 (SCF) E3 
ubiquitin ligase complex in Xenopus laevis[20].  Another intriguing possibility is 
that the DNA is directly cut, thus allowing for KU to escape.  Indeed, one study 
showed in yeast that MRN performed an endonucleoytic incision to the DNA, 
followed by digestion of the DNA to allow for KU removal[17].  These are all 
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intriguing possibilities, but it is important to note that they were performed in 
different biological systems.   
Another question that remains is the mechanism by which ATM is 
activated.  Our data demonstrates that direct interaction between the MRN 
complex (NBS1 specifically) with ATM is not required for ATM to be activated, 
which was the previous model in the field[4].  One possibility is that ATM is 
activated directly by DNA ends.  In 1999, Stephen Jackson’s group published a 
report showing that ATM binds directly to DNA[21].  Furthermore, they showed 
that purified ATM phosphorylates p53 after stimulation by DNA[21].  This data 
supports the notion that, indeed, ATM can become activated in the absence of 
MRN.  However, these were in vitro studies using purified proteins and so 
additional experiments will need to be conducted to confirm these results in 
mammalian cells.  Another intriguing hypothesis is that ATM becomes activated 
from by-products of DNA damage.  Reactive oxygen species (ROS) are formed 
during the normal metabolism of oxygen and have important roles in cell 
signaling and homeostasis[22].  During times of environmental stress, including 
exposure to ultra-violet light (UV), ROS levels can increase dramatically[23].     
Tanya Paull’s group demonstrated in 2010 that ATM acts as a redox sensor in 
addition to its role as a sensor of DSBs[24].  They showed direct activation of 
ATM by oxidative stress independent of DSBs and the MRN complex.  However, 
they also observed that ROS-dependent activation of ATM did not lead to 
phosphorylation of H2AX, and so this seems like an unlikely mechanism for our 
study[24].  Another possibility is that ATM is activated by an unknown mediator 
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protein in the absence of both MRN and KU.  One probable candidate is ataxia-
telangiectasia and rad3-related protein (ATR), a kinase activated by the presence 
of single-stranded DNA[25].  Penny Jeggo’s group showed that ATM 
phosphorylation at Serine 1981 is ATR-dependent and ATM-independent 
following replication fork stalling or UV treatment[26].  Thus, it is possible that 
long stretches of single-stranded DNA are being created as intermediates during 
end-resection, leading to activation of ATM by ATR.  To test this hypothesis, we 
could treat Mre11-/-Ku70-/- cells with an ATR inhibitor and look for activation of 
ATM and phosphorylation of downstream substrates after DNA damage[27].  
Studies using the ATR inhibitor VE-821 have been marred by the fact that 
increased inhibition of ATR also led to inhibition of ATM and DNA-PKcs.  For 
these reasons, it would be interesting to test the new ATR inhibitor known as 
VX-970, which is the first selective inhibitor of ATR to be entered into clinical 
trials[28].  Finally, in vitro experiments demonstrated that ATM could be 
activated in the absence of MRN in Xenopus egg extracts, but only when there 
were high levels of DNA ends present[29].  If ATM can be activated directly by 
DNA ends, it is possible that MRN and KU allow ATM to access the DNA, and 
MRN then functions to maximize ATM activation and signaling.  Mammalian 
biology is significantly more complex than the above in vitro experiments, and 
so future experiments will need to test this hypothesis in a cellular model.   
Perhaps the most clinically relevant conclusion from our study is that 
some ATM-dependent responses can be restored in the absence of both MRN 
and KU.  From this data, we can propose a novel therapeutic approach for the 
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treatment of patients with MRN-deficiency.  Patients with mutations in the 
MRE11 gene have ATLD, characterized by progressive cerebellar ataxia and a 
varied predisposition to cancer[13, 15].  Patient cells have low levels of the MRN 
complex, defects in cell cycle checkpoint activation, hypersensitivity to radiation, 
and an increase in chromosomal aberrations as compared to controls[15].  While 
MRN deficiency in mice leads to embryonic lethality, patient mutations are 
hypomorphic, thus preserving essential functions of the MRN complex for human 
development[30].   Our findings point to the intriguing possibility that inhibiting 
KU in ATLD patients could restore ATM-dependent functions (Figure 5.1A).  A 
novel specific inhibitor of the KU70/80 heterodimer was recently created using 
an in silico, pocket-based drug discovery approach[31].  Experiments confirmed 
KU-inhibitory activity of the small molecule inhibitor in the low micro-molar range, 
capable of disrupting the binding of the KU heterodimer to DNA substrates and 
impairing KU-dependent activation of DNA-PKcs[31].  It would be interesting to 
investigate the use of this small molecule inhibitor in Mre11-/- cells to determine 
if inhibition of KU and subsequent DNA-PKcs activity restores ATM-dependent 
phosphorylation of H2AX, MDC1 recruitment to DSBs, and the G2/M checkpoint.  
If so, drug studies can then move onto ATLD mouse models and eventually 
human patients.   
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Roles for MRN and CDK2 interaction in S-phase checkpoint control  
Summary and Insights 
In Chapter III, I investigated the biological functions of MRE11 interaction 
with cyclin dependent kinase 2 (CDK2).  Our lab first described the MRE11-CDK2 
interaction in 2012.  Buis et al. showed that MRE11 interaction with CDK2 is 
required for CTIP phosphorylation and interaction with BRCA1, which, in part, 
regulates HR capacity in normally dividing cells[32]. The MRE11 C-terminus is 
required for interaction with CDK2, which is absent in an inherited patient allele 
termed ataxia-telangiectasia-like disorder 1 (ATLD1).  These studies 
demonstrated that functions of the MRN complex are not restricted to DNA 
damage responses, but include regulating HR capacity during the normal 
mammalian cell cycle[32].   
My thesis work has been focused on further understanding roles for the 
MRE11-CDK2 interaction in response to DNA DSBs and in cell cycle checkpoint 
function.  We first set out to investigate the consequences of DNA damage induced 
by IR on the MRE11-CDK2 interaction.  We found that IR led to disruption of the 
MRE11-CDK2 interaction in an ATM-dependent manner.  We also found that IR 
treatment caused a decrease in CDK2 catalytic activity levels in cells at timepoints 
where we also observed disruption of the MRE11-CDK2 interaction.  Previous 
studies have demonstrated conflicting data of how cells respond to ionizing 
radiation treatment.  One study showed that 10Gy IR caused a decrease in 
catalytic CDK2 activity in the human osteosarcoma cancer cell line, U2OS, 1-2 
hours post-treatment[33].  However, another paper showed that 10Gy caused an 
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increase in CDK2 activity levels in response to IR up to 10 hours post-treatment in 
the chicken B cell line DT40[34].  Perhaps responses to inhibition of CDK2 activity 
after IR depend on cell type or the organism from which they are derived.   Future 
studies will need to investigate if other types of DNA damage (such as aphidicolin-
induced replication stress) also disrupt the interaction and if the disruption is 
dependent on additional DNA damage kinases (i.e. ATR or DNA-PKcs).  While we 
cannot definitively say if the disruption of the interaction after IR caused the 
decreased CDK2 activity levels, it led us to hypothesize that the MRE11-CDK2 
interaction is a component of an S-phase checkpoint pathway.     
The intra-s-phase checkpoint is activated to delay progression through S-
phase allowing time for DNA repair to occur before mitosis and to prevent the 
accumulation of genomic damage.  Several S-phase checkpoint pathways have 
been previously described[33, 35-39].  One pathway is thought to be controlled by 
the ATM signaling machinery, in which checkpoint kinase 2 (CHK2)-mediated 
degradation of M-phase inducer phosphatase 1 (CDC25A) causes inhibition of 
CDK2 activity and inhibition of cell division control protein 45 homolog (CDC45) 
onto chromatin, which in turn, inhibits DNA replication[33, 35].  This data is 
supported by the fact that cells derived from patients with A-T caused by mutations 
in the ATM gene, exhibit a radioresistant DNA synthesis (RDS) phenotype, in 
which cells do not inhibit DNA replication in response to IR[40].   
Because ATM activation is primarily controlled by the MRN complex, it makes 
sense that MRE11 could have unknown roles in controlling the S-phase 
checkpoint.  Previous studies have investigated the role of the MRN complex in 
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RDS.  MEF cells derived from Mre11ATLD1/ATLD1 mice (mice expressing one of two 
Mre11 alleles which results in C-terminal truncation of the MRE11 protein) 
exhibited a severe defect in inhibition of DNA synthesis after IR.  These mice were 
viable, but embryonic viability in homozygous mothers was dramatically 
reduced[41].  Additionally, primary fibroblast cells derived from patients with 
mutations in NBS1 and MRE11 were found to have an intermediate radioresistant 
DNA synthesis phenotype[35].  Importantly, loss of any of the components of the 
MRN complex leads to embryonic lethality in mice[30, 42, 43].  Thus, MRE11 
patient alleles must be caused by hypomorphic mutations that retain functions 
necessary for embryonic development in humans.  
We previously generated a germline mouse allele in which Mre11 is 
conditionally deleted, leading to deficiency of the entire MRN complex[30].  We 
utilized MRE11-deficient MEFs from these mice and show that loss of the MRN 
complex leads to lower basal levels of CDK2 activity in cells.  In response to IR, 
cells displayed a severe defect in inhibition of catalytic CDK2 activity, comparable 
to defects caused by ATM-deficiency, and an intermediate RDS phenotype.  This 
data suggests that the MRN complex contributes to inhibition of CDK2 activity after 
IR.  The intermediate RDS phenotype we observed mirrors the results found in 
human NBS1 and MRE11-mutant patients[33].  This data is surprising, as we 
expected that loss of the entire MRN complex would generate a complete RDS 
phenotype, like the one seen in ATM null cells, since MRN-deficiency causes loss 
of ATM signaling.  One possibility is that another kinase, such as ATR or DNA-
PKcs, can substitute for ATM in facilitating S-phase checkpoint functions when 
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MRN is absent.  The lower basal levels of CDK2 activity can be explained by the 
slow proliferation and severe genomic instability characteristic of these cells due 
to loss of the entire MRN complex[30]. 
Because ATLD patient cells have low levels of the MRN complex, structure-
function studies can be difficult to perform[13, 15].  Thus, we generated an 
Mre11ATLD1-mutant expressing cell line in which the MRE11 C-terminus is 
truncated and endogenous MRE11 is deleted by the Cre/LoxP system[44].  We 
have previously demonstrated that MRE11 C-terminal truncation still allows for 
MRN complex formation and ATM signaling[44].  Thus, any defect found in this 
mutant can be attributed to loss of the MRE11 C-terminus specifically, and not due 
to low levels of the MRN complex and subsequent loss of ATM signaling.  We 
found lower basal levels of CDK2 activity in these cells, comparable to MRE11-
deficiency.  In response to IR, MRE11 C-terminal truncation still allowed for 
inhibition of CDK2 activity and DNA synthesis.  This data would suggest that the 
S-phase checkpoint defects seen previously in the Mre11ATLD1/ATLD1 mice and 
MRE11 and NBS-mutated patients is indeed caused by low levels of the MRN 
complex and loss of ATM signaling, and not due, specifically, to loss of the MRE11 
C-terminus alone.  
 However, another hypothesis is that what looks like an intact S-phase 
checkpoint in the MRE11 C-terminal mutant is in fact “constitutively active”.   A 
constitutively active checkpoint in the MRE11 C-terminal mutant would signify that 
the MRE11 C-terminus is indeed important for S-phase checkpoint function, and 
that this is independent from ATM-signaling.  If the checkpoint were always on, we 
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would predict that cells would grow slowly and have decreased basal levels of 
CDK2 activity.  Indeed, these are phenotypes we observed in MRE11 C-terminal 
truncated mutated cells.  The lower levels of CDK2 activity caused by loss of the 
MRE11 C-terminus mimicked the lower levels observed due to loss of the entire 
MRN complex.  Another interpretation of this data is that genetic disruption of the 
MRE11-CDK2 interaction mimics IR-induced disruption of the interaction, leading 
to lower levels of CDK2 activity.  To further investigate this phenotype, we 
measured cell proliferation rates and genomic instability in these cells.  We 
observed growth defects in the MRE11 C-terminal truncation mutant comparable 
to the defects in proliferation caused by MRE11-deficiency.  However, we 
observed only a mild genomic instability phenotype in the MRE11 C-terminal 
truncation mutant.  In contrast, MRE11-deficiency is known to cause serve 
genomic instability[30].  This data would suggest that the mild genomic instability 
observed in the MRE11 C-terminal truncation mutant is not sufficient to cause the 
slow proliferation and low levels of basal CDK2 activity.   Additionally, deficiency 
of MRE11 nuclease activity did not impact CDK2 activity levels.   
Together, our data points toward specific functions of the MRE11 C-terminus 
in controlling CDK2 activity levels that are separate from MRE11 nuclease activity.  
We conclude from these studies that the MRE11 C-terminus has roles for 
maintaining normal levels of CDK2 activity, and that it accomplishes this task 
through its interaction with CDK2.  Therefore, the MRE11-CDK2 interaction 
represents a novel S-phase checkpoint pathway for controlling CDK2 activity in 
response to DNA damage.   
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Future Directions 
There are many questions left to investigate.  We initially observed that 
disruption of the MRE11-CDK2 interaction after IR treatment is dependent on ATM, 
but the mechanism remains unclear.  One hypothesis is that ATM phosphorylates 
the C-terminus of MRE11 after DNA damage, and that this phosphorylation event 
causes MRE11 and CDK2 to dissociate.  A recently published paper demonstrated 
that, indeed, the MRE11 C-terminus has several SQSQ sites, which are ATM 
phosphorylation motifs, and that ATM phosphorylates these sites after IR[45, 46].  
To test this hypothesis, we could mutate the Serines to Alanines within the SQSQ 
sequences, thus generating unphosphorylatable mutants, and observe the 
interaction status following IR treatment.  It would also be interesting to utilize mass 
spectrometry to identify additional interaction partners or post-translational 
modifications of the MRE11 C-terminus.    
Furthermore, the mechanism behind the decrease in basal CDK2 activity in 
the MRE11-mutants remains unclear.  Full activation of CDKs requires binding of 
CDKs to a cyclin and phosphorylation on an activating site.  Inhibitory 
phosphorylation on CDKs inhibit CDK2 activity.  We did not observe any difference 
in phosphorylation of CDK2 on Tyrosine 15, an inhibitory phosphorylation event, 
in our MRE11-mutant cells that could explain the decrease in basal levels of CDK2 
activity.  However, we did find that the MRE11-deficient and MRE11 C-terminal 
truncated mutant cells had lower levels of CDK2 Threonine 160 phosphorylation, 
which in theory, could reduce CDK2 catalytic activity.  There was no difference in 
Cyclin A binding in these cells.  It is known that the activating threonine residue is 
 204 
 
located in a loop of amino acids termed the T-loop, which blocks access of ATP to 
the catalytic domain.  Crystal structure studies have shown that binding of a cyclin 
to CDK causes a conformational change in the CDK which makes it more 
accessible for the activating phosphorylation.  Therefore, it would be interesting in 
the future to perform structural studies to examine how loss of the MRE11 C-
terminus affects the structure of the MRE11 protein.  Perhaps the C-terminus is 
important for allowing the T-loop to become accessible for activating 
phosphorylation and loss of the MRE11 C-terminus results in a blocked catalytic 
domain, resulting in reduced phosphorylation of Threonine 160 and decreased 
CDK2 catalytic activity.  Additionally, I would be curious to know how ionizing 
radiation affects the structures of both MRE11 and CDK2.  It is possible that 
ionizing radiation also causes a conformational change in one of these proteins, 
leading to dissociation of the interaction.  
Buis et al. determined that the MRE11 C-terminus is essential for interaction 
with CDK2, and that disruption of this portion of the protein leads to a significant 
decrease in phosphorylation of the CDK2 substrate CTIP[32].  Other substrates of 
CDK2 have recently been identified, including NBS1, C-MYC, and RAG2[47-50].  
It has been shown that CDK2 phosphorylates NBS1 on Serine 432 and that this 
phosphorylation is important for protecting cells from IR-induced cell death[51].  
This data demonstrates a specific requirement for the catalytic activity of CDK2 in 
the survival of human cells during the DNA damage response.  Another study 
found that this modification stimulates MRN-dependent conversion of DSBs into 
structures that are substrates for repair by HR[47].  In future studies, it would be 
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intriguing to determine if CDK2-dependent phosphorylation of NBS1 occurs in the 
absence of the MRE11 C-terminus.  If not, this data would suggest that the MRE11 
C-terminus, through interaction with CDK2, is required for CDK2-dependent 
phosphorylation of NBS1 to facilitate the protection of cells from IR and for the 
stimulation of DSB repair by HR.  Moreover, a defect in CDK2-dependent 
phosphorylation of NBS1 could, in part, explain the lower levels of CDK2 activity 
caused by loss of the MRE11 C-terminus. 
CDK2 has also been found to have roles in regulating V(D)J recombination 
through CDK2-dependent phosphorylation of RAG2 on Threonine 490.  Mutation 
of this site abolishes degradation of RAG2 protein, which results in aberrant 
recombination events during V(D)J recombination[49].  The cell cycle dependence 
of V(D)J recombination suggests it may be interesting in future studies to 
determine how genetic disruption of the MRE11-CDK2 interaction affects 
lymphogenesis and V(D)J recombination in mice.   
Interestingly, hypomorphic mutations in the MRN complex cause a variety of 
clinical phenotypes in human patients, including cancer predisposition.  Individuals 
with NBS exhibit a predisposition to cancer, immunodeficiency, and 
microcephaly[15].  A predisposition for cancer in ATLD is variable, but two 
Japanese brothers with ATLD recently died of pulmonary adenocarcinoma[52].  In 
addition, the Mre11ATLD1ATLD1 mouse was not prone to malignancy, suggesting that 
the severe checkpoint failure and chromosomal instability observed in the mouse 
were insufficient to enhance the initiation of tumorigenesis[41].  To determine roles 
for the MRE11 C-terminus in tumorigenesis, it would be interesting to delete this 
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region of the MRE11 protein in mice and evaluate them for tumor formation.  
Additionally, the MRE11 C-terminus could be specifically deleted in B-lymphocytes 
and the mice monitored for lymphoid tumors.  By deleting the MRE11 C-terminus, 
any results would be attributed to that region of the protein specifically, and not 
due to low levels of the MRN complex and loss of ATM signaling as in the 
Mre11ATLD1/ATLD1 mouse model. 
We have preliminary data suggesting that the MRE11-CDK2 interaction is 
not disrupted after IR in two human cancer cells lines: U2OS and HeLa.  We 
hypothesize that disruption of the MRE11-CDK2 after DNA damage is important 
for initiating the S-phase checkpoint by lowering CDK2 activity levels.  If this is true, 
one might expect that the interaction cannot be disrupted in cancer cells, thus 
promoting CDK2 activity and uncontrolled cell division.  Indeed, our cancer cell 
data supports this hypothesis.  It will be important in future studies to investigate 
the status of the MRE11-CDK2 interaction in additional human cancer cell lines.   
Furthermore, if disruption of the MRE11-CDK2 interaction is truly important for 
regulating the S-phase checkpoint, a small molecule inhibitor for this interaction 
could be a useful therapeutic tool in the treatment of cancer.  Synthetically 
disrupting the interaction in cancer cells would theoretically restore S-phase 
checkpoint functions, allowing for DNA repair to occur and thus preventing 
genomic instability and tumorigenesis (Figure 5.1B).  
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Roles for MRN in tumorigenesis 
 
Summary and Insights 
 In Chapter IV, I sought to further understand roles for the MRN complex in 
the initiation and progression of cancer.  It is known that mutations in DNA repair 
and cell cycle checkpoint genes can lead to inherited syndromes associated with 
a predisposition to cancer.  For example, inherited deficiencies in ATM lead to the 
disease ataxia-telangiectasia (A-T), which presents with clinical features such as 
immunodeficiency, sensitivity to ionizing radiation, and lymphomas[14, 53].  
Likewise, hypomorphic mutations in MRE11 cause the disease ataxia-
telangiectasia-like disorder (ATLD), which is characterized by cerebellar ataxia 
and a variable predisposition to cancer[15].  Hypomorphic mutations in NBS1 lead 
to Nijmegen breakage syndrome in which patients present with a severe 
predisposition to cancer, immunodeficiency, and microcephaly[54].  While mice 
lacking components of the MRN complex do not survive, no known human alleles 
are null, suggesting that human patients have partial loss-of-function mutations 
which still allow for functions of the MRN complex necessary for human 
development[42, 43, 55].  The cancer-prone phenotypes linked with MRN-
associated diseases suggest MRN functions as a tumor suppressor and is 
necessary for the prevention of cancer development. 
To further investigate how MRN functions in cancer, we examined the 
impact of MRE11-deficiency and MRE11 nuclease deficiency in B-lymphocytes in 
engineered mouse models in our lab.  We utilized CD19-cre conditional alleles, 
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which express cre recombinase specifically in B cells, to delete MRE11 in 
lymphocytes[56].  We also crossed mice to germline p53 knockout mice[57].  
Surprisingly, the MRE11 deficiencies did not predispose mice to 
lymphomagenesis.  Some of the mice had thymic lymphomas of T-cell origin, a 
common outcome of p53 deficiency[58].  Additionally, some of the mice had 
nonlymphoid tumors.  MRE11/p53-deficient B cells were also observed to possess 
oncogenic chromosomal translocations, including translocations between the 
immunoglobulin heavy locus (IgH) and the proto-oncogene MYC.  The observation 
that mice harboring MRE11-deficient B cells did not succumb to lymphogenesis 
would suggest that MRE11, in some capacity, is required for oncogenesis.  This 
would further refute the notion that MRE11 is a classic tumor suppressor.   
  To further access the roles of MRE11 in tumorigenesis, we examined the 
impact of MRE11 deficiency and MRE11 nuclease deficiency in Artemis/p53 null 
mice, which are strongly prone to the development of lymphomas[59].  Again, to 
our surprise, we observed that MRE11 deficient mice in these cohorts primarily 
developed thymic tumors and no mice developed pro-B lymphomas.  This data 
would suggest that MRE11 mutation suppresses pro-B lymphoma development in 
a mouse model in which they normally arise[59, 60].  Additionally, chromosomal 
translocations were observed in MRE11 and MRE11/ARTEMIS-deficient 
fibroblasts, implying that chromosomal translocations can be generated in the 
absence of MRE11.  The lack of tumors in these mice is unexpected given that 
several other DNA repair mouse models, including DNA Ligase IV, Xrcc4, and 
Artemis, which, when combined with p53 deficiency, predominantly predispose the 
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mice to B-cell lymphomas characterized by IgH:MYC chromosomal 
translocations[59-62].  However, we cannot rule out the possibility that we were 
not able to detect B-cell lymphomas before thymic tumor development in the 
MRE11/p53-deficient mice.     
The MYC proto-oncogene was first discovered for its role in retrovirally-
mediated tumorigenesis and later for its activation and overexpression through 
chromosomal translocations in Burkitt’s lymphoma[63, 64].  In normal biology, 
MYC protein is a transcription factor that has roles in DNA replication, cell 
proliferation, and cell growth[65].  During DNA replication, CDC45 is loaded onto 
the pre-replication complex and this process initiates DNA replication in S-phase, 
which is also controlled by the activity of CDKs[66].  C-MYC has been found to 
directly interact with CDC45, thus stabilizing components of the pre-replication 
complex[67, 68].  MYC overexpression, on the other hand, deregulates S-phase, 
resulting in replication stress and genomic instability[65, 69-71].  In some cases, 
MYC causes normal cells to grow and replicate DNA, but these cells cannot divide 
and become polyploid.  Additionally, MYC overexpression can enforce replication 
in a manner that results in DSBs, by either blocking DNA repair or increasing 
oxidative stress, causing DNA damage[70].  With this knowledge, we hypothesized 
that MRE11 may promote the survival of cells harboring oncogenic translocations 
and investigated the impact of MYC overexpression and MRE11 deficiency on cell 
survival.  Interestingly, we found that inhibition of MRE11 nuclease activity, using 
the inhibitor Mirin, selectively increased DNA damage and apoptosis in U2OS cells 
overexpressing the C-MYC oncogene, suggesting that C-MYC overexpressing 
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cells rely on MRE11 nuclease activity for survival.  Therefore, MRE11 is not a 
classic tumor suppressor.  Together, our study supports the conclusion that 
MRE11 nuclease activity may be required for the progression of cancer and that 
inhibiting the nuclease activity of MRE11 could serve as a promising target in C-
MYC-driven cancer.   
 
Future Directions 
In future studies, it would be interesting to delete MRE11 specifically in the 
T-cell lineage and examine mice for the development of thymic tumors.  While 
lymphomas are frequently characterized by MYC overexpression and IgH:MYC 
translocations, thymic tumors typically are not[72].  Therefore, if the mice succumb 
to thymic tumors, this data would suggest that MRE11 specifically functions in 
MYC-driven cancers.  On the other hand, an absence of thymic tumors would 
suggest that MRE11 functions in a wider range of cancers not specifically 
characterized by MYC overexpression.  
While we primarily focused our attention on the consequences of C-MYC 
overexpression in oncogenesis, N-MYC amplification is associated with cancers 
as well, including retinoblastoma and neuroblastoma[73, 74].  Importantly, the 
amplification of N-MYC is found in approximately 25% of neuroblastoma cases and 
correlates with high-risk disease and prognosis[75].  Amplification of N-MYC 
currently represents the best characterized genetic marker in neuroblastoma[75].  
Because N-MYC has roles in cell proliferation, growth, and apoptosis, similarly to 
C-MYC, it would be interesting to utilize patient neuroblastoma cells that 
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overexpress N-MYC in our studies to test the effect of MRE11 nuclease inhibition 
on cell survival.   Indeed, Petroni et al. showed in 2016 that the MRN complex is 
required for N-MYC-dependent proliferation in N-MYC overexpressing cells and 
that inhibition of MRN resulted in DNA damage, activation of the DNA damage 
response, and cell death[76, 77].   Thus, studies using Mirin could provide 
evidence of a therapeutic role for MRE11 nuclease activity in N-MYC driven 
neuroblastoma. 
Additionally, it would also be intriguing to investigate the development of 
tumors in the well-characterized E mu-myc transgenic mouse model, which has a 
high incidence for spontaneous lymphoma and leukemia in B cells, upon treatment 
with an MRE11 nuclease inhibitor[78].  If our hypothesis is correct, I would predict 
a decrease in size and number of B cell tumors as compared to untreated controls.  
Likewise, we could utilize patient-derived Burkitt Lymphoma B cells, which have 
IgH:MYC translocations and exhibit overexpression of C-MYC, to test the efficacy 
of MRE11 nuclease inhibitors on development of colonies in a colony forming 
assay[64].  Anchorage-independent growth, a hallmark of cancer, is the ability of 
transformed cells to grow independently of a solid surface.  The soft agar colony 
formation assay is a well-established method for characterizing this capability in 
vitro and is one of the most stringent tests for malignant transformation in cells[79].  
Therefore, I would predict treatment with an MRE11 nuclease inhibitor to prevent 
colony formation of Burkitt Lymphoma B cells.    
We have previously shown that MRE11 interacts with CDK2 and that this 
interaction has roles for regulating homologous recombination in normally dividing 
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cells[32].  Additionally, the MRE11 C-terminus is required for interaction with CDK2 
and is absent in an ATLD patient allele[32].  Recently, C-MYC was identified as a 
substrate of CDK2.  Several reports have demonstrated that CDK2 
phosphorylates C-MYC on Serine 62 and that this phosphorylation has a role in 
suppressing oncogene and replication stress-induced senescence[50, 80].  This 
data suggests that CDK2 could potentially be used as a therapeutic target in C-
MYC-driven cancers.  In future studies, it would be interesting to determine if 
MRE11, through interaction with CDK2, is required for CDK2-dependent 
phosphorylation of C-MYC and in suppression of oncogene-induced 
senescence.   To test this hypothesis, we could overexpress C-MYC in an 
MRE11 C-terminal truncation mutant (in which the MRE11-CDK2 interaction is 
genetically disrupted) and measure cell proliferation.  If the MRE11 C-terminus 
is important for suppression of oncogene-induced senescence, I would expect 
that overexpression of C-MYC would selectively inhibit proliferation in the 
MRE11 C-terminal truncation mutant as compared to controls.  
  Although the inherited hypomorphic mutations of the MRN complex in 
humans lead to cancer predisposition, complete loss of the MRN complex in mice 
is not compatible with malignancy, as these mice are not viable[30, 42, 43].  This 
suggests that hypomorphic mutations of MRN retain functions needed for 
tumorigenesis (and embryonic development).  We hypothesize that the nuclease 
activity of MRE11 is one of the functions that supports cancer development.  This 
notion is supported by the fact that no human inherited MRN mutations disrupt the 
nuclease activities of MRE11.  For example, the patient allele MRE11ATLD1 is 
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caused by loss of the MRE11 C-terminus[15].  Patients with MRE11ATLD1 present 
with varied predisposition to cancer, but some patients have been reported to have 
breast cancer[81].  This mutation likely maintains sufficient nuclease activity for 
tumorigenesis given that it still allows for organism survival and the N-terminal 
nuclease domain maintains its activity and structure even in the absence of the C-
terminus.   
 Defects in the DNA damage response due to oncogenic activation or tumor 
suppressor inactivation lead to replication stress, a phenomenon unique to cancer 
cells in which DNA replication persists to meet the demands of unrestrained cell 
proliferation, despite the presence of unrepaired DNA lesions[82, 83].    Thus, 
replication stress causes genomic instability and further potentiates oncogenic 
transformation.  In normal cells, replication stress can be countered by the DNA 
damage response.  However, in cancer cells where the DNA damage response is 
defective, high levels of replication stress may induce cancer cell death and 
counteract cancer progression[83, 84].  Thus, further enhancing replication stress 
may provide a promising alternative to treat cancer[85].  Indeed, our studies 
demonstrate that pharmacologic inhibition of MRE11 nuclease activity by the small 
molecular inhibitor, Mirin, selectively decreases survival of MYC overexpressing 
cells (Figure 5.1C)[86].  Further studies will need to be conducted, especially in 
mice, before Mirin or other MRE11 nuclease inhibitors become viable options for 
clinical trials in humans.  Other drugs using this “synthetic lethality” approach are 
already FDA approved, including the PARP1 inhibitor, Olaparib[87].  Several other 
drugs are in in Phase I or II trials, including drugs that target the DNA repair 
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proteins checkpoint kinase 1 (CHK1) and ATR[88, 89].  It will be important to 
investigate how these drugs can be used in combination with other therapies and 
possible mechanisms of drug resistance.  In conclusion, increased understanding 
of oncogene-induced DNA replication will greatly contribute to the development of 
novel cancer therapies.   
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Concluding Remarks 
 In summary, my thesis work has contributed to advances in our 
understanding of the MRN complex in DNA damage responses and signaling, cell 
cycle checkpoint control, and in oncogenesis.  Through my work, I discovered that 
MRN is not absolutely required for activation of ATM, that the MRE11 C-terminus 
has roles in controlling normal levels of CDK2 activity through direct interaction 
with CDK2, and that MRE11 nuclease activity is a potential therapeutic target in 
MYC-driven cancers (Figure 5.2).   
An important goal of studying the MRN complex has always been to 
uncover mechanisms underlying cancer initiation and progression that can 
eventually lead toward development of clinical therapies.  My studies have 
revealed that the biology of the MRN complex in relation to cancer is more 
complicated than previously thought.  It appears that this DNA repair complex has 
both pro- and anti-tumor capabilities.  Roles for the MRN complex in preventing 
cancer are evident by the fact that patients who have hypomorphic mutations in 
members of the complex are predisposed to cancers.  Additionally, MRN’s 
functions in facilitating DNA repair and cell cycle checkpoints are central for 
persevering the integrity of the genome.  My work also shows that MRN has roles 
in controlling CDK2 activity important for regulation of S-phase checkpoint 
functions.  This data, together, supports the notion that MRN is a tumor 
suppressor.  On the other hand, we show that B-cell specific deficiency of MRN or 
MRE11 nuclease activity does not predispose mice to lymphomas and prevented 
lymphogenesis in another mouse model prone to these tumors.  We also show 
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that inhibition of MRE11 nuclease activity selectively kills cells overexpressing the 
oncogene C-MYC.  These studies suggest that some functions of the MRN 
complex, such as MRE11 nuclease activity, promote oncogenesis.  It is surprising 
and perplexing that the MRN complex can have functions that both suppress and 
promote oncogenesis and future studies will need to further unravel these 
mysteries, especially in relation to the development of anti-cancer drugs that target 
this complex.  There are many questions that remain unanswered, but I hope my 
work contributes toward future avenues of investigation in the lab with the goal of 
one day positively impacting patients who are fighting cancer. 
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